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Abstract	  
Choline	   is	   an	   essential	   nutrient	   for	   eukaryotic	   cells,	   where	   it	   is	   used	   as	   precursor	   for	   the	  
synthesis	   of	   choline-­‐containing	   phospholipids,	   such	   as	   phosphatidylcholine	   (PC).	   Our	   experiments	  
showed	  –	  for	  the	  first	  time	  –	  that	  Trypanosoma	  brucei,	  the	  causative	  agent	  of	  human	  African	  sleeping	  
sickness,	  is	  able	  to	  take	  up	  choline	  from	  the	  culture	  medium	  to	  use	  for	  PC	  synthesis,	  indicating	  that	  
trypanosomes	  express	  a	  transporter	  for	  choline	  at	  the	  plasma	  membrane.	  Further	  characterization	  in	  
procyclic	  and	  bloodstream	  forms	   revealed	   that	  choline	  uptake	   is	   saturable	  and	  can	  be	   inhibited	  by	  
HC-­‐3,	  a	  known	  inhibitor	  of	  choline	  uptake	  in	  mammalian	  cells.	  	  
To	  obtain	  additional	  insights	  on	  choline	  uptake	  and	  metabolism,	  we	  investigated	  the	  effects	  
of	   choline-­‐analogs	   that	   were	   previously	   shown	   to	   be	   toxic	   for	   T.	   brucei	   parasites	   in	   culture.	  
Interestingly,	   we	   found	   that	   all	   analogs	   tested	   effectively	   inhibited	   choline	   uptake	   into	   both	  
bloodstream	  and	  procyclic	   form	  parasites.	  Subsequently,	   selected	  compounds	  were	  used	   to	  search	  
for	   possible	   candidate	   genes	   encoding	   choline	   transporters	   in	   T.	   brucei,	   using	   an	   RNAi	   library	   in	  
bloodstream	  forms.	  We	  identified	  a	  protein	  belonging	  to	  the	  mitochondrial	  carrier	  family,	  previously	  
annotated	  as	  TbMCP14,	  as	  prime	  candidate.	  Down-­‐regulation	  of	  TbMCP14	  by	  RNAi	  prevented	  drug-­‐
induced	   loss	   of	   mitochondrial	   membrane	   potential	   and	   conferred	   8-­‐fold	   resistance	   of	   T.	   brucei	  
bloodstream	  forms	  to	  choline	  analogs.	  Conversely,	  over-­‐expression	  of	  the	  carrier	  increased	  parasite	  
susceptibility	   more	   than	   13-­‐fold.	   However,	   subsequent	   experiments	   demonstrated	   that	   TbMCP14	  
was	  not	  involved	  in	  metabolism	  of	  choline.	  Instead,	  growth	  curves	  in	  glucose-­‐depleted	  medium	  using	  
RNAi	  or	  knock-­‐out	  parasites	   suggested	   that	  TbMCP14	   is	   involved	   in	  metabolism	  of	  amino	  acids	   for	  
energy	  production.	  Together,	  our	  data	  demonstrate	  that	  the	  identified	  member	  of	  the	  mitochondrial	  
carrier	   family	   is	   involved	   in	  drug	  uptake	   into	   the	  mitochondrion	  and	  has	   a	   vital	   function	   in	  energy	  
production	  in	  T.	  brucei.	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Preface	  
Trypanosomes	  are	  extraordinary	  organisms.	  Several	  features	  about	  their	  (structural)	  biology	  
and	   biochemistry	   attracted	   my	   curiosity,	   such	   as	   the	   fascinating	   structure	   and	   dynamics	   of	   the	  
kinetoplast	   (see	   [1]	   for	   a	   stimulating	   review	   on	   this	   topic).	   By	   accident,	   the	   mitochondrion	   of	  
Trypanosoma	   brucei	   became	   a	   major	   field	   of	   interest	   during	   my	   thesis	   when	   I	   discovered	   that	   a	  
mitochondrial	   carrier	   protein	  mediated	   the	   action	   of	   trypanocidal	   choline	   analogs,	   allowing	  me	   to	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1.	  Introduction	  
1.1	  Heavy	  burden	  for	  African	  countries	  
African	   Trypanosomiases	   include	   human	   and	   animal	   diseases	   that	   are	   caused	   by	  
trypanosomes.	  The	  animal	  form	  of	  the	  disease	  is	  called	  “Nagana”,	  which	  in	  Zulu	  means	  “powerless”	  
or	   “low	   in	   spirit”,	   and	   is	   caused	   by	   T.	   congolense,	   T.	   vivax	  or	   T.	   brucei.	   The	   infection	   causes	  mild	  
symptoms	  in	  wild	  animals	  while	  domesticated	  animals	  often	  suffer	  from	  a	  more	  aggressive	  form	  of	  
Nagana,	   which	   is	   often	   fatal	   if	   not	   treated.	   Human	   African	   Trypanosomiasis	   (HAT)	   is	   known	   as	  
sleeping	   sickness	   and	   occurs	   in	   two	   different	   forms:	   the	   chronic	   form	   is	   caused	   by	   T.	   brucei	  
gambiense	   and	   is	  distributed	   in	  Northern	  and	  Western	  Africa.	   It	   is	   responsible	   for	  90%	  of	   cases	  of	  
sleeping	  sickness	   [2].	  The	  acute	   form	   is	  caused	  by	  T.	  brucei	   rhodesiense,	  prevalent	   in	  Southern	  and	  
Eastern	  Africa	  and	  being	  responsible	  for	  10%	  of	  cases	  of	  sleeping	  sickness	  [2].	  The	  distribution	  of	  HAT	  
corresponds	  to	  the	  range	  of	  the	  insect	  vector,	  the	  tsetse	  fly,	  and	  includes	  36	  countries	  in	  sub-­‐Saharan	  
Africa,	  with	  approximately	  70	  million	  people	   in	  a	   surface	  of	  1.55	  million	  km2	  being	  at	  moderate	   to	  
very	  high	  risk	  of	  contracting	  HAT	  [3].	  	  
	  	   Together,	  sleeping	  sickness	  and	  Nagana	  represent	  a	  very	  heavy	  burden	  to	  the	  development	  
of	  rural	  areas	  of	  Africa.	  The	  human	  disease	  reduces	   labor	  resources	  and	  the	  animal	  related	  disease	  
deprives	   the	   human	   population	   from	   meat,	   milk,	   and	   draught	   animal	   power.	   The	   Food	   and	  
Agriculture	  Organization	  (FAO)	  estimates	  that	  Africa	  loses	  annually	  an	  equivalent	  of	  US$	  1.5	  billion	  in	  
income	  from	  agriculture	  as	  a	  result	  of	  African	  Trypanosomiases	  [4].	  No	  vaccines	  are	  available	  against	  
HAT,	   primarily	   because	   T.	   brucei	   bloodstream	   forms	   are	   elegantly	   elusive	   to	   recognition	   by	   the	  
immune	  system	  by	  constantly	  changing	  the	  expression	  of	  surface	  proteins	  (see	  Chapter	  1.5).	  
1.2	  Life	  cycle	  of	  T.	  brucei	  
T.	  brucei	   are	  dixenous	  parasites,	   i.e.	  parasites	  having	  with	  a	   life	   cycle	   in	   two	  different	  host	  
species.	  First,	  the	  tsetse	  fly	  from	  genus	  Glossina	  ssp.	  and	  invertebrate	  host	  of	  T.	  brucei,	  takes	  a	  blood	  
meal	  from	  an	  infected	  mammalian	  ingesting	  a	  tsetse-­‐infective	  form,	  called	  stumpy	  because	  of	  their	  
morphology.	   Stumpy	   forms,	   which	   are	   not	   proliferative,	   starts	   differentiation	   into	   procyclic	   forms	  
inside	  the	  midgut	  of	  the	  fly	   in	  order	  to	  guarantee	  their	  survival	  (Figure	  1).	  This	   is	  the	  establishment	  
stage	   of	   tsetse	   infection,	   in	  which	   the	   procyclic	   forms	   escape	   from	  digestion	   and	   proliferate	   [5,6].	  
When	  conditions	  are	  favorable,	  procyclic	  forms	  migrate	  to	  the	  salivary	  glands	  of	  a	  tsetse	  and	  undergo	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infective	   form	   called	   metacyclic.	   Metacyclics	   are	   non-­‐proliferative,	   and	   morphologically	   different	  
from	   procyclic	   forms	   and	   epimastigotes.	   During	   a	   second	   blood	   meal,	   metacyclic	   forms	   are	  
inoculated	  into	  a	  mammalian	  host	  and	  develop	  into	  another	  blood	  stage,	  called	  long	  slender	  form	  [7]	  
(Figure	   1).	   Long	   slender	   parasites	   are	   replicative	   forms	   able	   to	   express	   a	   pool	   of	   variant	   surface	  
glycoproteins.	  	  
	  
Figure	   1.	   T.	   brucei	   life	   cycle.	   The	   cycle	   starts	   when	   tsetse-­‐infective	   ‘short’	   stumpy	   forms	   (a)	   are	  
ingested	  by	   the	   fly	  and	  differentiates	   into	  procyclic	   forms	   (b).	   Inside	   the	   fly’s	  midgut,	   the	  procyclic	  
forms	   continue	   differentiation	   into	   epimastigotes	   (c)	   and	   to	   metacyclic	   (d)	   forms.	   When	   a	   new	  
mammalian	   is	   bitten,	   the	   metacyclic	   forms	   enter	   in	   bloodstream	   and	   differentiates	   into	   the	  
replicative	   ‘long’	   slender	   forms	   (e),	   which	   differentiates	   into	   an	   intermediate	   stage	   (f)	   before	  
becoming	   ‘short’	   stumpy	  again	   (a)	   [6].	   The	  blue	   line	   surrounding	   the	   cell	   body	   represents	   the	  VSG	  
coat.	   Notice	   the	   mitochondrion	   development	   from	   f	   to	   b.	   Copied	   on	   03.03.14,	   08:30	   am	   from:	  
http://www.ilri.org/InfoServ/Webpub/fulldocs/Ilrad90/Trypano.htm	  .	  
	  
1.3	  Treatment	  of	  Nagana	  and	  sleeping	  sickness	  
Treatment	  of	  Nagana	   is	   commonly	  based	  on	  carcinogenic	  drugs	   like	  ethidium	  bromide	  and	  
isometamidium	   chloride,	   which	   can	   compromise	   the	   meat	   used	   for	   human	   consumption	   if	   not	  
carefully	   administrated.	   In	   addition,	   suramin	   and	   diminazene	   aceturate,	   both	   with	   considerable	  
toxicity	   to	   cattle,	   are	   used	   for	   treatment	   [8].	   There	   are	   five	   approved	   drugs	   to	   treat	   HAT	   [9].	  
Pentamidine	   and	   suramin	   are	   used	   in	   a	   first	   stage	   when	   parasites	   are	   still	   present	   in	   the	  
hemolymphatic	  tissue.	  The	  second	  stage	  is	  characterized	  by	  the	  invasion	  of	  parasites	  into	  the	  central	  
nervous	  system	  (CNS)	  and	  is	  treated	  with	  melarsoprol	  or	  combinations	  of	  nifurtimox	  and	  eflornithine	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most	  toxic	  of	  all	  causing	  encephalopathies	  in	  5%	  of	  cases.	  Moreover,	  there	  are	  well-­‐known	  examples	  
of	  cross-­‐resistance	   in	  the	  field	  [10,11]	  demonstrating	  that	  development	  of	  resistant	  strains	   is	  a	  real	  
threat.	  Hence,	  additional	  efforts	  to	  optimize	  the	  treatment	  of	  sleeping	  sickness	  and	  to	  develop	  new	  
drugs	  are	  needed.	  However,	  despite	  new	  research	  technologies,	  development	  of	  novel	  and	  efficient	  
drugs	  is	  not	  an	  easy	  task.	  To	  illustrate	  this	  point,	   I’m	  going	  to	  describe	  some	  inspiring	  stories	  about	  
how	  the	  currently	  approved	  anti-­‐kinetoplastid	  drugs	  were	  discovered.	  
1.4	  Discovery	  of	  trypanocidal	  drugs	   	  
From	   1896	   to	   1906	   Africa	   faced	   a	   devastating	   epidemic	   of	   sleeping	   sickness	   that	   was	  
responsible	  for	  300’000-­‐500’000	  deaths	  in	  Congo,	  Uganda	  and	  Kenya	  [12].	  This	  terrible	  outcome	  led	  
various	  colonial	  administrations	  to	  ask	  scientists	  to	  develop	  a	  cure	  for	  sleeping	  sickness.	  At	  that	  time	  
the	   field	   of	  medicinal	   chemistry,	   i.e.	   identification,	   synthesis	   and	   development	   of	   therapeutic	   use,	  
was	  only	  emerging	  and	  used	  for	  the	  first	  time	  to	  seek	  for	  a	  new	  compound	  against	  sleeping	  sickness	  
[13].	  The	  development	  of	   the	   first	  anti-­‐kinetoplastid	   took	  advantage	  of	   the	  well-­‐advanced	  dyestuff	  
market	  in	  Germany	  and	  the	  talent	  of	  a	  visionary	  scientist,	  Paul	  Ehrlich,	  who	  was	  the	  first	  to	  use	  dyes	  
in	   the	  development	  of	   chemotherapies	   [13].	   In	   1901,	   Ehrlich	   tested	  more	   than	  100	   synthetic	   dyes	  
against	  T.	  equinum,	  causative	  of	  ‘mal	  de	  caderas’	  in	  equids,	  and	  T.	  b.	  brucei,	  resulting	  in	  the	  selection	  
of	  only	  one	  reactive	  dye,	  named	  Nagana	  red	  (Figure	  2)	  [13].	  The	  curative	  effects	  of	  Nagana	  red	  in	  T.	  
equinum-­‐infected	   mice	   was	   not	   satisfactory,	   which	   made	   Ehrlich	   hypothesize	   that	   this	   could	   be	  
explained	  by	  the	  low	  solubility	  of	  the	  compound.	  A	  few	  years	   later,	  a	  derivative	  of	  Nagana	  red	  was	  
synthesized	   by	   Ludwig	   Benda	   and	   Cassella	   Farbwerke	   and	   was	   named	   Trypan	   red	   [13].	   The	   new	  
compound	  was	  found	  to	  cure	  T.	  equinum-­‐infected	  mice,	  but	  was	  not	  active	  against	  other	  species	  of	  
Trypanosoma.	  In	  1906,	  the	  German	  pharmaceutical	  company	  Bayer	  took	  over	  the	  task	  to	  find	  a	  new	  
trypanocidal	  compound	  and	   identified	  a	  blue	  dye	  named	  as	  Trypan	  blue	   (Figure	  2)	   to	  be	  very	  toxic	  
against	  all	  species	  of	  trypanosomes	  [14,15].	  However,	  it	  was	  not	  suitable	  to	  treat	  humans	  because	  of	  
its	  side	  effect:	  the	  skin	  of	  patients	  was	  becoming	  blue.	  Only	   in	  1917,	  after	  screening	  between	  1000	  
naphtalene	  ureas	   a	   very	  promising	   compound	  was	   selected	  and	   tested,	   showing	   to	  be	  effective	   in	  
eliminating	  trypanosomes	  in	  animal	  and	  humans	  [16].	  The	  drug	  was	  re-­‐named	  suramin	  (Figure	  2)	  and	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Figure	   2.	   Chemical	   structures	   of	   sulphated	   naphthylamine	   derivatives	  with	   trypanocidal	   activities.	  
Suramin	  is	  the	  oldest	  approved	  drug	  against	  HAT,	  it	  still	  in	  use	  to	  treat	  the	  first	  stage	  of	  the	  disease.	  
Adapted	  figure	  reproduced	  from	  Steverding	  2010	  [13].	  
	  
Arsenicals	  were	  first	  mentioned	  to	  exert	  curative	  properties	  by	  missionary	  David	  Livingston	  
who	  recommended	  Fowler’s	  Solution	  (a	  solution	  of	  1%	  potassium	  arsenite)	  to	  treat	  sleeping	  sickness	  
[13].	   In	   1902,	   Charles	   Louis	   Alphonse	   Laveran,	   a	   French	   physician	   who	   discovered	   the	   malaria	  
parasite,	   and	   the	   French	   zoologist	   Felix	   Mesnil	   reported	   that	   sodium	   arsenite	   was	   effective	   in	  
clearing	   trypanosomes	   from	   infected	   laboratory	   animals	   despite	   the	   fact	   that	   few	   days	   later	  
parasitaemia	   increased	   again	   and	   caused	   death	   of	   the	   experimental	   animals	   [17].	   Few	   other	  
arsenicals	  were	   tested	   during	   subsequent	   years,	   one	   of	   them	   being	   atoxyl	   (Figure	   3)	   [18],	   initially	  
believed	   to	   have	   marginal	   toxicity	   to	   humans,	   but	   later	   proved	   wrong	   by	   Robert	   Koch	   [13].	   A	  
promising	  derivative	  of	  atoxyl,	  arsenophenylglycine	  (Figure	  3),	  was	  tested	  in	  humans	  in	  1907	  and	  was	  
shown	   to	   be	   effective	   and	   safe,	   except	   in	   a	   low	   number	   of	   patients	   who	   developed	   a	   strong	  
hypersensitive	  reaction	  [13,19].	  In	  the	  same	  period,	  Paul	  Ehrlich	  obtained	  another	  analog	  of	  atoxyl	  as	  
an	  attempt	   to	   improve	  chemotherapeutic	  properties	   to	   treat	   sleeping	  sickness	  but	   this	   time,	   there	  
was	  no	  trypanocidal	  activity.	  However,	  a	  short	  time	  later,	  Ehrlich	  and	  his	  collaborator,	  Satachito	  Hata,	  
showed	   that	   the	   same	   atoxyl	   analog	  was	   effective	   against	   syphilis	   and	   it	   became	   the	   first	   reliable	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saves”.	   In	  1919,	   two	  American	  scientists	   synthesized	   tryparsamide	   (Figure	  3),	  a	  derivative	  of	  atoxyl	  
and	  the	  first	  effective	  drug	  against	  the	  second	  stage	  of	  sleeping	  sickness	  [20].	  In	  spite	  of	  toxic	  effects	  
on	  optical	  nerves	  of	  patients,	   tryparsamide	  was	  used	  until	  1960s	   [13].	   It	  was	  1938	  when	   the	  Swiss	  
pathologist,	  microbiologist	  and	  chemist	  Ernst	  Friedheim	  synthesized	  melarsen,	  a	  melamide	  derivative	  
of	  atoxyl,	  which	  later	  was	  combined	  with	  dimercaprol,	  an	  antidote	  used	  against	  poisoning	  by	  arsenic	  
gas,	  to	  generate	  melarsoprol	  (Figure	  3)	  [13,21].	  The	  main	  advantage	  of	  melarsoprol	  was	  that	  it	  didn’t	  
affect	   the	   optic	   nerve,	   however,	   it	   caused	   reactive	   encephalopathies	   in	   5%	   of	   patients,	  with	   1-­‐5%	  
mortality	   [6].	   Melarsoprol	   is	   still	   the	   only	   effective	   drug	   to	   treat	   the	   second	   stage	   of	   T.	   brucei	  
rhodesiense	  sleeping	  sickness.	  
	  
	  
Figure	  3.	   Chemical	   structures	  of	   arsenicals	  with	   trypanocidal	   activity.	  Only	  melarsoprol	   is	   currently	  
used	  in	  the	  treatment	  of	  second	  stage	  of	  HAT.	  Adapted	  figure	  reproduced	  from	  Steverding	  2010	  [13].	  
	  
As	  early	  as	  1929,	  an	  innovative	  method	  to	  cultivate	  trypanosomes	  for	  short	  times	  led	  to	  the	  
discovery	   that	   this	   parasite	   uses	   large	   amounts	   of	   glucose	   for	   normal	   growth	   [22].	   Additionally,	  
trypanosome-­‐infected	  animals	   treated	  with	   insulin	  were	  shown	  to	   live	   longer	  and	  showed	  reduced	  
parasitaemia	  [23].	  As	  a	  result	  of	  this	  observation,	  a	  search	  for	  compounds	  able	  to	  reduce	  glycaemia	  
led	   to	   the	   discovery	   of	   the	   trypanocidal	   effect	   of	   a	   diamidine,	   called	   synthalin	   (Figure	   4)	   [13,24].	  
However,	  the	  effect	  against	  trypanosomes	  was	  later	  shown	  to	  be	  due	  to	  the	  toxic	  effect	  of	  synthalin	  
itself	  and	  not	  because	  of	  the	  hypoglycemic	  action	  [25].	  As	  a	  result,	  a	  large	  number	  of	  diamidines	  was	  
synthesized	   and	   tested	   against	   trypanosomes,	   leading	   to	   the	   discovery	   of	   the	   highly	   trypanocidal	  
compounds	   pentamidine	   and	   stilbamidine	   (Figure	   4)	   [26,27].	   This	   improved	   action	   against	  
trypanosomes	  was,	  in	  part,	  due	  to	  the	  replacement	  of	  the	  polymethylene	  group,	  present	  in	  synthalin,	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discontinued,	  whereas	   pentamidine	   is	   still	   used	   against	   the	   first	   stage	   of	  T.	   b.	   gambiense	   sleeping	  
sickness.	  
	  
Figure	   4.	   Chemical	   structures	   of	   diamidines	  with	   trypanocidal	   activity.	   Adapted	   figure	   reproduced	  
from	  Steverding	  2010	  [13].	  
	  
Eflornithine	   (Figure	   5)	  was	   initially	   developed	   in	   the	   1970s	   as	   a	   potential	   anti-­‐cancer	   drug	  
[28,29].	  Only	  later	  it	  was	  found	  to	  cure	  T.	  b.	  brucei	  infections	  in	  murine	  models	  without	  any	  apparent	  
side	  effects	   [30].	  Eflornithine	   is	  known	  to	   irreversibly	   inhibit	   the	  activity	  of	  ornithine	  decarboxylase	  
[29],	   the	   first	   enzyme	   involved	   in	   polyamine	   biosynthesis.	   This	   inhibition	   causes	   depletion	   of	  
putrecine	   and	   spermidine,	   leading	   to	   reduced	   levels	   of	   trypanothione,	   an	   essential	   antioxidant	   in	  
trypanosomes	   [31].	   In	   1990,	   eflornithine	   was	   approved	   for	   the	   treatment	   of	   HAT	   caused	   by	   T.	   b.	  
gambiense	  and	  is	  currently	  the	  only	  treatment	  available	  for	  melarsoprol-­‐refractory	  sleeping	  sickness.	  
Interestingly,	   it	  has	  been	  shown	  that	  efflornithine	   is	  not	  active	  against	  T.	  b.	  rhodesiense	  due	  to	  the	  
rapid	  turnover	  of	  ornithine	  decarboxylase	  in	  this	  sub-­‐species,	  with	  a	  half-­‐time	  of	  4.3	  h	  compared	  to	  
18-­‐19	   h	   in	   T.	   b.	   gambiense	   [32].	   In	   2009,	   the	   combination	   of	   eflornithine	   and	   nifurtimox,	   a	  
trypanosomal	  drug	  initially	  used	  only	  against	  T.	  cruzi,	  was	  approved	  to	  treat	  the	  second	  stage	  of	  T.	  b.	  
gambiense	   sleeping	  sickness	   [33].	  This	  combination	   therapy	  resulted	   in	  a	  cheaper,	   safer	  and	  easier	  





	   13	  
	  
Figure	   5.	   Chemical	   structures	   of	   eflornithine	   and	   nifurtimox,	   both	   used	   as	   a	   combination	   therapy	  
against	   second	   stage	   of	   T.	   b.	   gambiense	   sleeping	   sickness.	   Adapted	   figure	   reproduced	   from	  
Steverding	  2010	  [13].	  
	  
1.5	  Antigenic	  variation,	  the	  reason	  for	  chemotherapy 
	  	   By	  definition,	  antigenic	  variations	  are	  changes	  in	  antigenic	  identity	  occurring	  more	  frequently	  
than	  random	  mutation	  rates	   [34].	  The	  concept	  of	  antigenic	  variation	   in	  Trypanosoma	   research	  was	  
better	  accepted	  after	  the	  practical	  observation	  of	  waves	  of	  parasitaemia	  during	  T.	  brucei	   infections	  
published	  in	  1910	  [35].	  This	  observation	  was	  only	  possible	  after	  the	  development	  of	  better	  methods	  
to	   count	  parasites	  and	  permitted	   the	   link	  between	  waves	  of	  parasitaemia	  and	  waves	  of	   fever	   that	  
occur	  during	  sleeping	  sickness	  [5].	  
	  As	  an	  extracellular	  parasite,	  T.	  brucei	   is	  unable	  to	  hide	  from	  the	  mammalian	   immune	  system.	  As	  a	  
result	  of	  this	  evolutionary	  pressure,	  parasites	  have	  developed	  the	  keen	  strategy	  of	  antigenic	  variation	  
to	  escape	   from	  death	  by	   the	   immune	   response.	  This	  process	   is	  based	  on	  changes	   in	   the	  parasite’s	  
surface	   coat,	  which	   constitutes	  with	   >95%	  of	   a	   particular	   type	  of	   glycoprotein,	   the	   variant	   surface	  
glycoprotein	   (VSG).	   A	   single	   type	  of	   VSG	   is	   expressed	   at	   a	   time	   from	  a	   repertoire	   of	   an	   estimated	  
1000	   genes	   [36].	   The	   active	   expression	   site	   of	   VSG	   is	   called	   bloodstream	   expression	   site	   (BES)	   or	  
metacyclic	  expression	  site	   (MES),	  depending	  on	  the	  parasite	  stage	  the	  activation	  has	  occurred.	  The	  
sites	  are	  present	  in	  telomeric	  regions	  of	  chromosomes.	  In	  the	  case	  of	  BES,	  there	  are	  an	  estimated	  20-­‐
40	   repeats	   in	   the	  genome.	  Each	  one	  produces	  a	  single	  polycistronic	   transcription	  unit	  of	  dozens	  of	  
kilobases	   [34],	   which	   also	   contains	   several	   other	   genes	   named	   expression-­‐site-­‐associated	   genes	  
(ESAGs)	  [36].	  At	  any	  given	  time	  only	  one	  expression	  site	  is	  activated	  and	  only	  one	  VSG	  is	  transcribed.	  
Therefore,	  trypanosomes	  have	  two	  possible	  mechanisms	  to	  change	  VSG	  expression.	  They	  can	  either	  
replace	  the	  VSG	  gene	  within	  the	  active	  expression	  site	  or	  use	  a	  different	  expression	  site	  to	  produce	  a	  
different	  VSG	  molecule	  [34].	  Thus,	  the	  variety	  of	  possible	  antigens	  expressed	  in	  trypanosomal	  surface	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trypanosomal	   antigens	   in	   the	   course	   of	   infection.	  T.	   brucei	   takes	  much	   shorter	   time	   to	   change	   its	  
pool	  of	  antigens	  than	  the	  immune	  system	  to	  mount	  and	  exert	  a	  specific	  response	  against	  them.	  As	  a	  
result,	  parasites	  that	  still	  expressing	  previous	  types	  of	  antigens	  are	  killed	  by	  the	  host	  defense	  but	  a	  
minority	  of	  parasites	  expressing	  a	  new	  type	  of	  antigen	  will	  replicate	  without	  being	  recognized	  by	  the	  
immune	  system	  (Figure	  6).	  
	  
Figure	  6.	  Waves	  of	  parasitaemia	  caused	  by	  antigenic	  variation.	  By	  the	  time	  the	  immune	  system	  of	  the	  
mammalian	  host	  mounted	  an	  efficient	   response	  against	  T.	   brucei,	   some	  parasites	   are	  expressing	  a	  
different	   type	   of	   surface	   antigen	   and	   are	   able	   to	   grow	   without	   interference	   until	   a	   new	   immune	  
response	  is	  mounted.	  	  Downloaded	  from	  [37].	  	  
1.6	  Trypanosomatidae	  diversity	  
According	   to	   a	   recent	   review	   [38],	   the	   identification	   of	   trypanosomatids	   in	   insects	   was	  
documented	   for	   the	   first	   time	   in	   1851	   by	   Burnett	   [39],	   and	   the	   first	   genera,	   Leptomonas	   and	  
Herpetomonas,	  were	  established	  in	  1880	  by	  Kent	  [40].	  It	  was	  1895	  when	  the	  Scottish	  pathologist	  and	  
microbiologist	   Sir	  David	  Bruce	  described	  T.	  brucei	   as	   the	  causative	  of	   cattle	  Nagana	  demonstrating	  
the	  veterinary	  relevance	  of	  trypanosomatids	  [12],	   leading	  to	  the	  subsequent	  discovery	  of	  the	  agent	  
of	  sleeping	  sickness	  in	  1909	  [41].	  In	  1903,	  another	  Scottish	  pathologist,	  William	  Leishman,	  reported	  a	  
case	   of	   a	   soldier	   who	   served	   at	   Dum	   Dum,	   in	   the	   British	   India,	   and	   died	   in	   a	   state	   of	   gross	  
emancipation	  and	  enlargement	  of	   the	  spleen	  [42,43].	   In	  this	  case,	  Leishman	  could	  detect	  unknown	  
parasites	   in	   slide	   preparations	   of	   spleen	   taken	   post	   mortem.	   In	   the	   same	   year,	   the	   physiologist	  
Charles	  Donovan	   found	   the	   same	  parasites	   in	   several	  patients	  with	  enlarged	   spleen	  and	   the	  name	  
Leishmania	  donovani	  was	  then	  suggested	  [44].	  In	  1904,	  L.	  donovani	  was	  accepted	  by	  most	  scientists	  
as	  a	  new	  species	  of	  trypanosomatid	  and	  found	  to	  be	  the	  causative	  agent	  of	  kala	  azar,	  an	  intermittent	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unequivocally	   identified	   as	   the	   vector	   for	   kala	   azar	   [46].	   A	   third	   pathogenic	   trypanosomatid	   was	  
found	   in	   late	  1907,	  when	   the	  Brazilian	  physician	  Carlos	  Chagas	  was	   coordinating	  prophylactic	   anti-­‐
malarian	   campaigns	   in	  Minas	  Gerais	   and	   heard	   about	   a	   blood-­‐sucking	   ‘barber	   bug’,	   because	   of	   its	  
predilection	  for	  biting	  victim’s	  face.	  Chagas	  found	  a	  new	  species	  of	  trypanosome	  in	  the	  hindgut	  of	  the	  
bug	  and,	  soon	  afterwards,	  the	  same	  parasite	  was	  found	  in	  the	  blood	  of	  a	  small	  girl	  as	  well	  as	  her	  cat’s	  
blood	   [47,48].	   In	   subsequent	   analyses,	   Chagas	   succeeded	   in	   reproducing	   the	   infection	   in	   small	  
animals	   and	   in	   recovering	   and	   identifying	   these	   parasites	   from	   these	   animals.	   This	   was	   the	   first	  
description	  of	  the	  causative	  agent	  of	  American	  trypanosomiasis,	  Trypanosoma	  cruzi,	  named	  after	  his	  
friend	  and	  mentor,	  Oswaldo	  Cruz.	  By	   reading	   the	  historical	   records,	   I	   realized	   that	  Chagas’	  work	   is	  
one	  of	  the	  most	  complete	  and	  detailed	  descriptions	  of	  a	  new	  pathogen	  together	  with	  the	  consequent	  
pathology	  in	  the	  history	  of	  science.	  In	  the	  year	  1909,	  Chagas	  published	  the	  systematic	  description	  of	  
the	   parasite	   and	   its	   development	   in	   the	   vector,	   the	   clinical	   development	   of	   T.	   cruzi	   in	   the	  
intermediate	   and	   definitive	   hosts,	   his	   attempts	   to	   culture	   the	   parasite	   in	   the	   laboratory	   and	   the	  
course	   of	   infection	   in	   experimental	   animals	   [49,50].	   Two	   years	   later,	   he	   published	   a	   complete	  
description	  of	  the	  human	  pathology	  known	  as	  Chagas’	  disease	  [51].	  	  
By	  mid-­‐1960s,	  Hoare	  and	  Wallace	  used	  peculiarities	  in	  morphology	  and	  life	  cycle	  to	  redefine	  
the	  taxonomic	  system	  of	  Trypanosomatidae	  [52].	  Currently,	  the	  number	  of	  named	  species	  of	   insect	  
trypanosomatids	  is	  close	  to	  400	  [38],	  although	  this	  number	  is	  certainly	  underestimated.	  A	  study	  from	  
2001	   analyzed	   2’500	   insect	   hosts	   and	   found	   a	   few	   hundred	   of	   new	   presumptive	   species	   of	  
trypanosomatids,	   supporting	   that	   the	   group	   is	   immensely	   diverse	   [53].	   Nonetheless,	   from	   the	   12	  
potential	   subfamilies	  of	   trypanosomes	  proposed	   in	  Maslov	  et	  al.	   [38],	  all	  of	   them	  are	   infectious	   to	  
insects	   (with	   few	  exceptions:	   see	  Chapter	  1.7)	  but	  only	   two	   include	  agents	  of	  human	  diseases,	   i.e.	  
Trypanosoma	  clade	  and	  Leishmaniinae	  subfamily	  [38],	  showing	  that	  evolution	  of	  trypanosomatids	  is	  
closely	   connected	   to	   their	   insect	   hosts.	   However,	   an	   impressive	   example	   of	   the	   plasticity	   of	  
trypanosomes	  is	  the	  existence	  of	  monoxenic	  species	  that	  lost	  their	  capacity	  to	  infect	  the	  invertebrate	  
host,	   becoming	   infectious	   only	   to	  mammals;	   these	   are	  T.	   equiperdum,	   causative	   agent	   of	   a	   horse	  
disease	  called	  dourine,	  and	  T.	  evansi,	  a	  pathogenic	  parasite	  able	  to	   infect	  many	  different	  mammals	  
causing	  a	  disease	  most	  frequently	  known	  as	  surra.	  	  
1.7	  Dyskinetoplastic	  (DK)	  trypanosomes	  
T.	  evansi	  and	  T.	  equiperdum	  have	  adapted	  to	  live	  without	  parts	  or	  the	  whole	  mitochondrial	  
DNA	   (kinetoplast,	   kDNA);	   thus,	   they	  are	  known	  as	  dyskinetoplastic	   (DK)	   trypanosomes.	  Since	   there	  
are	  no	  vectors	  spreading	  the	   infection	  of	  these	  two	  agents,	  they	  are	  mechanically	  transmitted,	  and	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equiperdum	   is	  mainly	   by	   sexual	   route	   and	  T.	   evansi	   by	   biting	   flies	   [55].	   The	   natural	   emergence	   of	  
these	   two	   species	   stimulates	   discussions	   in	   the	   field	   of	   evolution	   of	   trypanosomes,	   e.g.	   there	   are	  
diverging	  opinions	  whether	  or	  not	  T.	  equiperdum	  and	  T.	  evansi	  should	  be	  considered	  sub-­‐species	  of	  
T.	  brucei	   [54,56].	  Nevertheless,	  the	  study	  of	  these	  atypical	  species	  of	  trypanosomes	  brought	  recent	  
astonishing	  results	  that	  are	  contributing	  to	  the	  understanding	  of	  not	  only	  evolutionary	  concepts	  but	  
also	  to	  the	  general	  biology	  of	  trypanosomes,	  mitochondrial	  function	  and	  drug	  development	  against	  
trypanosomiases.	   The	   mainstay	   for	   this	   breakthrough	   was	   caused	   by	   the	   discussion	   about	   the	  
function	   of	   kDNA	   in	   bloodstream	   form	   parasites	   [57]	   and	   how	   T.	   equiperdum	   and	   T.	   evansi	   have	  
naturally	   lost	   their	   kDNA	   [58].	   Since	   this	   topic	   is	   one	   of	   the	   most	   inspiring	   stories	   in	   the	   field	   of	  
trypanosomes,	  I	  would	  like	  to	  briefly	  cover	  it.	  
kDNA	  of	  T.	   brucei	   contains	   20-­‐50	   copies	   of	  maxicircles	   (∼23	   kb,	   Figure	   7),	  which	   encode	   a	  
typical	   set	   of	   rRNA	   and	   protein-­‐coding	   genes,	   including	   subunits	   of	   the	   respiratory	   chain	   [1,58].	  
Expression	   of	  most	   of	   genes	   present	   in	  maxicircles	   requires	   a	   unique	   form	   of	   post-­‐transcriptional	  
editing	  before	   translation	   in	   functional	  proteins	   [57].	  Guide	  RNAs	  are	   involved	   in	   regulation	  of	   this	  
individual	   editing	   and	   are	   encoded	   by	   minicircles	   of	   kDNA,	   which	   are	   structures	   of	   ∼1-­‐kb	   with	  
tremendous	  diversity	  in	  T.	  brucei	  (Figure	  7).	  
	  
	  
Figure	   7.	   Electron	  microscopy	   picture	   of	   an	   isolated	   kDNA	   network	   from	  Chritidia	   fasciculate.	   The	  
long	  strands	  of	  DNA	  are	  maxicircles	  and	  the	  small	  loops	  are	  minicircles.	  Reproduced	  from	  [1].	  Inset,	  
immunofluorescence	  picture	  (self-­‐taken)	  of	  procyclic	  form	  of	  T.	  brucei	  stained	  with	  DAPI	  illustrating	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T.	   equiperdum	   strains	   normally	   still	   contain	   their	  maxicircles	   but	   have	   lost	   their	  minicircle	  
diversity,	   while	   T.	   evansi	   strains	   don’t	   have	   maxicircles	   and	   can	   either	   present	   minicircle	  
homogeneity	  or	  are	  akinetoplastic	  (lost	  completely	  all	  kDNA)	  [54,58,59].	  Consequently,	  both	  species	  
are	  unable	  to	  express	  functional	  mitochondrial	  genes	  and	  differentiate	  into	  insect-­‐stage	  forms.	  	  
In	  contrast	  to	  T.	  equiperdum	  and	  T.	  evansi,	  the	  kDNA	  is	  essential	  for	  bloodstream	  forms	  of	  T.	  
brucei.	   The	   kDNA	   encodes	   for	   the	   subunit	   A6	   of	   the	   Fo	   component	   of	   F1Fo-­‐ATP	   synthase	   in	   the	  
mitochondrion	  [58].	  In	  bloodstream	  forms,	  the	  F1Fo-­‐ATP	  synthase	  is	  working	  in	  the	  reverse	  direction,	  
pumping	   protons	   from	   mitochondrial	   matrix	   to	   the	   intermembrane	   space	   generating	   the	  
mitochondrial	  membrane	  potential	  (ΔΨm)	  [60,61,62].	  Thus,	  although	  bloodstream	  form	  parasites	  do	  
not	   generate	   ATP	   via	   oxidative	   phosphorylation,	   they	   are	   still	   depending	   on	   F1Fo-­‐ATP	   synthase	   to	  
generate	  the	  ΔΨm	  [62,63].	  This	  raises	  an	   intriguing	  question:	  how	  can	  dyskinetoplastic	  parasites	  be	  
viable?	  The	  answer	  came	  years	  after	  the	  clever	  hypothesis	  discussed	   in	  [58],	  which	  was	  elaborated	  
based	   on	   two	   observations:	   I)	   drug-­‐induced	   dyskinetoplastic	   bloodstream	   form	   trypanosomes	   are	  
viable	  and,	  thus,	  still	  possess	  the	  ΔΨm	  necessary	  for	  mitochondrial	  function	  in	  T.	  brucei;	  and	  II)	  there	  
were	  examples	   in	  yeast	  and	  mammalian	  cells	   lacking	   the	  mitochondrial	  genome,	  and	  consequently	  
subunits	  of	  the	  ATP	  synthase,	  which	  were	  still	  able	  to	  generate	  a	  ΔΨm	  because	  of	  rare	  compensatory	  
mutations	   in	  nuclear-­‐DNA-­‐encoded	  subunits	  of	  the	  ATP	  synthase.	  Hence,	  Schnaufer	  et	  al.	  proposed	  
compensatory	  mutations	  might	   also	   be	   present	   in	   T.	   brucei	   to	   allow	   a	   functional	   ATP	   synthase	   in	  
absence	   of	   kDNA	   [58].	   Recently,	   and	   several	   years	   after	   the	   initial	   hypothesis,	   the	   very	   exciting	  
finding	   of	   Dean	   et	   al.	   elucidated	   the	   compensatory	   mechanism	   for	   the	   loss	   of	   kDNA	   [59].	   They	  
demonstrated	   that	   a	   point	   mutation	   in	   the	   nuclear-­‐DNA-­‐encoded	   gene	   of	   the	   γ subunit	   of	   the	   F1	  
component	   of	   F1Fo-­‐ATP	   synthase	   can	   compensate	   for	   complete	   loss	   of	   kDNA	   in	   T.	   brucei	   [59].	  
Furthermore,	  they	  established	  a	  potentially	  interesting	  strain	  of	  T.	  brucei	  that	  tolerates	  loss	  of	  kDNA	  
and	   can	   be	   used	   for	   the	   study	   of	   drug	   action,	   and	   essential	   mechanisms	   of	   replication	   and	  
maintenance	  of	  kDNA.	  In	  Chapter	  3.1	  of	  this	  thesis,	  I	  have	  used	  this	  cell	  line	  to	  investigate	  the	  mode	  
of	  action	  of	  choline	  analogs.	  
1.8	  Choline	  transport	  systems 
Trypanosomes	   need	   to	   build	  membranes	   to	   divide	   and	   keep	   proliferating.	   For	   this	   reason,	  
they	  need	  to	  scavenge	  lipid	  precursors	  in	   large	  amounts	  to	  synthesize	  membrane	  lipids.	  One	  of	  the	  
most	   required	   lipid	   precursors	   in	   eukaryotic	   cells	   is	   choline,	   which	   is	   used	   as	   a	   head	   group	   of	  
phosphatidylcholine	   (PC),	   an	  abundant	  membrane	  glycerophospholipid	   (covered	   in	   the	  next	   topic),	  
and	   of	   sphingomyelin	   (SM)	   [64].	   Therefore,	   as	   discussed	   later	   in	   this	   introduction,	   mechanisms	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describe	  in	  more	  details	  the	  different	  systems	  for	  choline	  uptake	  in	  human	  cells,	  the	  reference	  used	  
to	  initiate	  our	  studies	  on	  choline	  uptake	  in	  trypanosomes.	  
Choline	   is	   a	  quaternary	  amine	   (trimethyl-­‐β-­‐hydroxy-­‐ethylammonium,	  Figure	  8),	  which	   is	   an	  
essential	  nutrient	  for	  eukaryotic	  cells.	   In	  humans,	   it	  plays	  a	  role	  not	  only	   in	  the	  synthesis	  of	  PC	  and	  
SM	  but	  also	  as	  a	  methyl-­‐group	  donor	   in	  methionine	  metabolism	  [65]	  as	  well	  as	   in	   synthesis	  of	   the	  
neurotransmitter	  acetylcholine	  [66,67].	  Laboratory	  animals	  fed	  with	  a	  choline-­‐deficient	  diet	  develop	  
spontaneous	   carcinoma	  of	   the	   liver	   and	   generally	   increase	   sensitivity	   to	   carcinogens	   [68].	   It	   is	   the	  
only	  type	  of	  nutritional	  deficiency	  known	  to	  have	  such	  deleterious	  effect	  [69].	  
	  
Figure	  8.	  Chemical	  structure	  of	  choline.	  Taken	  from	  [70].	  
	  
As	  a	  positively	  charged	  quaternary	  ammonium,	  choline	  cannot	  cross	  biological	  membranes.	  
Characterization	   of	   choline	   uptake	   in	   human	   cells	   using	   radiolabeled	   choline	   and	   hemicholinium-­‐3	  
(HC-­‐3),	   the	   best	   characterized	   inhibitor	   of	   choline	   uptake	   [71],	   identified	   three	   different	   transport	  
systems:	   I)	   low-­‐affinity	   non-­‐specific	   transport,	   II)	   high-­‐affinity	   Na+-­‐dependent	   transport,	   and	   III)	  
intermediate-­‐affinity	   Na+-­‐independent	   transport	   [72].	   All	   three	   systems	   are	   carrier-­‐mediated,	   i.e.	  
they	  follow	  Michaelis-­‐Menten	  kinetics.	  
	   The	   low-­‐affinity	   non-­‐specific	   transport	   system	   is	   represented	   by	   the	   polyspecific	   organic	  
cation	  transporter	  (OCT)	  family,	  comprising	  of	   five	  members	  that	  are	  present	   in	  different	  organs	  of	  
the	  human	  body	  (Table	  1).	  OCT	  proteins	  are	  not	  specific	  for	  choline	  and	  are	  not	  sensitive	  to	  HC-­‐3.	  The	  
physiological	   role	   of	   OCT	   proteins	   in	   choline	   transport	   has	   not	   been	   firmly	   established.	   OCT1	  was	  
shown	  to	  transport	  choline	  when	  transiently	  expressed	  in	  HEK	  cells	  [73].	  Additionally,	  expression	  of	  
OCT1	  and	  OCT2	  in	  Xenopus	  oocytes	  mediated	  choline	  uptake	  with	  low	  affinity,	  i.e.	  with	  Km	  values	  of	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Table	  1.	  Different	  systems	  for	  choline	  transport	  in	  humans.	  Adapted	  from	  [72].	  
	  
The	   high-­‐affinity	   choline	   transport	   system	   has	   a	   Km	   value	   for	   choline	   at	   0.5-­‐3	   µM	   and	   is	  
sensitive	  to	  low	  concentrations	  of	  HC-­‐3,	  with	  Ki	  values	  at	  ∼1-­‐3	  µM	  [75]	  (Table	  1).	  In	  addition,	  choline	  
transport	   is	   energy-­‐	   and	   Na+-­‐dependent.	   High-­‐affinity	   choline	   transport	   is	   linked	   to	   acetylcholine	  
biosynthesis	   in	   neurons	   [76,77,78].	   The	   best-­‐known	   representative	   of	   this	   transport	   system	   in	  
humans	  is	  the	  protein	  named	  CHT1,	  which	  is	  expressed	  in	  cholinergic	  neurons	  [79,80].	  	  
The	  third	  transport	  system,	   intermediate-­‐affinity	  choline	  transport,	  has	  Km	  values	  of	  20-­‐200	  
µM	  and	  is	  less	  effectively	  inhibited	  by	  HC-­‐3,	  showing	  	  Ki	  values	  of	  20-­‐200	  µM.	  It	  is	  Na+-­‐independent	  
and	  demonstrates	  specificity	   to	  choline	   [72]	   (Table	  1).	   It	   is	   represented	  by	   the	  choline	   transporter-­‐
like	  (CTL)	  family,	  which	  includes	  five	  members	  (CTL1-­‐5),	  with	  CTL1	  being	  the	  most	  thoroughly	  studied	  
[81].	  CTL1	  was	   initially	  shown	  to	  restore	  choline	   transport	   in	  choline	   transport-­‐deficient	  yeast	   [82].	  
Furthermore,	   expression	   of	   Torpedo	   CTL1	   in	   Xenopus	   oocytes	   increased	   Na+-­‐independent	   high-­‐
affinity	   choline	   uptake	   [82].	   CTL	   proteins	   contain	   10	   highly	   conserved	   transmembrane	   domains	  
(TMDs),	  with	   their	  N-­‐	   and	  C-­‐termini	   likely	   localized	   intracellularly	   (Figure	  9).	   They	  are	  expressed	   in	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Figure	  9.	  Representation	  of	  mouse	  CTL1	  with	  10	  transmembrane	  domains	  with	  a	  large	  and	  variable	  
loop	  between	  transmembrane	  domains	  1	  and	  2,	  which	  is	  potentially	  glycosylated.	  Figure	  copied	  from	  
[72].	  
	  
To	  date,	   no	   choline	   transporter	  has	  been	   identified	   in	   any	  protozoa.	  However,	   it	   has	  been	  
demonstrated	   that	   acquisition	   of	   choline	   is	   carrier-­‐mediated	   in	   Plasmodium	   [83]	   and	   Leishmania	  
[84].	  Moreover,	  characterization	  of	  choline	  uptake	   into	  free	   intraerythrocytic	  stages	  of	  Plasmodium	  
falciparum	  indicated	  an	  intermediate-­‐affinity	  transport	  system	  (Km	  of	  ∼25	  µM)	  that	  does	  not	  depend	  
on	  sodium	  ions	  [83].	  In	  Leishmania	  major,	  uptake	  of	  choline	  was	  shown	  to	  be	  specific	  for	  choline	  with	  
a	   low	  micromolar	   Km	   (=2.5	   µM),	   and	   also	   Na+-­‐independent	   [84].	   Hence,	   some	   features	   of	   choline	  
transport	   in	  Plasmodium	   and	   Leishmania	   suggest	   the	   presence	   of	   a	   system	   related	   to	   the	   human	  
ubiquitous	   CTL	   proteins,	   i.e.	   a	   Na+-­‐independent,	   intermediate-­‐affinity	   choline	   uptake	   system	   [72].	  
Our	   work	   showed	   -­‐	   for	   the	   first	   time	   -­‐	   that	   a	   related	   system	   is	   also	   present	   in	   T.	   brucei	   [85].	  
Therefore,	   we	   reasoned	   that	   choline	   carrier	   in	   trypanosomes	   could	   be	   related	   to	   the	   human	   CTL	  
proteins	   and,	   by	   in	   silico	   search,	   we	   found	   several	   choline	   transporter	   candidates	   in	   T.	   brucei	  
genome.	  We	  empirically	   investigated	   the	  effect	  of	  down-­‐regulation	  of	   these	  candidates	  by	  RNAi	   in	  
different	   conditions	   and	   expressed	   some	   of	   them	   in	   heterologous	   systems	   but,	   unfortunately,	   the	  
results	  were	  inconclusive	  [85]	  (manuscript	  also	  found	  in	  Chapter	  2.1).	  	  
1.9	  Phosphatidylcholine	  (PC)	  biosynthesis	  in	  trypanosomes	  
Membrane	   lipids	   are	   divided	   in	   three	   major	   groups:	   I)	   phospholipids	   comprise	   of	  
glycerophospholipids,	  which	  are	  related	  to	  phosphatidic	  acid	  (Figure	  10),	  and	  sphingophospholipids;	  
II)	   sterols	   comprise	  of	   polycyclic	   compounds	   like	   cholesterol,	   the	  most	   abundant	   sterol	   in	   animals,	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presence	   of	   single	   or	   multiple	   sugar	   moieties,	   are	   not	   ubiquitous	   being	   present	   in	   more	  







Figure	  10.	  Chemical	  structure	  of	  phosphatidic	  acid,	  the	  precursor	  of	  glycerophospholipids.	  
	  
	  
The	  phospholipid	  composition	  of	  T.	  brucei	  bloodstream	  and	  procyclic	  forms	  is	  comparable	  to	  
that	   other	   eukaryotic	   cell.	   Phosphatidylcholine	   (PC)	   and	   phosphatidylethanolamine	   (PE)	   represent	  
the	   most	   abundant	   glycerophospholipids,	   comprising	   45–60%	   and	   10–20%,	   respectively,	   of	   total	  
phospholipids	   (Figure	   11).	   Phosphatidylinositol	   (PI),	   phosphatidylserine	   (PS)	   and	   cardiolipin	   (CL)	  
represent	  minor	  glycerophospholipid	  classes	  and	  account	  for	  6–12%,	  <4%	  and	  <3%,	  respectively	  [86].	  
Taken	  that	  into	  account,	  metabolism	  of	  PC,	  the	  most	  abundant	  phospholipid,	  is	  a	  critical	  process	  for	  
any	  fast	  growing	  eukaryotic	  cell,	  including	  trypanosomes.	  	  
	  
Figure	   11.	   Relative	   distribution	   of	   phospholipid	   classes	   phosphatidylcholine	   (PC),	  
phosphatidylethanolamine	  (PE),	  phosphatidylinositol	  (PI),	  phosphatidylserine	  (PS)	  and	  sphingomyelin	  
(SM),	  in	  T.	  brucei	  procyclic	  and	  bloodstream	  forms.	  Figure	  taken	  from	  [86].	  	  
	  
PC	   is	   synthesized	   by	   two	   different	   routes	   in	   trypanosomes:	   I)	   it	   can	   be	   formed	   using	   lyso-­‐
phosphatidylcholine	  (lyso-­‐PC)	  as	  a	  precursor,	  which	  is	  taken	  up	  and	  acylated	  to	  PC	  [87];	  or	  II)	  it	  can	  be	  
formed	   via	   the	   CDP-­‐choline	   branch	   of	   the	   Kennedy	   pathway	   [88]	   using	   choline	   and	   diacylglycerol	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   By	   definition,	   lyso-­‐phospholipids	   (lyso-­‐PLs)	   are	   characterized	   by	   a	   single	   acyl	   chain	   and	   a	  
polar	   head	   group,	   which	   in	   the	   case	   of	   lyso-­‐PC	   is	   choline.	   It	   has	   been	   demonstrated	   that	  
trypanosomes	   metabolize	   lyso-­‐PLs	   more	   rapidly	   than	   their	   corresponding	   phospholipids	   [90].	  
Possibly	   because	   of	   the	   simpler	   chemical	   structure	   of	   lyso-­‐PC,	   which	   renders	   these	   lipids	   more	  
hydrophilic	  and	  versatile	  compared	  to	  their	  corresponding	  phospholipids.	  Because	  the	  conversion	  of	  
lyso-­‐PC	   to	   PC	   is	   rapid	   (only	   one	   CoA-­‐dependent	   acylation	   is	   necessary,	   see	   Figure	   12)	   and	   high	  
concentrations	  of	  lyso-­‐PC	  is	  present	  in	  human	  blood	  (about	  200-­‐300	  µM	  [91,92],	  i.e.	  about	  10x	  higher	  
than	   free	   choline	   [93]),	   lyso-­‐PC	   is	   likely	   the	   main	   route	   for	   synthesis	   of	   PC	   in	   bloodstream	   form	  
parasites	  [89].	  In	  contrast,	  however,	  marginal	  uptake	  of	  choline	  has	  been	  shown	  in	  bloodstream	  form	  
trypanosomes	  isolated	  from	  rats	  [89].	  	  
Synthesis	  of	  PC	   from	   free	  choline	  occurs	  via	   the	  Kennedy	  pathway,	  named	  after	  Eugene	  P.	  
Kennedy,	   who,	   together	   with	   Samuel	   B.	  Weiss,	   first	   described	   this	   pathway	   as	   a	   crucial	   route	   for	  
biosynthesis	  of	  glycerophospholipids	  in	  all	  eukaryotic	  cells	  [88].	  The	  Kennedy	  pathway	  (Figure	  12)	  is	  
divided	   into	   two	  branches,	   the	  CDP-­‐choline	  branch	   that	   leads	   to	   the	   synthesis	  of	   PC	  and	   the	  CDP-­‐
ethanolamine	   branch,	   leading	   to	   PE	   synthesis.	   In	   the	   CDP-­‐choline	   branch,	   free	   choline	   is	  
phosphorylated	  by	  choline	  kinase	  and	  subsequently	  activated	  into	  CDP-­‐choline	  by	  choline-­‐phosphate	  
citidyltransferase.	  Finally,	  activated	  choline	   is	   transferred	  to	  diacylglycerol	  by	  choline/ethanolamine	  
phosphotransferase	   (CEPT),	   forming	   PC	   (Figure	   12).	   Note	   that	   CEPT	   has	   been	   characterized	   and	  
shows	   dual	   specificity	   for	   CDP-­‐choline	   and	   CDP-­‐ethanolamine,	   and	  was	   shown	   to	   be	   essential	   for	  
growth	   of	   T.	   brucei	   in	   culture	   [94].	   The	   CDP-­‐ethanolamine	   pathway	   involves	   the	   activity	   of	  
ethanolamine	   kinase	   and	   ethanolamine-­‐phosphate	   cytidylyltransferase	   to	   phosphorylate	  
ethanolamine	   and	  activate	   into	  CDP-­‐ethanolamine,	   respectively.	   Ethanolamine	  phosphotransferase	  
(EPT)	   catalyzes	   the	   final	   step	   leading	   to	   the	   formation	   of	   PE.	   Interestingly,	   PE	   produced	   by	   EPT	  
comprises	  of	  alk-­‐1-­‐enyl-­‐acyl-­‐type	  species	  whereas	  the	  synthesis	  of	  PE	  by	  CEPT	  produces	  diacyl-­‐type	  
species	  of	  PE	  (Figure	  12),	  suggesting	  that	  the	  two	  enzymes	  may	  be	  located	  in	  different	  compartments	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Figure	   12.	   Synthesis	   of	   PC	   and	   PE	   by	  T.	   brucei	   via	   Kennedy	   pathway.	   Substrates	   from	  CDP-­‐choline	  
branch	  is	  represented	  in	  gray	  and	  involved	  enzymes	  in	  orange.	  CDP-­‐ethanolamine	  branch	  is	  in	  green	  
and	  purple.	  CEPT	  shows	  dual	  specificity	  (orange	  and	  purple)	  with	  higher	  affinity	  to	  CDP-­‐choline.	  *Not	  
present	   in	   T.	   brucei.	   Abbreviations:	   CK,	   choline	   kinase;	   CCT,	   cholinephosphate	   cytidyltransferase;	  
CEPT,	   choline/ethanolamine	   phosphotransferase;	   EK,	   ethanolamine	   kinase;	   ET,	   ethanolamine	  
cytidyltransferase;	   ethanolamine	   phosphotransferase;	   PEMT,	   phosphatidylethanolamine	   N-­‐
methyltransferase;	   LPCAT,	   lysophosphatidylcholine	   acyltransferase;	   AAG,	   alk-­‐1-­‐enyl-­‐acylglycerol;	  
DAG,	  diacylglycerol.	  
	  
There	   is	   an	   alternative	   route	   to	   form	   PC	   that	   depends	   on	   the	   activity	   of	  
phosphatidylethanolamine	   N-­‐methyltrasferases,	   which	   catalyze	   the	   methylation	   of	   PE	   to	   PC	   [95]	  
(PEMT,	   Figure	   12).	   A	   homolog	   of	   this	   enzyme	   is	   present	   in	   Leishmania	   but	   so	   far	   it	   has	   not	   been	  
characterized	  experimentally	  [96].	  In	  contrast,	  no	  homolog	  has	  been	  found	  in	  the	  T.	  brucei	  genome.	  
In	  addition,	  labeling	  of	  T.	  brucei	  lipids	  using	  radiolabeled	  ethanolamine	  or	  serine	  did	  not	  result	  in	  the	  
formation	  of	  radioactive	  PC	  [94],	   indicating	  that	  trypanosomes	  do	  not	  have	  this	  pathway.	  Hence,	  T.	  
brucei	  likely	  relies	  only	  on	  the	  Kennedy	  pathway	  for	  de	  novo	  PC	  synthesis.	  
1.10	  Choline	  analogs:	  development	  and	  current	  knowledge	  
In	   trypanosomes,	  as	  well	  as	   in	  Plasmodium,	   there	   is	  a	  huge	  demand	   for	   lipid	  precursors	   to	  
permit	   parasite	   growth	   within	   the	   human	   host.	   As	   in	   trypanosomes,	   PC	   represents	   the	   most	  
abundant	  lipid	  in	  plasmodial	  membranes.	  Thus,	  pathways	  involved	  in	  PC	  synthesis	  are	  potential	  drug	  
targets	  against	  sleeping	  sickness	  and	  malaria.	  In	  Plasmodium-­‐infected	  erythrocytes,	  uptake	  of	  choline	  
is	   substantially	   increased	   compared	   to	   erythrocytes	   from	   healthy	   controls	   [97].	   Inhibition	   of	   this	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number	   of	   choline	   analogs	   have	   been	   screened	   for	   their	   potential	   to	   interfere	   with	   choline	  
metabolism	   and	   PC	   synthesis	   in	   Plasmodium	   (reviewed	   in	   [98]).	   The	   researchers	   involved	   in	   the	  
design	   and	   synthesis	   of	   these	   compounds	   chose	   a	   stepwise	   strategy	   of	   structure-­‐activity-­‐
relationships	  (SARs)	  to	  optimize	  the	  their	  potency	  and,	  in	  a	  later	  stage	  of	  the	  study,	  to	  promote	  their	  
pharmacodynamics	   in	   mammals	   [99].	   Along	   the	   study,	   a	   group	   of	   compounds	   classified	   as	   bis-­‐
quaternary	  ammonium	  salts,	  with	  the	  leading	  compound	  named	  G25	  (Figure	  13),	  was	  found	  to	  have	  
extremely	  high	  efficiency	  against	  Plasmodium,	  both	  in	  vitro	  [99]	  and	  in	  vivo	  [100].	  However,	  toxicity	  
and	  bioavailability	  of	  bis-­‐quaternary	  ammonium	  salts	   in	  mammals	  were	  not	  satisfactory.	  Therefore,	  
the	  quaternary	  ammonium	  ring	  was	  replaced	  by	  a	  thiazolium	  ring,	  present	  in	  Vitamin	  B1,	  to	  reduce	  
its	  toxicity	  and	  increase	  oral	  absorption,	   leading	  to	  the	  second	  generation	  of	  compounds	  called	  bis-­‐
thiazolium	  salts	  [101]	  (Figure	  13).	  In	  a	  new	  screening	  approach,	  two	  of	  these	  compounds,	  named	  T3	  
and	   T4,	   turned	   out	   to	   be	   superior	   to	   currently	   available	   anti-­‐malarials	   in	   animal	   studies	   [102].	   At	  
present,	  T3	   is	   in	  phase	   II	  of	   clinical	   trials	   since	  2008	   to	   treat	   severe	  malaria	   [103].	   Subsequently,	   a	  
third	  generation	  of	  compounds,	  including	  a	  group	  of	  2-­‐amino	  pyridinium	  salts	  and	  bis-­‐alkylamidines,	  
with	   the	   leading	   compounds	   being	  MS1,	   M38	   and	  M53,	   were	   designed	   to	   minimize	   side	   effects,	  
mainly	  in	  the	  CNS	  [104].	  	  
	  
Figure	  13.	  Chemical	  structures	  of	  anti-­‐malarial	  choline	  analogs.	  Adapted	  figured	  reproduced	  from	  
[70].	  
	  
The	   most	   accepted	   view	   of	   the	   mode	   of	   action	   of	   choline	   analogs	   in	   Plasmodium	   is	   the	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into	  the	  parasite	  [100,105,106,107].	  Additionally,	  there	  is	  evidence	  that	  bis-­‐thiazolium	  salts,	  T16	  [83]	  
and	   T3	   [103],	   are	   transported	   by	   the	   Plasmodium	   choline	   carrier.	   More	   recently,	   in	   vitro	   studies	  
showed	   that	   selected	  compounds	  belonging	   to	   the	  different	  groups	  of	   choline	  analogs	  also	  display	  
high	   toxicity	   to	   T.	   brucei	   bloodstream	   forms	   [70].	   The	   tests	   were	   also	   carried	   out	   using	   strains	  
resistant	  against	  diamidines	  and	  arsenicals	  and	  showed	  little	  or	  no	  significant	   increase	  in	  resistance	  
to	  choline	  analogs,	   indicating	  the	  absence	  of	  cross-­‐resistance	  [70].	  Phospholipid	  analyses	  suggested	  
that	   choline	   analogs	   didn’t	   affect	   the	   lipid	   content	   in	  T.	   brucei	   [70],	   contrasting	  with	   the	   reported	  
mode	  of	  action	  in	  Plasmodium.	  Very	  recently,	  our	  own	  work	  showed	  that	  certain	  choline	  analogs	  are	  
potent	   inhibitors	   of	   choline	   uptake	   in	   T.	   brucei	   [85],	   however,	   inhibition	   kinetics	   suggested	   that	  
choline	  uptake	  was	  not	  the	  main	  target	  of	  these	  compounds	  since	  they	  displayed	  high	  toxicity	  even	  
when	  used	   in	  much	   lower	   concentrations	   than	   the	   IC50	   values	   for	   inhibition	  of	   choline	  uptake	   [85]	  
(manuscript	   found	   in	   Chapter	   2.1).	   Alternatively,	   choline	   analogs	   were	   proposed	   to	   affect	  
mitochondria	  by	  decreasing	  the	  ΔΨm	  in	  T.	  brucei,	  leading	  to	  parasite	  death	  in	  culture	  [70].	  	  
1.11	  The	  mitochondrion	  of	  T.	  brucei	  
Stumpy	  form	  trypanosomes	  encounter	  a	  very	  different	  environment	  when	  they	  are	  taken	  up	  
from	  the	  mammalian	  host	  into	  the	  tsetse	  fly	  midgut.	  To	  adapt	  to	  the	  change	  in	  nutrient	  availability,	  
the	  rudimentary	  mitochondrion	  of	  bloodstream	  form	  trypanosomes	  undergoes	  dramatic	  alterations	  
during	   parasite	   differentiation	   to	   procyclic	   forms	   [108,109].	   The	   most	   striking	   change	   occurs	   in	  
mitochondrial	   energy	   production.	   Long	   slender	   bloodstream	   forms	   have	   a	   very	   simple	   energy	  
metabolism,	   relying	  mostly	   on	   glycolysis	   for	   ATP	   production	   [110,111].	   In	   special	   organelles	   called	  
glycosomes,	   glucose	   is	   degraded	   to	   3-­‐phosphoglycerate,	   which	   is	   then	   further	  metabolized	   in	   the	  
cytosol	   to	   pyruvate,	   the	   excreted	   metabolic	   end	   product.	   Pyruvate	   formation	   is	   catalyzed	   by	  
pyruvate	   kinase	   (number	   12	   in	   Figure	   14),	   which	   uses	   phosphoenolpyruvate	   (PEP)	   and	   ADP	   as	  
substrates	  producing	  pyruvate	  and	  ATP	   [112],	   thus,	  no	  net	  ATP	   synthesis	  occurs	   in	   the	  glycosome.	  
The	   redox	  balance	  within	   the	  glycosome	   is	  maintained	  by	  a	  glycerol-­‐3-­‐phosphate	   shuttle,	   together	  
with	   glycerol-­‐3-­‐phosphate	   oxidase	   (number	   38	   in	   Figure	   14)	   present	   in	   the	   outer	   leaflet	   of	   inner	  
mitochondrial	  membrane	   [113].	   Bloodstream	   forms	   parasites	   can	   sustain	   this	   pathway	   for	   energy	  
production	  because	  they	  live	  in	  a	  nourishing	  environment	  in	  the	  mammalian	  blood	  that	  contains	  high	  
concentrations	  of	  glucose.	  	  
However,	   it	   should	   be	   noted	   that	   even	   though	   energy	   metabolism	   in	   bloodstream	   form	  
parasites	   does	   not	   involve	   oxidative	   phosphorylation,	   mitochondrial	   function	   and	   biogenesis	   are	  
essential	   at	   this	   stage	   of	   the	   parasite	   life	   cycle	   [60].	   In	   particular,	   the	   mitochondrion	   plays	   an	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above),	   maintaining	   mitochondrial	   translation	   [114],	   regulating	   mtDNA	   expression	   [58],	   and	   for	  
mitochondrial	   fatty	   acid	   synthesis	   [115].	   The	  electrochemical	  proton	  gradient	   (ΔΨm)	   is	   essential	   to	  
energize	  translocation	  of	  proteins	  and	  transport	  co-­‐factors	  across	  the	  inner	  mitochondrial	  membrane	  
to	   maintain	   mitochondrial	   function	   [114,116].	   The	   mitochondrion	   of	   T.	   brucei	   bloodstream	   forms	  
lacks	  complexes	  III	  and	  IV	  of	  the	  respiratory	  chain,	  thus	  the	  ΔΨm	  is	  generated	  by	  the	  activity	  of	  the	  
F1Fo-­‐ATP	   synthase,	   which	   is	   working	   in	   the	   reverse	   direction,	   i.e.	   pumping	   protons	   from	  
mitochondrial	  matrix	  to	  the	  intermembrane	  space	  [60,61,62].	  
In	  contrast,	  in	  procyclic	  forms,	  the	  end	  product	  of	  glycolysis,	  pyruvate,	  is	  not	  excreted	  
but	  is	  further	  metabolized	  in	  the	  mitochondrion	  and	  degraded	  mainly	  to	  acetate.	  Acetate	  production	  
is	   catalyzed	   by	   acetate:succinate	   CoA-­‐transferase	   (ASCT,	   number	   24	   in	   Figure	   14)	   and	   involves	   a	  
succinate/succinyl-­‐CoA	   cycle	   that	   generates	   ATP	   by	   substrate	   level	   phosphorylation	   [117].	   In	   the	  
tsetse	   midgut,	   glucose	   supply	   is	   very	   limited,	   except	   immediately	   after	   a	   blood	   meal	   when	   the	  
glucose	   concentration	   increases	   and	   is	   quickly	   consumed	   by	   the	   insect	   (∼15	   minutes,	   [118]).	   In	  
contrast,	  proline	  is	  an	  abundant	  carbon	  source	  in	  the	  tsetse	  midgut	  [119,120],	  what	  led	  some	  authors	  
to	   speculate	  more	   than	   three	   decades	   ago	   that	   this	   amino	   acid	   is	   a	   key	   source	   of	   energy	   for	   the	  
insect	  forms	  of	  T.	  brucei	  [121,122].	  But	  only	  a	  compelling	  study	  by	  Lamour	  et	  al.	   less	  than	  a	  decade	  
ago	   has	   systematically	   investigated	   the	   metabolism	   of	   proline,	   elucidating	   its	   role	   in	   energy	  
metabolism	  of	  procyclic	  forms	  [123].	  The	  same	  study	  demonstrated	  that	  glucose,	   if	  available,	   is	  the	  
preferred	   carbon	   source	   of	   procyclic	   forms,	   however	   in	   glucose-­‐depleted	   conditions	   uptake	   of	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Figure	   14.	   Schematic	   representation	   of	   carbon	   sources	   in	   T.	   brucei.	   Figure	   and	   legend	   were	  
reproduced	  from	  [123].	  
Abbreviations:	   AA,	   amino	   acid;	   AOB,	   amino	   oxobutyrate;	   1,3BPGA,1,3-­‐bisphosphoglycerate;	   C,	  
cytochrome	  c;	  Cit,	  citrate;	  CoASH,	  coenzyme	  A;	  DHAP,	  dihydroxyacetone	  phosphate;	  F-­‐6-­‐P,	  fructose	  
6-­‐phosphate;	  FBP,fructose	  1,6-­‐bisphosphate;	  G-­‐3-­‐P,	  glyceraldehyde	  3-­‐phosphate;	  G-­‐6-­‐P,	  glucose	  6-­‐
phosphate;	  GLU,	  glutamate;	  Gly-­‐3-­‐P,	  glycerol	  3-­‐phosphate;	   IsoCit,isocitrate;	  2Ket,	  2-­‐ketoglutarate;	  
OA,	   2-­‐oxoacid;	   Oxac,	   oxaloacetate;	   3-­‐PGA,	   3-­‐phosphoglycerate;	   Pi,	   inorganic	   phosphate;	   PPi,	  
inorganic	  pyrophosphate;_SAG,	  glutamate	  _-­‐semialdehyde;	  SucCoA,	   succinyl-­‐CoA;	  UQ,	  ubiquinone	  
pool.	   Enzymes	   are	   as	   follows:	   1,	   hexokinase:	   2,	   glucose-­‐6-­‐phosphate	   isomerase;	   3,	  
phosphofructokinase;	   4,	   aldolase;	   5,	   triose-­‐phosphate	   isomerase;	   6,	   glycerol-­‐3-­‐phosphate	  
dehydrogenase;	   7,	   glycerol	   kinase;8,	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase;	   9,	  
phosphoglycerate	   kinase;	   10,	   phosphoglycerate	   mutase;	   11,	   enolase;	   12,	   pyruvate	   kinase;	  
13,phosphoenolpyruvate	   carboxykinase;	   14,	   pyruvate	   phosphate	   dikinase;	  15,	   glycosomal	  malate	  
dehydrogenase;	  16,	  glycosomal	  fumarase;	  17,NADH-­‐dependent	  fumarate	  reductase;	  18,	  glycosomal	  
adenylate	   kinase;	   19,	   malic	   enzyme;	   20,	   alanine	   aminotransferase;	   21,	   pyruvate	  
dehydrogenasecomplex;	   22,	   acetate:succinate	   CoA-­‐transferase;	   23,	   unknown	   enzyme,	   possibly	  
acetyl-­‐CoA	   synthetase;	   24,	   succinyl-­‐CoA	   synthetase;	   25,	   citrate	   synthase;	   26,	   aconitase;	   27,	  
isocitrate	   dehydrogenase;	   28,	   2-­‐ketoglutarate	   dehydrogenase	   complex;	   29,	   succinate	  
dehydrogenase	  (complexII	  of	  the	  respiratory	  chain);	  30,	  mitochondrial	  fumarase;	  31,	  mitochondrial	  
malate	  dehydrogenase;	  32,	  proline	  dehydrogenase;	  33,	  pyrroline-­‐5carboxylate	  dehydrogenase;	  34,	  
glutamate	   aminotransferase;	   35,	   glutamate	   dehydrogenase;	   36,	   L-­‐threonine	   dehydrogenase;	   37,	  
acetyl-­‐CoA:glycineC-­‐acetyltransferase;	   38,	   glycerol-­‐3-­‐phosphate	   oxidase;	   39,	   rotenone-­‐insensitive	  







	   28	  
When	  cultivated	  in	  standard	  medium	  (i.e.	  in	  the	  presence	  of	  6	  mM	  glucose),	  substrate	  level	  
phosphorylation	   is	   the	  main	   route	   for	   ATP	   production	   by	  mitochondria	   of	   procyclic	   forms	   and,	   in	  
consequence,	   respiratory	   chain	   and	   F1Fo-­‐ATP	   synthase	   activities	   are	   down-­‐regulated	   [124].	  
Accordingly,	   oxidative	   phosphorylation	   is	   not	   strictly	   essential	   in	   procyclic	   forms,	   as	   was	  
demonstrated	  by	  inhibition	  of	  the	  ATP	  synthase	  by	  oligomycin,	  resulting	  in	  a	  decrease	  in	  cell	  growth,	  
but	   not	   in	   death	   of	   the	   parasite	   [123].	   In	   contrast,	  when	   experiments	  were	   conducted	   in	   glucose-­‐
depleted	   conditions,	   sensitivity	   to	   oligomycin	   increased	   2’000-­‐5’000	   times,	   suggesting	   that	   when	  
procyclic	  forms	  switch	  to	  proline	  metabolism	  oxidative	  phosphorylation	  becomes	  essential	  [123,125].	  
1.12	  Mitochondrial	  carrier	  family	  (MCF)	  
The	   inner	  mitochondrial	  membrane	   is	   impermeable	   to	  metabolites	   indicating	   the	  existence	  
of	  a	  number	  of	  carriers	  that	  contribute	  to	  the	  constant	  traffic	  between	  different	  cell	  compartments,	  
i.e.	  mitochondrial	  matrix	  and	  cytosol	  [126].	  A	  group	  of	  carriers	  involved	  in	  this	  traffic	  belongs	  to	  the	  
mitochondrial	  carrier	  family	  (MCF),	  which	  are	  structurally	  related	  mitochondrial	  proteins	  responsible	  
for	  the	  transport	  of	  mono-­‐,	  di-­‐,	  and	  tricarboxylates,	  inorganic	  phosphates	  and	  nucleotides,	  co-­‐factors	  
such	   as	   FAD	   and	   NAD+,	   or	   cations	   or	   zwitterions	   such	   as	   ornithine,	   carnitine,	   spermidine	   and	  
glutamine	   [127].	   The	   primary	   structure	   of	   the	   carriers	   consists	   of	   three	   repetitions	   in	   tandem	   of	  
about	   100	   amino	   acids	   in	   length	   with	   two	   alpha	   helices	   connected	   by	   a	   hydrophilic	   loop	   and	   a	  
signature	  sequence	  [128,129].	  Both	  the	  carboxy-­‐	  and	  amino-­‐terminal	  ends	  of	  the	  MCF	  proteins	  are	  
exposed	  to	   the	   intermembrane	  space	   [128].	  The	  structure	  of	   the	  bovine	  ATP/ADP	  carrier	  has	  been	  
resolved	  with	  2.2	  Å	  resolution	  [130]	  and	  brought	  new	  insights	  in	  the	  understanding	  of	  the	  structure	  
of	   MCF	   members:	   i)	   it	   exhibits	   a	   three-­‐fold	   pseudo-­‐symmetry	   in	   line	   with	   the	   sequence	   repeat	  
described	  above	   [129];	   ii)	   the	   structure	  has	  been	  highly	  used	   as	   a	   template	   for	   building	  homology	  
models	  for	  various	  carriers	  [127].	  
The	   genome	  of	  Saccharomyces	   cerevisiae	  was	  predicted	   to	  encode	  34	  MCF	  proteins	   [131],	  
whereas	  the	  Arabidopsis	  thaliana	  [132,133]	  and	  human	  genome	  [134]	  were	  predicted	  to	  encode	  58	  
and	  67	  MCF	  proteins,	  respectively.	  A	  search	  of	  the	  T.	  brucei,	  T.	  cruzi	  and	  L.	  major	  genomes	  predicted	  
24	  putative	  MCF	  proteins	  with	  significant	  homology	  to	  mitochondrial	  carriers	  from	  other	  eukaryotes	  
[135].	   Comparisons	   to	   previously	   described	   and	   functionally	   characterized	   MCF	   proteins	   from	  
different	  eukaryotes	  allowed	  to	  assign	  putative	  function	  to	  most	  of	  the	  24	  MCF	  members	  in	  T.	  brucei.	  
However,	  functional	  studies	  have	  been	  done	  for	  only	  two	  of	  the	  T.	  brucei	  MCF	  proteins	  [136].	  Very	  
recently,	  we	  have	  used	  a	  previously	  established	  RNAi	  library	  [137]	  to	  screen	  for	  genes	  in	  the	  T.	  brucei	  
genome	   involved	   in	   the	   mode	   of	   action	   of	   choline	   analogs	   known	   as	   anti-­‐malarials	   (described	   in	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a  b  s  t  r  a  c  t
Choline  is an  essential  nutrient  for eukaryotic  cells,  where  it  is  used  as  precursor  for  the synthesis
of  choline-containing  phospholipids,  such  as phosphatidylcholine  (PC).  According  to published  data,
Trypanosoma  brucei  parasites  are  unable  to take  up  choline  from  the  environment  but  instead  use  lyso-
phosphatidylcholine  as precursor  for choline  lipid  synthesis.  We now  show  that  T. brucei  procyclic  forms
in  culture  readily  incorporate  [3H]-labeled  choline  into  PC,  indicating  that trypanosomes  express  a  trans-
porter  for  choline  at  the  plasma  membrane.  Characterization  of the  transport  system  in  T. brucei  procyclic
and  bloodstream  forms  shows  that  uptake  of choline  is independent  of sodium  and  potassium  ions  and
occurs  with  a  Km in  the low micromolar  range.  In addition,  we  demonstrate  that  choline  uptake  can  be
blocked  by  the  known  choline  transport  inhibitor,  hemicholinium-3,  and  by  synthetic  choline  analogs
that  have  been  established  as anti-malarials.  Together,  our  results  show  that  T.  brucei  parasites  express
an  uptake  system  for  choline  and  that  exogenous  choline  is used  for  PC  synthesis.
© 2013 Elsevier B.V. All rights reserved.
1. Introduction
By definition, endoparasites scavenge nutrients from their hosts.
Among the essential nutrients for kinetoplastids and apicomplex-
ans are precursors like choline, ethanolamine and myo-inositol for
the synthesis of phospholipids, the major structural components of
membranes in protozoan parasites [1].
In Trypanosoma brucei,  the causative agent of human African
sleeping sickness and the related animal disease, Nagana, phos-
phatidylcholine (PC) represents the most abundant phospholipid
class, representing 45–60% of total phospholipid [2]. The forma-
tion of PC can be initiated by uptake of lyso-phosphatidylcholine
(lyso-PC) from the environment, followed by CoA-dependent acy-
lation to PC [3]. This pathway has been shown to contribute most
of the PC in T. brucei bloodstream forms [4]. Alternatively, PC can
be synthesized de novo via the CDP-choline branch of the Kennedy
Abbreviations: PC, phosphatidylcholine; lyso-PC, lyso-phosphatidylcholine; HC-
3,  hemicholinium-3; CTL, choline transporter-like; TLC, thin layer chromatography.
! Corresponding author at: Institute of Biochemistry and Molecular Medicine,
University of Bern, Bühlstrasse 28, 3012 Bern, Switzerland. Tel.: +41 31 631 4113;
fax: +41 31 631 3737.
E-mail address: peter.buetikofer@ibmm.unibe.ch (P. Bütikofer).
pathway, using choline as precursor [4]. The enzymes of the CDP-
choline pathway have been identified and experimentally verified
in T. brucei [5,6]. In addition, RNAi studies revealed that the path-
way is essential in both T. brucei bloodstream [1] and procyclic [6]
forms. In contrast, little and conflicting data are available on the
acquisition of the precursor molecule, choline, for de novo PC syn-
thesis via the CDP-choline pathway. Marginal uptake of choline has
been reported in T. brucei bloodstream forms isolated from rats [4],
however, this finding was  not confirmed in more recent studies
[7,8].
Choline uptake in mammals is mediated via several distinct
transport systems. Based on ion dependence and susceptibility to
the specific inhibitor, hemicholinium-3 (HC-3) [9], choline trans-
port can occur via (i) low-affinity facilitated diffusion, mediated by
polyspecific organic cation transporters, (ii) intermediate-affinity,
sodium-independent transport, using choline transporter-like
(CTL) proteins, and (iii) high-affinity, sodium-dependent transport,
catalyzed by high-affinity choline transporters [10]. In humans,
organic cation transporters and CTL proteins are ubiquitously dis-
tributed. In contrast, high-affinity choline transporters primarily
occur in cholinergic neurons, where they mediate uptake of choline
for acetylcholine synthesis [11,12].
Choline transport systems have also been identified and char-
acterized in Plasmodium and Leishmania.  Uptake of choline in these
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parasites is sodium-independent, can be inhibited by HC-3, and
occurs with affinities in the low micromolar range (2.5–25 !M),
suggesting that it is mediated by intermediate-affinity CTL pro-
teins [13,14]. Interestingly, a group of synthetic choline analogs
was shown to effectively inhibit choline uptake in both groups of
parasites [7,14]. It has been suggested that in Plasmodium the drugs
may  act via interference with phospholipid biosynthesis [14–18].
Some of these choline analogs have been used as anti-malarials
[15].
In the present study, we show for the first time that choline
is readily taken up by T. brucei bloodstream and procyclic forms
in culture. We  characterize the transport system, which is inde-
pendent of Na+ and K+ ions, and show that it is inhibited by HC-3
and synthetic choline analogs. Our analyses also demonstrate that
exogenous choline is used by trypanosomes for PC synthesis.
2. Materials and methods
2.1. Reagents
All reagents were of analytical grade and purchased from Merck
(Darmstadt, Germany), Sigma–Aldrich (Buchs, Switzerland) or ICN
Biomedicals (Tägerig, Switzerland). Antibiotics and fetal bovine
serum (FBS) were obtained from Invitrogen (Basel, Switzerland).
DNA polymerases were purchased from Promega (Madison,
USA). Primers and sequencing services were from Microsynth AG
(Balgach, Switzerland). All restriction enzymes were purchased
from Fermentas (Nunningen, Switzerland). methyl-[3H]choline
chloride (60 Ci/mmol; [3H]choline), myo-[2-3H(N)]inositol
(15–20 Ci/mmol; [3H]inositol) and [1-3H]ethanolamine hydrochlo-
ride (40–60 Ci/mmol; [3H]ethanolamine) were from American
Radiolabeled Chemicals (St. Louis, USA), and ["-32P]-dCTP
(3000 Ci/mmol) from PerkinElmer Life Sciences (Schwerzenbach,
Switzerland). Kodak MXB  and BioMax MS  films were from Kodak
SA (Lausanne, Switzerland).
2.2. Trypanosomes and culture conditions
T. brucei strain Lister 427 procyclic forms were cultured at 27 !C
in SDM-79 containing 5% (v/v) heat-inactivated FBS. T. brucei blood-
stream and procyclic forms expressing T7 RNA polymerase and a
tetracycline repressor [19] were cultured at 37 !C in HMI-9 contain-
ing 10% (v/v) heat-inactivated FBS and 27 !C in SDM-79 containing
15% (v/v) heat-inactivated FBS, respectively, in the presence of
25 !g/ml hygromycin, and 15 !g/ml G418. The derived clones con-
taining different double-stranded RNA constructs against putative
choline transporter genes were cultured in the presence of an addi-
tional 2 !g/ml puromycin or 1 !g/ml phleomycin. Generation of
double-stranded RNA was induced by the addition of 1 !g/ml tetra-
cycline.
2.3. Choline uptake in T. brucei
T. brucei procyclic and bloodstream forms were grown to a den-
sity of 1.0–1.5 x 107 and 1.0–1.5 x 106 cells/ml, respectively, washed
once in 25 ml  of assay buffer (130 mM NaCl, 10 mM HEPES, 5 mM
KCl, 1 mM CaCl2, 3 mM MgCl2, 5 mM NaH2PO4 and 5 mM glucose,
pH 7.0) by centrifugation (1250 x g, 10 min, 24 !C) and resuspended
in the same buffer, pre-warmed at 27 !C and 37 !C, respectively, at
a density of 5 x 107 cells/ml. Parasites were then incubated for 3,
6 and 9 min  in 96-well plates at room temperature (for procyclic
forms) or 37 !C (for bloodstream forms) in the presence of 65 nM
(0.8 !Ci) [3H]choline and 120 nM to 62.5 !M (final concentrations)
non-labeled choline per well in a total volume of 200 !l. Uptake of
[3H]choline was terminated by rapidly transferring the samples to
96-well microplates containing 1.2 !M pore size GF/C glass fiber
filters (UniFilter-96 GF/C, Perkin Elmer Life Sciences), immediately
followed by filtration. After washing the pellets four times with
100 !l assay buffer, the samples were air-dried, resuspended in
40 !l scintillation fluid and counted in a 1450 MicroBeta Trilux
top counter (Perkin Elmer Life Sciences). Uptake of [3H]choline
was linear over 9 min  for all concentrations tested. The results
from 4–5 independent experiments were used for calculation of
Km values, using Graphpad Prism 5 software and Lineweaver–Burk
transformation. Choline uptake inhibition experiments were per-
formed using 65 nM [3H]choline and 1 !M non-labeled choline in
the absence or presence of different concentrations of inhibitors. To
study the ion dependence of choline uptake, trypanosomes were
incubated in the absence of Na+, K+, or both ions, by replacing
Na+ for K+, or vice versa (135 mM,  final concentrations), or using
135 mM N-methylglucamine instead of Na+ and K+, respectively, in
the assay buffer. No NaH2PO4 was used in these experiments.
2.4. Incorporation of [3H]choline into T. brucei lipids
Metabolic labeling of trypanosomes with [3H]choline and
[3H]ethanolamine (to control for cell viability and phospho-
lipid synthesis) was done essentially as described before [20].
Briefly, [3H]choline (1 !Ci/ml) or a mixture of [3H]choline
and [3H]ethanolamine (2 !Ci/ml and 0.25 !Ci/ml, respectively)
was added to T. brucei procyclic forms at a density of
0.8–1.2 x 107 cells/ml and incubated in the absence or presence
of G25 or MS1  (5 !M or 10 !M,  respectively, final concentra-
tions) for 2 h at 27 !C. Subsequently, parasites were spun down,
washed with ice-cold buffer (10 mM Tris, 144 mM NaCl, pH 7.4) to
remove unincorporated label, and phospholipids were extracted
with 2 x 10 ml  chloroform:methanol (2:1, by volume). Lipids were
then separated by one-dimensional thin-layer chromatography
(TLC) using Silica Gel 60 plates in a solvent system composed of
chloroform:methanol:acetic acid:water (25:15:4:2, by volume). On
each plate, appropriate phospholipid standards were run along-
side the samples to be analyzed. Lipid spots were visualized by
exposing the plates to iodine vapor. Radioactivity was detected by
scanning the air-dried plates with a radioisotope detector (Berthold
Technologies, Regensdorf, Switzerland) and quantified using the
Rita Star® software provided by the manufacturer. Alternatively,
plates were sprayed with EN3HANCE (PerkinElmer Life Sciences)
and exposed to MXB  film at "70 !C.
2.5. Drug sensitivity assays
Susceptibility of T. brucei bloodstream forms to G25 was
assessed by Alamar blue assays [21]. Briefly, serial dilutions of
G25 starting at 10 !M (using a 10 mM stock solution) were pre-
pared in HMI-9 medium containing 10% (v/v) FBS in 96-well plates
(100 !l total volume). Parasites were added to a final density of
1 x 104 cells/ml. After incubation for 70 h at 37 !C, 10 !l of Alamar
blue solution (12.5 mg  resazurin/100 ml  buffer) was added to all
wells and incubation was continued for another 2 h at 37 !C. Fluo-
rescence was measured using a spectromax GEMINI plate reader at
544 nm excitation, 590 nm emission and 570 nm cutoff.
2.6. In silico identification of genes encoding candidate choline
transporters
All T. brucei proteins with two or more predicted [22] trans-
membrane domains were hierarchically clustered into similarity
groups based on all pairwise global alignments [23]. For each clus-
ter a hidden Markov model profile was  made with ClustalW [24]
and hmmbuild of the HMMer  package [25]. The same procedure
was carried out with the well-annotated proteomes of Homo sapi-
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pooled profiles were clustered based on HMM–HMM alignment
carried out with HHsearch [26]. This allowed to tentatively anno-
tate T. brucei multispanning transmembrane protein families of
unknown function.
2.7. RNAi-mediated gene silencing
The nucleotide sequences of the genes encoding the putative
CTL transporters, Tb927.10.6720, Tb927.10.6730, Tb927.10.6740,
Tb927.10.6750 and Tb927.10.6760, show a high degree of iden-
tity and, thus, were targeted for down-regulation by RNAi
using a single stem loop construct. In contrast, Tb927.10.530
shows no significant sequence homology to the other can-
didate CTL transporter genes and was down-regulated using
a different construct. Cloning of the gene fragments into the
tetracycline-inducible vector, pALC14 (a kind gift of André Schnei-
der, University of Bern), was performed as described previously
[27], using PCR products obtained with primers Tb6720-60-
F (5!-GCCCAAGCTTGGATCCCGGCTCCATTTGCTTTGGG-3!) and
Tb6720-60-R (5!-CGTCTAGACTCGAGTACACACGTGGAGGTGCTG-
3!) (spanning nucleotides 924–1472 of Tb927.10.6730),
resulting in plasmid pRS6720-60, and Tb530-F (5!-
GCCCAAGCTTGGATCCACCTGATGAAGCCCGAGTG-3!) and Tb530-R
(5!-CGTCTAGACTCGAGGCTGAGTGATGGTGGGAAG-3!) (span-
ning nucleotides 12–580 of Tb927.10.530) resulting in plasmid
pJPM530. Plasmid extraction was performed using Qiagen Plasmid
Midi Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Before transfection of T. brucei parasites,
plasmid DNA was  linearized with NotI, extracted with phenol and
chloroform and precipitated with ethanol.
2.8. Stable transfections of trypanosomes
T. brucei 29-13 procyclic forms were harvested at mid-log phase,
washed once in buffer (132 mM NaCl, 8 mM KCl, 8 mM Na2HPO4,
1.5 mM KH2PO4, 0.5 mM magnesium acetate, 0.09 mM calcium
acetate, pH 7.0) and resuspended in the same buffer to a density of
8 x 107 cells/ml. Subsequently, 440 !l of parasite suspension were
mixed with 15 !g of linearized plasmids pRS6720-60 or pJPM530
and transferred to a 0.2-cm pulse cuvette (Bio-Rad). Electroporation
was conducted with a BTX Electroporation 600 system (Axon Lab,
Baden, Switzerland) with one pulse (1.5 kV charging voltage, 2.5 kV
resistance, 25 microfarads capacitance timing, and 186 resistance
timing). Cells were immediately inoculated in 10 ml  of procyclic
or bloodstream form medium. Dilutions were plated into 24-well
plates and after 24 h selected for antibiotic resistance by addition
of 2 !g/ml puromycin. Clones were obtained by limiting dilution.
2.9. RNA isolation, quantitative PCR and Northern blot analysis
Total RNA was isolated using the SV Total RNA Isolation Sys-
tem (Promega), following the manufacturer’s instructions. cDNA
was synthesized from total RNA (0.1–0.5 !g) using SuperScript
II reverse transcriptase (Invitrogen). Quantitative PCR was  per-
formed using Applied Biosystems ViiA7 real-time PCR system.
The reaction mixture consisted of 1x Fast Sybr Green master mix
(Applied Biosystems, Switzerland) and 0.9 !M forward and reverse
primers. For Northern blotting, total RNA (10–15 !g) was  separated
on formaldehyde–agarose gels (1% agarose, 2% formaldehyde in
20 mM Mops, containing 8 mM sodium acetate and 1 mM EDTA, pH
7.0) and transferred to Amersham Hybond-N+ nylon membranes
(GE Healthcare, Buckinghamshire, UK). The PCR products used to
construct the RNAi stem loop vectors were used as templates to
make the [32P]-labeled probes by random priming, using Prime-
a-Gene Labeling System (Promega). Hybridization was  performed
overnight at 60 "C in hybridization buffer containing 7% (w/v) SDS,
1 mM EDTA, 0.5 M Na2HPO4, 24 mM H3PO4, pH 7.2, and the mem-
brane was analyzed by autoradiography using BioMax MS  film and
a TransScreen-HE intensifying screen. Ribosomal RNA was  visual-
ized on the same formaldehyde–agarose gel by ethidium bromide
staining to control for equal loading.
2.10. Expression of candidate choline transporters in yeast and
uptake assays
S. cerevisiae strain BY4741 (MATa his3!1  leu2!0 met15!0
ura3!0) and the hnm1 mutant strain Y04444 (MATa his3!1
leu2!0 met15!0  ura3!0 YGL077c::kanMX4) were purchased
from Euroscarf (Institute of Microbiology, University of Frankfurt).
Transformation was  performed as described [28] and transfor-
mants were selected on standard synthetic dextrose minimal
medium supplemented with leucine (100 mg/l), histidine (20 mg/l)
and methionine (20 mg/l). For uptake studies, yeast cells were
grown to logarithmic phase, harvested at an OD600 of approxi-
mately 0.5, washed twice in water, and resuspended in buffer A
(50 mM potassium phosphate, pH 5.0–7.5, containing 0.6 M sor-
bitol) to a final OD600 of 6. Prior to uptake measurements, cell
suspensions were supplemented with 100 mM  glucose and incu-
bated for 5 min  at 30 "C. To start the reaction, 130 !l of cell
suspension were added to 130 !l of buffer A, containing 0.2 !Ci
[3H]choline and 10 !M unlabeled choline. Samples were removed
after 0.5, 1, 2, and 5 min, transferred to 4 ml  of ice-cold buffer A,
filtered on glass fiber filters and washed twice with 4 ml  of ice-
cold buffer A. Tritium uptake was  determined by liquid scintillation
counting.
3. Results
3.1. Choline uptake in T. brucei
In T. brucei bloodstream forms, uptake of choline for PC syn-
thesis has been reported to be negligible, or absent [4,7]. We  now
found that incubation of T. brucei procyclic forms for 2 h in the pres-
ence of [3H]choline resulted in the labeling of a major lipid class, as
revealed by TLC analysis combined with fluorography and radioiso-
tope scanning (Fig. 1). Co-migration with phospholipid standards
Fig. 1. Biosynthesis of [3H]PC in T. brucei.  Procyclic form trypanosomes (4 x 107 para-
sites) were incubated in the presence 1 !Ci/ml [3H]choline for 2 h in 5 ml culture
medium. Phospholipids were extracted using organic solvents and separated by
TLC. [3H]-labeled lipids were analyzed by radioisotope scanning, and fluorography
(inset). The arrows refer to the migration of a phosphatidylcholine (PC) standard run
on  the same TLC plate. The site of sample application (O) and the migration distance





	   34	  
J.P. Macêdo et al. / Molecular & Biochemical Parasitology 190 (2013) 16– 22 19
applied on the same TLC plate and chromatography in several dif-
ferent solvent systems, including a two-dimensional separation
system, identified the labeled lipid class as PC. Upon longer label-
ing and exposure times, a second minor [3H]-labeled lipid class
was detected (result not shown) and identified as sphingomyelin
by co-migration with lipid standards. Similar observations were
also made when T. congolense procyclic forms in culture were incu-
bated in the presence of [3H]choline (result not shown). Together,
these findings suggest that [3H]choline is taken up by T. brucei
procyclic forms and used for the synthesis of choline-containing
phospholipids.
To further characterize choline uptake in T. brucei procyclic
forms, parasites were incubated in buffer containing [3H]choline
(65 nM,  final concentration) in the presence of unlabeled choline
(62.5 !M,  final concentration) for up to 9 min. Determination of
the amounts of radioactivity in parasites after rapid removal of the
supernatant by filtration and repetitive washing showed a time-
dependent linear increase in cell-bound [3H]choline (Fig. 2A). To
determine the kinetic parameters of choline uptake, parasites were
incubated in the presence of trace amounts of [3H]choline and
increasing concentrations of unlabeled choline. For each choline
concentration, samples were taken after 3, 6 and 9 min  and
showed linear increase in [3H]choline uptake over time (results
not shown; see Fig. 2A as an example). The data show that
choline uptake follows Michaelis–Menten kinetics and is saturable
(Fig. 2B). The combined results reveal that choline is taken up
in T. brucei procyclic forms with a Km of 2.0 ± 0.5 !M and Vmax
of 8.1 ± 2.1 pmol/min x 107 cells (mean values ± standard devia-
tions of duplicate determinations from 5 separate experiments)
(Fig. 2B and C). Choline uptake was temperature-dependent since
no choline uptake was  observed when parasites were incubated
in the presence of [3H]choline for 1 h on ice. Choline uptake
also occurred linearly in T. brucei bloodstream forms in culture
(Fig. 2D) and showed similar saturation kinetics (Fig. 2E). Under
similar conditions as for procyclic trypanosomes, bloodstream form
parasites took up choline with a Km of 7.2 ± 4.8 !M and Vmax of
5.7 ± 3.1 pmol/min x 107 cells (mean values ± standard deviations
of duplicate determinations from 4 separate experiments) (Fig. 2E
and F).
3.2. Characterization of choline uptake
Choline transport in T. brucei was  further characterized by
measuring uptake of [3H]choline in procyclic forms in the pres-
ence of structurally related compounds. The results show that
the choline transport inhibitor, HC-3 (50 !M, final concentration),
reduced [3H]choline uptake by 67%, while betaine, carnitine and
ethanolamine had no effect (Fig. 3A). As positive control for com-
petition, parasites were incubated in the presence of unlabeled
choline (50 !M,  final concentration), resulting in >90% inhibition
of [3H]choline uptake. In mammalian cells, sensitivity to HC-3 is
often used to determine if choline uptake occurs via high, interme-
diate or low affinity transport [10]. Thus, we determined the affinity
of the choline transport system to HC-3 by measuring uptake of
choline (at 1 !M)  in the presence of increasing concentrations of
HC-3. Our results show that inhibition occurred with IC50 values
of 27 ± 10 !M (Fig. 3B) and 61 ± 10 !M (not shown) in T. brucei
procyclic and bloodstream forms, respectively.
Dependence of choline uptake on extracellular monovalent
cations was studied by incubating T. brucei procyclic forms in buffer
lacking Na+, K+, or both ions. The results show that the ion com-
position had little effect on choline uptake (Fig. 3C). In addition,
the presence of high concentrations of the Na+/K+ pump inhibitor,
ouabain (pre-incubated for 1 h at 2 mM,  final concentration), had
no effect on [3H]choline uptake. In contrast, we found that addi-
tion of uncouplers of oxidative phosphorylation, 2,4-dinitrophenol
(50–250 !M,  final concentration) and CCCP (10 !M,  final concen-
tration), inhibited [3H]choline uptake by 52.7–93.6% and 94.7%,
respectively (values from three and two  determinations, respec-
tively). Together, these results indicate that choline transport in
Fig. 2. Km determination of choline uptake. Uptake of choline: T. brucei procyclic (panel A) and bloodstream (panel D) forms were incubated in assay buffer containing 65 nM
[3H]choline and 62.5 !M unlabeled choline for indicated times and the amounts of cell-bound radioactivity were determined by scintillation counting. Km determination: T.
brucei  procyclic (B and C) and bloodstream (E and F) forms were incubated in the presence of increasing concentrations of choline (0.12–62.5 !M)  for up to 9 min. At selected
time  points, uptake of radioactivity was determined and the results were analyzed according to Michaelis–Menten (B and E) or by Lineweaver–Burk transformation (panels
C  and F). Data points represent mean values ± standard deviations of duplicate determinations from two  separate experiments done on the same day using parasites from
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Fig. 3. Inhibition of choline uptake. T. brucei procyclic forms were incubated
in  buffer containing 65 nM [3H]choline and 1 !M unlabeled choline for 10 min
and the amounts of cell-bound radioactivity were determined by scintillation
counting. Panel A: Inhibition of [3H]choline uptake by the addition of unlabeled
choline, hemicholinium-3 (HC-3), betaine, carnitine (each at 50 !M, final concen-
trations), and ethanolamine (100 !M,  final concentration) relative to control. Panel
B:  inhibition of [3H]choline uptake by the addition of increasing concentrations
of  HC-3. Panel C: [3H]choline uptake in the absence of potassium (Na+-buffer),
sodium (K+-buffer), or both cations (NMG-buffer). Uptake is expressed relative
to  control parasites incubated in assay buffer. The data points represent mean
values ± standard deviations of triplicate determinations from three independent
experiments.
T. brucei is not driven by a sodium or potassium gradient, but is
dependent on mitochondrial energy production and/or is proton-
driven.
3.3. Inhibition of choline transport by choline analogs
It has been shown that choline transport in Plasmodium and
Leishmania can be inhibited by several choline analogs [7,14]. We
now show that these compounds also effectively block [3H]choline
uptake in T. brucei procyclic forms. In the presence of the
choline-derived analogs MS1, G25, T3, T4, and T1 (5 !M,  final con-
centrations; the structures of the compounds are given in [7]),
Fig. 4. Inhibition of choline uptake by choline analogs. Panel A: T. brucei procyclic
forms were incubated in buffer containing 65 nM [3H]choline and 1 !M unlabeled
choline in the absence (control) or presence of choline analogs (5 !M,  final concen-
trations) for 10 min  and the amounts of cell-bound radioactivity were determined
by  scintillation counting. The data points represent mean values ± standard devia-
tions of triplicate determinations from three independent experiments. Panel B: T.
brucei procyclic forms (4 x 107 parasites in 5 ml  culture medium) were incubated for
2  h with 2 !Ci/ml [3H]choline and 0.25 !Ci/ml [3H]ethanolamine (as control) in the
absence (top panel) or presence (bottom panel) of 5 !M G25. Subsequently, lipids
were extracted and analyzed by TLC, and radiolabeled products were detected by
radioisotope scanning. The arrows indicate the migration of phosphatidylcholine
(PC) and phosphatidylethanolamine (PE) standards run on the same TLC plate. O,
site of sample application; F, migration distance of solvent front.
[3H]choline uptake was inhibited by >80–95% compared to control
values (Fig. 4A). Since the compounds have been shown to be toxic
for T. brucei upon longer exposure [7], cell viability and trans-
port activity during drug treatment was verified by incubating
parasites in the presence of [3H]inositol or [3H]ethanolamine. We
found that 30 min  of drug exposure had no effect on [3H]inositol or
[3H]ethanolamine uptake into T. brucei procyclic forms (results not
shown). In addition, our results showed that while treatment of T.
brucei procyclic forms with G25 completely prevented [3H]PC for-
mation (as a result of inhibition of [3H]choline uptake; see Fig. 4A),
the synthesis of [3H]PE was not affected (Fig. 4B). Together, these
results show that choline analogs specifically inhibit uptake of
choline in T. brucei procyclic forms without altering transport of
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Fig. 5. Effect of G25 on choline uptake and parasite viability. Panel A: T. brucei
bloodstream forms (5 x 106 parasites) were incubated in buffer containing 65 nM
[3H]choline and 1 !M unlabeled choline in the presence of increasing concentrations
of G25 for 10 min  and the amounts of cell-bound radioactivity were determined
by  scintillation counting. Data points represent mean values ± standard errors of
triplicate determinations from one of two experiments. Panel B: susceptibility of T.
brucei bloodstream forms to G25 was  determined by Alamar blue assay as described
in  Section 2. Data points represent mean values ± standard deviations of triplicate
determinations from three independent experiments.
parasite viability during the experimental time frame (10 min  for
[3H]choline uptake studies and 2 h for determination of de novo
phospholipid synthesis).
Incubation of T. brucei procyclic and bloodstream forms in buffer
in the presence of 1 !M choline and increasing concentrations
of G25 revealed IC50 values for choline transport inhibition of
37.5 ± 9.2 nM (not shown) and 54.0 ± 5.0 nM (Fig. 5A), respectively.
Much higher concentrations of G25 were needed to inhibit choline
uptake when parasites were incubated in the presence of choline in
culture medium. For example, the addition of 1 !M G25, i.e. a value
close to 20-fold the IC50 measured in buffer, to T. brucei procyclic
and bloodstream forms in culture medium only inhibited choline
uptake by 77% and 75%, respectively (mean values from two sepa-
rate experiments). This difference can, at least in part, be attributed
to the amounts of choline present in the culture media (28.6 !M and
7.2 !M in HMI-9 and SDM-79, respectively). In addition, in agree-
ment with a previous report [7], we found that the EC50 value of
G25 for growth inhibition of T. brucei bloodstream forms, as deter-
mined using Alamar blue assays, was in the low nanomolar range
(70 ± 10 nM;  Fig. 5B), i.e. at a concentration that has no effect on
choline uptake in trypanosomes in culture medium. Thus, despite
being a potent inhibitor of choline uptake, G25 may  not exert its
toxic effect in T. brucei by inhibition of choline transport.
3.4. Search for a putative T. brucei choline transporter
Our results showing that choline uptake in T. brucei is Na+-
independent and inhibited by HC-3 with an IC50 in the low
micromolar range suggest that it may  occur via CTL-mediated
transport. A bioinformatics search aimed at de-orphanizing
putative transporters of T. brucei identified significant simi-
larity between a cluster of six T. brucei proteins and human
CTL transporters as determined by HMM-HMM  alignment [26]
(Suppl. Fig. 1). Five of the genes, Tb927.10.6720, Tb927.10.6730,
Tb927.10.6740, Tb927.10.6750 and Tb927.10.6760 (collectively
referred to as Tb927.10.20-60), are highly similar and are arranged
in tandem on chromosome 10, while the last gene, Tb927.10.530,
shows less sequence similarity to Tb927.10.20-60 and clearly
separates phylogenetically (Suppl. Fig. 1). To study a possi-
ble involvement of the gene products in choline uptake in T.
brucei, expression of Tb927.10.20-60 and Tb927.10.530 was down-
regulated by RNAi in procyclic forms. Because of the sequence
homology among the members of the Tb927.10.20-60 gene clus-
ter, we  designed a single construct to down-regulate transcript
levels of all five genes. Northern blot analysis showed that after
induction by tetracycline for 3 days, Tb927.10.20-60 mRNAs were
clearly decreased compared to control levels (Suppl. Fig. 2A). How-
ever, parasite growth was not affected during 12 days of culture
in the presence of tetracycline (Fig. 2A) and uptake of [3H]choline
was unchanged compared to control uninduced cells (results not
shown). Similarly, no difference in growth and [3H]choline uptake
was observed in T. brucei bloodstream forms after down-regulation
of Tb927.10.530 mRNA levels by 85% (Suppl. Fig. 2B, and results not
shown).
Furthermore, we  expressed Tb927.10.6740, Tb927.10.6760, and
Tb927.10.530 in an hnm1 yeast mutant lacking the gene encod-
ing the S. cerevisiae choline transporter, to study if the T. brucei
gene products could functionally complement Hnm1p. The results
showed that expression of the T. brucei genes in S. cerevisiae had no
effect on uptake of [3H]choline, while expression of HNM1 restored
[3H]choline transport (positive control) (Suppl. Fig. 3).
Finally, Tb927.10.6750 and Tb927.10.530 were expressed sep-
arately in Xenopus laevis oocytes to study choline transport in
a well-established expression system for carriers [29]. However,
using two-electrode voltage clamp measurements, no electrogenic
transport activity was  detected after injection of the corresponding
mRNAs (results not shown). In addition, no uptake of [3H]choline
was measured using tracer flux experiments. Together, these
results indicate that the T. brucei genes identified by sequence
comparison with human CTL transporters unlikely encode major
choline uptake systems in T. brucei.
4. Discussion
Early studies using T. brucei parasites isolated from the blood of
infected rats showed that in the presence of lyso-PC, bloodstream
form trypanosomes take up little choline from the environment
in vitro [4]. More recently, direct measurements using radioactive
substrates failed to detect choline uptake in T. brucei bloodstream
forms [7,8], suggesting that T. brucei parasites, which are considered
choline auxotrophs [1], lack a choline transport system and meet
their demand for choline by uptake of lyso-PC.
In contrast, we now show that T. brucei bloodstream and pro-
cyclic forms in culture readily take up choline. Using choline
concentrations of 0.12–62.5 !M,  uptake of choline occurred
temperature-dependent and linear over at least 9 min  and was
saturable, with Vmax values of 5.7 and 8.1 pmol/min x 107 for blood-
stream and procyclic forms, respectively. At present, it is unclear
why choline uptake was  not detected in a previous study [7].
Possible reasons may  include short incubation times (1 min), low
concentrations of choline (250 nM), and the use of bloodstream
form parasites isolated from infected rats.
Our observations that choline transport in trypanosomes (i)
follows Michaelis–Menten kinetics, with a Km in the low micro-
molar range, (ii) can be inhibited by the specific choline transport
inhibitor, HC-3, and (iii) is sodium- and potassium-independent,
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system. Similar observations have been reported in Plasmodium
[14] and Leishmania [13], suggesting that protozoan parasites may
rely on closely related transporters for choline uptake. However,
in none of these parasites, a choline transporter has been identi-
fied. Unfortunately, although we have identified genes encoding
candidate CTL proteins using a bioinformatics approach, neither
down-regulation of their expression in T. brucei bloodstream and
procyclic forms, nor their expression in Xenopus oocytes or S. cere-
visiae provided evidence of their involvement in choline transport.
It has previously been shown that PC synthesis via the CDP-
choline branch of the Kennedy pathway is essential for growth of
T. brucei bloodstream [1] and procyclic forms [6]. This observation
has been difficult to explain since trypanosomes lacked a trans-
port system for uptake of the precursor of the pathway, choline.
Our findings now resolve this conundrum by showing that choline
taken up from the environment is readily used for de novo PC syn-
thesis in T. brucei parasites in culture. Nevertheless, in the blood
of an infected human, the situation may  be different as the plasma
concentration of lyso-PC is up to 10-fold higher than that of choline
[30–32], suggesting that trypanosomes may  meet their demand for
precursors for PC synthesis primarily by uptake of lyso-PC.
Interestingly, our results show that choline transport in T. brucei
is inhibited by a set of synthetic choline analogs. These compounds
have previously been reported to block choline uptake in Plasmo-
dium and Leishmania [7,14]. In addition, they are highly toxic for
these parasites in culture, with EC50 values in the nanomolar range
in Plasmodium [15,33] and micromolar range in Leishmania [7]. Sim-
ilarly, we found that these choline analogs also inhibit proliferation
of T. brucei bloodstream (in agreement with a previous report [7])
and procyclic forms. However, considering the IC50 and EC50 values
of G25 in T. brucei bloodstream forms, it is unclear if the mode of
action is due to inhibition of choline uptake. In addition, at present
it is unknown how these drugs are taken up by protozoan parasites.
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Introduction	  
African	   trypanosomes	   are	   vector-­‐borne	   protozoans	   that	   cause	   serious	   public	   health	  
problems	   and	   uncountable	   economical	   losses	   in	   sub-­‐Saharan	   African	   countries.	   The	   current	  
chemotherapy	  against	  Trypanosoma	  brucei,	   the	  causative	  agent	  of	  human	  African	  trypanosomiasis,	  
or	  sleeping	  sickness,	  and	  a	  related	  cattle	  disease,	  called	  Nagana,	  is	  based	  on	  repetitive	  injections	  of	  
drugs	  with	  strong	  side	  effects.	  Treatment	  of	  Nagana	   is	  commonly	  based	  on	  carcinogenic	  drugs	   like	  
ethidium	  bromide	  and	  isometamidium	  chloride,	  and	  also	  on	  suramin	  and	  diminazene	  aceturate,	  both	  
with	  considerable	  toxicities	  to	  cattle	  [1].	  In	  the	  case	  of	  human	  African	  trypanosomiasis,	  pentamidine	  
and	  suramin	  are	  widely	  used	  during	  the	  first	  stage	  of	  the	  disease,	  when	  parasites	  are	  still	  present	  in	  
the	  hemolymphatic	  tissues.	  The	  second	  stage	  of	  sleeping	  sickness,	  which	  is	  characterized	  by	  parasite	  
invasion	   of	   the	   central	   nervous	   system,	   is	   treated	   with	   melarsoprol	   or	   a	   combination	   of	  
nifurtimox/eflornithine	   [2].	  Melarsoprol,	   the	  only	  drug	  against	  both	   forms	  of	   sleeping	   sickness,	   i.e.	  
caused	   by	   T.	   b.	   gambiense	   or	   T.	   b.	   rhodesiense,	   is	   highly	   toxic	   causing	   encephalopathies	   in	   5%	   of	  
cases.	   In	   addition,	   there	   are	   well-­‐known	   examples	   of	   cross-­‐resistance	   in	   the	   field	   [3,4],	  
demonstrating	  that	  selection	  of	  resistant	  strains	  is	  a	  real	  threat	  to	  human	  health	  in	  endemic	  regions.	  
Hence,	  more	  efforts	  to	  develop	  new	  drugs	  and	  optimize	  treatment	  for	  sleeping	  sickness	  are	  needed.	  
T.	  brucei	  and	  other	  protozoan	  parasites,	  by	  definition,	  acquire	  nutrients	  and	  building	  blocks	  
for	   rapid	   cell	   proliferation	   from	   their	   mammalian	   or	   insect	   hosts.	   However,	   recent	   reports	   have	  
shown	  that	  trypanosomatids	  not	  only	  acquire	  lipids	  for	  membrane	  formation	  from	  the	  environment,	  
but	  are	  also	  capable	  of	  de	  novo	  synthesis	  of	  all	  major	  membrane	  lipid	  classes	  [5].	  The	  most	  abundant	  
phospholipid	  class	   in	  T.	  brucei	  parasites	   is	  phosphatidylcholine	   (PC)	   [6],	  which	  can	  be	  generated	  by	  
acylation	  of	  lyso-­‐PC	  taken	  up	  from	  the	  host	  [7].	  Alternatively,	  PC	  can	  be	  produced	  from	  host-­‐derived	  
choline	  [8]	  by	  sequential	  action	  of	  three	  enzymes	  via	  the	  CDP-­‐choline	  pathway	  (reviewed	  in	  [5]).	  This	  
pathway	  is	  essential	  for	  survival	  of	  T.	  brucei	  parasites	  in	  culture	  [5].	  
PC	   is	   also	   the	  most	   abundant	   phospholipid	   class	   in	   the	  malaria	   parasite,	  Plasmodium	   spp.	  
(reviewed	   in	   [9]).	   Its	   synthesis	   can	   occur	   via	   multiple	   routes,	   including	   the	   CDP-­‐choline	   pathway	  
(reviewed	  in	  [10]).	  The	  inability	  to	  knock-­‐out	  individual	  genes	  involved	  in	  this	  pathway	  suggests	  that	  
PC	  formation	  via	  CDP-­‐choline	  is	  essential	  in	  Plasmodium	  [11].	  In	  addition,	  the	  uptake	  of	  the	  substrate	  
for	  this	  pathway,	  choline,	  can	  be	  inhibited	  by	  a	  set	  of	  choline	  analogs,	  which	  have	  been	  found	  to	  be	  
toxic	  for	  malaria	  parasites	  [12,13,14].	  However,	  at	  present	  it	  is	  unclear	  if	  these	  drugs	  affect	  parasite	  
viability	  due	  to	  their	  potency	  to	  prevent	  choline	  uptake	  or	  their	  inhibitory	  effect	  on	  enzymes	  of	  the	  
CDP-­‐choline	  pathway	  [15,16,17,18].	  Structural	  refinements	  of	  the	  drugs	  has	  lead	  to	  the	  development	  
of	   third	  and	  fourth	  generation	  compounds,	  one	  of	  which,	  named	  T3,	   is	  currently	   in	  clinical	   trials	   to	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toxic	   for	   T.	   brucei	   and	   Leishmania	   parasites	   [19].	   Their	   mode	   of	   action	   is	   unclear:	   although	   they	  
effectively	   inhibit	   choline	   uptake	   and,	   thus,	   de	   novo	   PC	   formation	   in	   T.	   brucei	   [8],	   they	   may	   kill	  
trypanosomes	  by	  affecting	  mitochondrial	  structure	  and	  function	  [8,19].	  
In	  the	  present	  study,	  we	  used	  three	  of	  the	  leading	  choline	  analogs,	  two	  bis-­‐tiazolium	  salts,	  T3	  
and	  T4,	  and	  a	  bis-­‐quartenary	  ammonium	  salt,	  G25,	   to	  elucidate	  the	  site	  and	  mode	  of	  action	  of	   the	  
compounds.	   For	   this,	  we	   screened	   an	   RNAi	   library	   previously	   established	   in	   T.	   brucei	   bloodstream	  
forms	  [20]	  to	  identify	  genes	  conferring	  parasite	  resistance	  towards	  the	  drugs.	  Interestingly,	  we	  found	  
that	   treatment	   of	   T.	   brucei	   bloodstream	   forms	   with	   these	   drugs	   selected	   parasite	   populations	   in	  
which	  the	  expression	  of	  a	  gene	  encoding	  a	  mitochondrial	  carrier	  was	  down-­‐regulated.	  
	  
Materials	  and	  methods	  
All	  reagents	  were	  of	  analytical	  grade	  and	  purchased	  from	  Merck	  (Darmstadt,	  Germany),	  Sigma-­‐
Aldrich	   (Buchs,	   Switzerland)	   or	   ICN	  Biomedicals	   (Tägerig,	   Switzerland).	   Antibiotics	   and	   fetal	   bovine	  
serum	  (FBS)	  were	  obtained	  from	  Invitrogen	  (Basel,	  Switzerland).	  Dialyzed	  fetal	  calf	  serum	  (FCS)	  was	  
obtained	  from	  BioConcept	  Amimed	  (Allschwil,	  Switzerland).	  DNA	  polymerases	  were	  purchased	  from	  
Promega	   (Madison,	   USA).	   Primers	   and	   sequencing	   services	   were	   from	   Microsynth	   AG	   (Balgach,	  
Switzerland).	  All	  restriction	  enzymes	  were	  purchased	  from	  Fermentas	  (Nunningen,	  Switzerland).	  [α-­‐
32P]-­‐dCTP	   (3000	   Ci/mmol)	   was	   from	   PerkinElmer	   Life	   Sciences	   (Schwerzenbach,	   Switzerland)	   and	  
Kodak	  MXB	  and	  BioMax	  MS	  films	  were	  from	  Kodak	  SA	  (Lausanne,	  Switzerland).	  
	  
Trypanosomes	  and	  culture	  conditions	  
T.	   brucei	   bloodstream	   forms	   co-­‐expressing	   T7	   RNA	   polymerase	   and	   a	   tetracycline	   repressor	  
[21]	  were	   cultured	   at	   37	   °C	   in	  HMI-­‐9	   containing	   10%	   (v/v)	   heat-­‐inactivated	   FBS.	  Derived	   clones	   to	  
down-­‐regulate	  or	  over-­‐express	  TbMCP14	  were	  cultured	  in	  the	  presence	  of	  2.5	  µg/ml	  phleomycin	  or	  
0.1	  µg/ml	  puromycin,	  respectively.	  TbMCP14	  knock-­‐out	  parasites	  were	  cultured	  in	  the	  presence	  of	  5	  
µg/ml	  hygromycin	  and	  2.5	  µg/ml	  blasticidin.	  T.	  brucei	  29-­‐13	  procyclic	  forms	  [21]	  were	  cultured	  at	  27	  
°C	  in	  SDM-­‐79	  containing	  10%	  (v/v)	  heat-­‐inactivated	  FBS,	  in	  the	  presence	  of	  25	  μg/ml	  hygromycin,	  and	  
15	   μg/ml	   G418.	   The	   derived	   clones	   containing	   different	   double-­‐stranded	   RNA	   constructs	   against	  
TbMCP14	   (Tb927.10.13120)	   were	   cultured	   in	   the	   presence	   of	   an	   additional	   2	   µg/ml	   puromycin.	  
TbMCP14	   conditional	   knock-­‐out	   procyclic	   forms	   were	   cultivated	   in	   the	   presence	   of	   5	   µg/ml	  
blasticidin,	   0.2	   µg/ml	   phleomycin	   and	   2	   µg/ml	   puromycin,	   and	   1	   µg/ml	   tetracycline	   to	   maintain	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medium	  was	  studied	  using	  SDM-­‐80	  [22],	  supplemented	  with	  9%	  dialyzed	  (10’000	  molecular	  weight	  
cut-­‐off)	  and	  heat-­‐inactivated	  FCS	  and	  1%	  non-­‐dialyzed	  and	  heat-­‐inactivated	  FBS.	  	  
	  
Drug	  sensitivity	  assays	  and	  screening	  of	  RNAi	  library	  
Susceptibility	  of	  T.	  brucei	  bloodstream	  forms	  to	  G25,	  T3	  and	  T4	  was	  assessed	  by	  Alamar	  blue	  
assays	  [23].	  Briefly,	  serial	  dilutions	  of	  G25,	  T3	  or	  T4	  starting	  at	  10,	  250	  or	  10	  µM	  (from	  10	  mM	  stock	  
solutions),	   respectively,	  were	  prepared	   in	  HMI-­‐9	  containing	  10%	   (v/v)	  FBS	   in	  96-­‐well	  plates	   (100	  µl	  
final	  volume).	  Parasites	  were	  added	  to	  a	  final	  density	  of	  1x104	  cells/ml.	  After	  incubation	  for	  70	  h	  at	  
37	  °C,	  10	  µl	  of	  Alamar	  blue	  solution	  (12.5	  mg	  of	  resazurin	  in	  100	  ml	  PBS,	  composed	  of	  137	  mM	  NaCl,	  
2.7	  mM	  KCl,	  10	  mM	  Na2HPO4,	  1.76	  mM	  KH2PO4,	  pH	  7.2)	  was	  added	  to	  all	  wells	  and	  incubation	  was	  
continued	   for	   another	  2	  h	   at	   37	   °C.	   Fluorescence	  was	  measured	  using	   a	   spectromax	  GEMINI	  plate	  
reader	   at	   544	   nm	   excitation,	   590	   nm	   emission	   and	   570	   nm	   cutoff.	   Drug	   screening	   using	   an	   RNAi	  
library	  constructed	  in	  T.	  brucei	  bloodstream	  forms	  was	  performed	  as	  described	  before	  [20].	  Briefly,	  a	  
frozen	  stabilate	  of	  3x106	  parasites	  was	  thawed	  in	  30	  ml	  HMI-­‐9	  supplemented	  with	  10%	  FBS	  and	  daily	  
diluted	  to	  the	  same	  density	  (3x106	  cells/30	  ml).	  After	  three	  passages,	  RNAi	  was	  induced	  by	  addition	  
of	  tetracycline	  to	  the	  culture.	  After	  three	  days,	  the	  parasite	  culture	  was	  split	  in	  flasks	  containing	  106	  
cells/10	  ml	  medium.	  Drug	  concentrations	  determined	  to	  kill	  98%	  of	  parasites	   (EC98)	  by	  Alamar	  blue	  
assays	   were	   used	   for	   selection	   of	   resistant	   parasites.	   EC98	   concentrations	   of	   G25,	   T3	   or	   T4	   were	  
added	   to	   the	   culture	   flasks,	   which	   were	   incubated	   until	   resistant	   clones	   started	   growing.	   Finally,	  
genomic	   DNA	   of	   resistant	   parasites	   was	   extracted	   and	   the	   putative	   DNA	   fragments	   conferring	  
resistance	   amplified	   by	   PCR,	   cloned	   into	   a	   PCRII-­‐TOPO	   vector	   (Invitrogen)	   and	   identified	   by	   DNA	  
sequencing.	  	  
	  
RNAi-­‐mediated	   gene	   silencing,	   over-­‐expression	   and	   generation	   of	   knock-­‐out	  
parasites	  
Two	  tetracycline-­‐inducible	  vectors	  (derivatives	  of	  pLew100	  [21]),	  both	  harboring	  an	   inducible	  
stem	   loop,	  were	  used	  to	  down-­‐regulate	  TbMCP14.	  A	   first	  plasmid,	   in	  which	  the	  stem	   loop	   is	  under	  
control	  of	  the	  PARP	  promoter	  [24],	  was	  used	  to	  transfect	  procyclic	  forms,	  whereas	  a	  second	  plasmid,	  
which	   is	   regulated	  by	  an	   rRNA	  promoter	   [25],	  was	  used	   to	   transfect	  bloodstream	   forms.	  TbMCP14	  
gene	   fragments	   were	   cloned	   into	   the	   vectors	   using	   PCR	   products	   obtained	   with	   primers	   1	   and	   2	  
(Table	  S1),	  resulting	  in	  plasmids	  pJPM14pc	  and	  pJPM14bs.	  
For	   over-­‐expression	   in	   procyclic	   and	   bloodstream	   form	   trypanosomes,	   the	   TbMCP14	   open	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based	  on	  pLew100	   [21,26],	   containing	  a	  C-­‐terminal	  extension	  encoding	  cMyc	   to	  allow	  tetracycline-­‐
inducible	   expression	   of	   cMyc-­‐tagged	   TbMCP14,	   resulting	   in	   plasmid	   pJPM14O.	   The	   same	   strategy	  
was	  used	  to	  induce	  over-­‐expression	  of	  the	  truncated	  version	  of	  TbMCP14	  except	  that	  a	  shorter	  open	  
reading	  frame	  (amplified	  using	  primers	  5	  and	  4,	  Table	  S1)	  was	  inserted	  in	  the	  vector.	  	  
Procyclic	   form	   TbMCP14	   conditional	   knock-­‐out	   parasites	   were	   generated	   stepwise	   by	   i)	  
replacing	   one	   of	   the	   endogenous	   alleles	   with	   a	   blasticidin	   resistance	   gene	   by	   homologous	  
recombination,	   ii)	   inserting	   an	   ectopic	   copy	   of	   TbMCP14,	   C-­‐terminally	   tagged	   with	   cMyc,	   and	   iii)	  
replacing	   the	   remaining	   endogenous	   allele	   of	   TbMCP14	   by	   a	   phleomycin	   resistance	   gene.	   The	  
corresponding	  vectors	  were	  generated	  as	  follows;	  first,	  a	  fragment	  of	  400	  nt	  from	  the	  5’-­‐UTR	  region	  
of	   TbMCP14	  was	   amplified	   using	   primer	   6,	   having	   an	   XhoI	   restriction	   site,	   and	   primer	   7,	   having	   a	  
HindIII	  restriction	  site	  (Table	  S1).	  Second,	  a	  fragment	  of	  458	  nt	  from	  the	  3’-­‐UTR	  region	  of	  TbMCP14	  
was	  amplified	  using	  primers	  8	  and	  9	  (Table	  S1).	  Subsequently,	  the	  two	  fragments	  were	  inserted	  into	  
vector	  pKOblast	   [27],	  which	  contains	   the	  procyclin	  EP1-­‐EP2	   intergenic	   region,	  a	  blasticidin	   resistance	  
gene,	  and	  the	  tubulin	   intergenic	  region,	  resulting	   in	  vector	  pJPM14KOblast.	  The	  blasticidin	  resistance	  
gene	  was	  then	  replaced	  by	  a	  phleomycin	  resistance	  gene	  using	  the	  flanking	  restriction	  sites	  AscI	  and	  
PacI,	  resulting	  in	  vector	  pJPM14KOphleo.	  
Plasmid	   extraction	  was	   performed	   using	  Qiagen	   Plasmid	  Midi	   Kit	   (Qiagen,	  Hilden,	  Germany)	  
according	  to	  the	  manufacturer’s	  instructions.	  Before	  transfection	  of	  T.	  brucei	  parasites,	  pLew-­‐based	  
plasmids	  were	  linearized	  with	  NotI	  while	  pKO	  plasmids	  were	  digested	  with	  XhoI/NotI	  to	  release	  linear	  
fragments	   containing	   the	   respective	   resistance	   genes	   flanked	   by	   sequences	   for	   homologous	  
recombination	  with	  TbMCP14.	  
	  
Stable	  transfections	  of	  trypanosomes	  
T.	  brucei	  procyclic	  and	  bloodstream	  forms	  were	  harvested	  at	  mid-­‐log	  phase,	  washed	  once	   in	  
buffer	  (132	  mM	  NaCl,	  8	  mM	  KCl,	  8	  mM	  Na2HPO4,	  1.5	  mM	  KH2PO4,	  0.5	  mM	  magnesium	  acetate,	  0.09	  
mM	   calcium	   acetate,	   pH	   7.0)	   and	   resuspended	   in	   fresh	   buffer	   at	   a	   density	   of	   8x107	   cells/ml.	  
Subsequently,	   440	   µl	   of	   parasite	   suspension	   were	  mixed	   with	   10-­‐15	   µg	   of	   digested	   plasmids	   and	  
transferred	   to	   a	   0.2-­‐cm	   pulse	   cuvette	   (Bio-­‐Rad).	   Electroporation	   was	   conducted	   with	   a	   BTX	  
Electroporation	  600	  system	  (Axon	  Lab,	  Baden,	  Switzerland)	  with	  one	  pulse	  (1.5	  kV	  charging	  voltage,	  
2.5	   kV	   resistance,	   25	   microfarads	   capacitance	   timing,	   and	   186	   resistance	   timing).	   Cells	   were	  
immediately	   inoculated	   in	   10	  ml	   of	   procyclic	   or	   bloodstream	   form	  medium.	   Dilutions	  were	   plated	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Northern	  blot	  analysis	  
Total	   RNA	   was	   isolated	   using	   the	   SV	   Total	   RNA	   Isolation	   System	   (Promega),	   following	   the	  
manufacturer’s	   instructions.	  cDNA	  was	  synthesized	   from	  total	  RNA	   (0.1-­‐0.5	  µg)	  using	  SuperScript	   II	  
reverse	   transcriptase	   (Invitrogen).	  Quantitative	  PCR	  was	  performed	  using	  Applied	  Biosystems	  ViiA7	  
real-­‐time	   PCR	   system.	   The	   reaction	  mixture	   consisted	   of	   1x	   Fast	   SYBR	   Green	  master	  mix	   (Applied	  
Biosystems,	   Switzerland),	   0.45	   µM	   forward	   and	   reverse	   primers	   (primers	   10	   and	   11,	   respectively,	  
Table	  S1).	  Telomerase	  reverse	  transcriptase	  mRNA	  was	  amplified	  using	  primers	  described	  in	  [28]	  and	  
was	  used	  as	  endogenous	  control	  for	  qPCR	  analyses.	  For	  Northern	  blotting,	  total	  RNA	  (10-­‐15	  μg)	  was	  
separated	  on	  formaldehyde-­‐agarose	  gels	  (1%	  agarose,	  2%	  formaldehyde	  in	  20	  mM	  Mops,	  containing	  
8	   mM	   sodium	   acetate	   and	   1	   mM	   EDTA,	   pH	   7.0)	   and	   transferred	   to	   Amersham	   Hybond-­‐N+	   nylon	  
membranes	   (GE	   Healthcare,	   Buckinghamshire,	   UK).	   The	   PCR	   products	   used	   to	   construct	   the	   RNAi	  
stem	   loop	  vectors	   served	  as	   templates	   to	  make	   the	   [32P]-­‐labeled	  probes	  by	   random	  priming,	  using	  
Prime-­‐a-­‐Gene	   Labeling	   System	   (Promega).	   Hybridization	   was	   performed	   overnight	   at	   60	   °C	   in	  
hybridization	  buffer	  containing	  7%	  (w/v)	  SDS,	  1	  mM	  EDTA,	  0.5	  M	  Na2HPO4,	  24	  mM	  H3PO4,	  pH	  7.2,	  and	  
the	   membrane	   was	   analyzed	   by	   autoradiography	   using	   BioMax	   MS	   film	   and	   a	   TransScreen-­‐HE	  
intensifying	   screen.	   Ribosomal	   RNA	   was	   visualized	   on	   the	   same	   formaldehyde-­‐agarose	   gel	   by	  
ethidium	  bromide	  staining	  to	  control	  for	  equal	  loading.	  
	  
Fluorescence	  microscopy	  
Parasites	  (106)	  were	  allowed	  to	  adhere	  to	  a	  microscopy	  slide	  for	  10	  min	  and	  then	  fixed	  with	  
4%	  paraformaldehyde	  in	  PBS.	  Subsequently,	  parasites	  were	  washed	  with	  PBS	  and	  permeabilized	  with	  
0.2%	   (w/v)	   Triton	   X-­‐100	   in	   PBS.	   After	   incubation	   in	   PBS	   containing	   2%	   bovine	   serum	   albumin	  
(blocking	  buffer)	  for	  30	  min,	  primary	  antibody	  in	  blocking	  solution	  was	  added	  for	  45	  min.	  Antibodies	  
used	  were	  mouse	  monoclonal	  anti-­‐cMyc	  9E10	  (Santa	  Cruz	  Biotechnology,	  Heidelberg,	  Germany)	  and	  
rabbit	  anti-­‐VDAC	  antiserum	  at	  dilutions	  of	  1:250	  and	  1:1000,	   respectively.	  After	  washing	  with	  PBS,	  
the	   corresponding	   secondary	   fluorophore-­‐conjugated	   antibodies,	   goat	   anti-­‐mouse	   Alexa	   Fluor	   594	  
and	   goat	   anti-­‐rabbit	   Alexa	   Fluor	   488	   (Invitrogen),	   respectively,	   at	   dilutions	   of	   1:100	   in	   blocking	  
solution,	  were	  added	   for	  45	  min.	   Free	  antibody	  was	   removed	  by	  washing	  with	  PBS	  and	   cells	  were	  
mounted	  with	  Vectashield	  containing	  4,6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI;	  Vector	  Laboratories).	  The	  
slides	  were	  analyzed	  using	  a	  Leica	  SP2	  microscope	  equipped	  with	  a	  100×	  oil	  objective.	  Photographs	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Flow	  cytometry	  
T.	  brucei	  bloodstream	  forms	  were	  incubated	  in	  the	  presence	  of	  80-­‐350	  nM	  G25	  for	  24	  or	  48	  
h.	   Aliquots	   of	   0.5	   ml	   were	   taken	   to	   measure	   mitochondrial	   membrane	   potential	   (ΔΨm)	   and	   cell	  
permeability	  by	  propidium	  iodide	  (PI)	  staining.	  The	  ΔΨm	  was	  measured	  by	  adding	  25	  nM	  or	  125	  nM	  
tetramethylrhodamine	   ethyl	   ester	   (TMRE)	   to	   bloodstream	   or	   procyclic	   form	   cultures,	   respectively.	  
After	  30	  min	  of	   incubation	  at	  37	   °C	   (bloodstream	   forms)	  or	  27	   °C	   (procyclic	   forms),	  parasites	  were	  
washed	  with	   and	   resuspended	   in	   PBS,	   and	   immediately	   analyzed	   by	   flow	   cytometry	   (FACScan	   BD,	  
equipped	  with	  Cytek	  solid	  state	  laser)	  using	  the	  FL2-­‐channel	  detector.	  The	  geometrical	  mean	  values	  
of	   10’000	   gated	   events	   were	   normalized	   according	   to	   the	   control	   samples.	   For	   evaluation	   of	   cell	  
permeability,	  10	  µg/ml	  of	  PI	  was	  added	  to	  the	  respective	  culture	  medium	  and	  incubated	  for	  10	  min	  
at	  37	  °C	  or	  27	  °C	  (for	  bloodstream	  or	  procyclic	  form	  experiments,	  respectively),	  protected	  from	  light.	  
Subsequently,	   0.5	   ml	   of	   parasite	   culture	   was	   transferred	   to	   FACS	   tubes	   and	   fluorescence	   was	  
measured	  using	  FL3-­‐channel	  detector.	  Ten	   thousand	  gated	  events	  were	  separated	   into	   two	  areas	   -­‐	  
according	   to	   fluorescence	   intensity	   -­‐	   as	   follows:	   the	   fluorescence	   intensity	   of	   a	   sample	   containing	  
digitonin-­‐permeabilized	   parasites	   was	  measured	   and	   referred	   to	   as	   PI-­‐positive	   (PI+).	   Fluorescence	  
intensities	  lower	  than	  this	  value	  were	  considered	  PI-­‐negative	  (PI-­‐).	  
	  
Results	  
Screening	  of	  RNAi	  library	  and	  identification	  of	  TbMCP14	  
Recently,	   an	   inducible	   RNAi	   library	   has	   been	   established	   in	   T.	   brucei	   bloodstream	   forms,	  
which	  allows	  an	  unbiased	  approach	  to	  identify	  genes	  involved	  in	  drug	  uptake	  or	  action	  [20].	  We	  have	  
used	  this	  library	  to	  elucidate	  the	  mode	  and	  site	  of	  action	  of	  a	  set	  of	  choline	  analogs	  known	  to	  be	  toxic	  
for	   parasitic	   protozoa,	   including	   T.	   brucei	   [14,16,19].	   In	   a	   first	   step,	   we	   determined	   the	  
concentrations	  of	  G25,	  T3	  and	  T4	  required	  to	  kill	  98%	  of	  T.	  brucei	  bloodstream	  forms	  after	  3	  days	  of	  
culture	  using	  Alamar	  blue	  assays	  (EC98)	  [20].	  The	  obtained	  values	  are	  shown	  in	  Fig.	  1A,	  together	  with	  
the	   EC50	   values	   to	   allow	   comparison	  with	   previously	   published	   data	   [19].	   The	   EC98	   concentrations	  
were	   subsequently	   used	   to	   treat	   separate	   trypanosome	   cultures	   with	   G25,	   T3	   and	   T4,	   following	  
induction	  of	  RNAi	  for	  60	  h	  with	  tetracycline	  (Fig.	  1B).	  After	  8	  days,	  parasites	  cultured	  in	  the	  absence	  
of	  tetracycline	  were	  dead,	  while	  resistant	  cells	  started	  to	  proliferate.	  After	  another	  3	  days	  of	  culture,	  
during	  which	  time	  parasites	  were	  kept	  in	  fresh	  medium	  to	  allow	  optimal	  growth,	  DNA	  was	  extracted	  
and	  inserts	  potentially	  conferring	  resistance	  towards	  the	  drugs	  were	  amplified	  using	  specific	  primers	  
[20].	   Interestingly,	   the	   individual	   screens	   using	   G25,	   T3	   and	   T4	   all	   resulted	   in	   selection	   of	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carrier	  protein	  14	  (TbMCP14;	  Tb927.10.13120),	  a	  member	  of	  a	  large	  family	  of	  mitochondrial	  carriers	  
[29].	  Screening	  with	  G25	  and	  T3	  selected	  parasites	  bearing	  the	  same	  RNAi	   insert,	  while	  T4	  selected	  
parasites	   harboring	   a	   different	   TbMCP14	   RNAi	   sequence	   (Fig.	   1C,	   bottom,	   indicated	   in	   color).	  
Tb927.10.13120	  has	  been	  annotated	  to	  comprise	  of	  an	  ORF	  of	  1035	  bp	  (TriTrypDB,	  GeneDB)	  and,	  by	  
transient	  transfection	  using	  a	  C-­‐terminally	  tagged	  protein,	  has	  previously	  been	  shown	  to	   localize	  to	  
the	   mitochondrion	   [29].	   However,	   recent	   results	   from	   transcriptome	   analyses	   suggested	   that	   a	  
second	  potential	  start	  codon	  171	  bp	  upstream	  of	  the	  annotated	  ATG	  may	  exist	  [30,31].	  Using	  RT-­‐PCR	  
involving	  a	  splice	  leader	  primer	  (primer	  12	  Table	  S1)	  and	  TbMCP14	  reverse	  primers	  (primers	  2	  and	  4,	  
Table	  S1),	  we	  amplified	   transcripts	   from	  T.	  brucei	  bloodstream	  and	  procyclic	   forms	  consistent	  with	  
Tb927.10.13120	   encoding	   an	   mRNA	   of	   1206	   bp	   (Fig.	   1C,	   right	   panel)	   with	   a	   predicted	   full-­‐length	  
protein	  of	  401	  amino	  acids.	  
	  
TbMCP14	  is	  closely	  linked	  to	  drug	  action	  
To	  verify	  the	  involvement	  of	  TbMCP14	  in	  drug	  resistance	  towards	  choline	  analogs,	  expression	  
of	  Tb927.10.13120	  was	  down-­‐regulated	  by	   inducible	  RNAi	   in	  T.	  brucei	  bloodstream	  forms.	  Addition	  
of	  tetracycline	  to	  parasites	  in	  culture	  showed	  no	  growth	  phenotype	  (Fig.	  2A),	  despite	  a	  reduction	  in	  
Tb927.10.13120	  transcript	  level	  by	  >70%	  (result	  from	  two	  independent	  experiments)	  as	  determined	  
by	   qPCR.	   The	   non-­‐essentiality	   of	   Tb927.10.13120	   as	   assessed	   by	   RNAi	   was	   not	   surprising	   since	  
trypanosomes	   selected	   from	   the	   RNAi	   library	   were	   viable	   after	   11	   days	   of	   RNAi	   induction	   (see	  
above).	   However,	   as	   expected,	   treatment	   of	   parasites	   after	   down-­‐regulation	   of	   Tb927.10.13120	  
expression	  showed	  increased	  resistance	  towards	  G25,	  T3,	  and	  T4	  (Fig.	  2B-­‐D).	  In	  Alamar	  blue	  assays,	  
the	  EC50	  values	  of	  TbMCP14-­‐depleted	  bloodstream	  form	  parasites	  for	  the	  drugs	  increased	  an	  average	  
of	   7-­‐fold	   compared	   to	   uninduced	   cells.	   Subsequently,	   Tb927.10.13120	   expression	   was	   also	   down-­‐
regulated	  using	  RNAi	  in	  T.	  brucei	  procyclic	  forms.	  Prolonged	  incubation	  of	  parasites	  in	  the	  presence	  
of	   tetracycline	   showed	   a	   decrease	   in	   Tb927.10.13120	  mRNA	   levels	   and	   a	   slight	   growth	  phenotype	  
(Fig.	   3A).	   In	   agreement	   with	   the	   results	   obtained	   in	   bloodstream	   forms	   (Fig.	   2B-­‐D),	   RNAi	   against	  
Tb927.10.13120	   conferred	   increased	   resistance	   (approximately	   3-­‐fold)	   of	   procyclic	   form	   parasites	  
towards	  T3	  (Fig.	  3B).	  
To	   further	   confirm	   the	   involvement	   of	   TbMCP14	   in	   drug	   action,	   we	   over-­‐expressed	   a	  
tetracycline-­‐inducible	   ectopic	   copy	   of	   cMyc-­‐tagged	   Tb927.10.13120	   in	   procyclic	   and	   bloodstream	  
form	   trypanosomes.	   Analysis	   by	   SDS-­‐PAGE	   and	   immunoblotting	   showed	   that	   cMyc-­‐TbMCP14	   was	  
expressed	   in	   the	   presence,	   but	   not	   in	   the	   absence,	   of	   tetracycline	   as	   a	   48	   kDa	   protein,	   and	   that	  
expression	   of	   full-­‐length	   cMyc-­‐TbMCP14	   conferred	   increased	   susceptibility	   (>10-­‐fold)	   to	   parasites	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expressing	  a	  truncated	  form	  of	  TbMCP14,	  which	  migrated	  after	  SDS-­‐PAGE	  and	  immunoblotting	  with	  
an	  apparent	  molecular	  mass	  of	  42	  kDa	  (Fig.	  3D).	  These	  results	  clearly	  demonstrate	  that	   the	  tagged	  
version	  of	  the	  full-­‐length	  protein	  is	  functional.	  
Additionally,	   viability	  of	  T.	  brucei	   bloodstream	   forms	  over-­‐expressing	   c-­‐Myc-­‐TbMCP14	   (full-­‐
length)	   cultured	   in	   the	   presence	   of	   various	   concentrations	   of	   G25	   was	   investigated	   by	   propidium	  
iodide	  (PI)	  staining.	  While	  dead	  parasites	  are	  permeable	  to	  PI,	  resulting	  in	  its	  intercalation	  into	  DNA	  
with	  subsequent	  fluorescence	  emission	  (PI	  positive),	  living	  parasites	  are	  impermeable	  to	  PI	  and	  show	  
no	   emission	  of	   fluorescence.	   The	   results	   show	   that	   over-­‐expression	   of	   TbMCP14	   slightly	   increased	  
toxicity	  of	  G25	  (Figure	  4,	  top	  right),	  whereas	  its	  down-­‐regulation	  had	  a	  protective	  effect	  on	  parasite	  
survival	   in	  the	  presence	  of	  the	  drug	  (Figure	  4,	  bottom	  right).	   In	  addition,	  the	  data	  show	  that	  G25	  is	  
only	  toxic	  for	  T.	  brucei	  bloodstream	  forms	  after	  prolonged	  incubation,	  i.e.	  72	  h	  (Fig.	  4,	  top	  left,	  green	  
line).	   Taken	   together,	   the	   results	   demonstrate	   that	   TbMCP14	   expression	   is	   closely	   linked	   to	   the	  
action	  of	  the	  choline	  analogs,	  G25,	  T3	  and	  T4.	  
	  
Localization	  of	  TbMCP14	  
In	  a	  previous	  report,	  the	  truncated	  version	  of	  TbMCP14	  has	  been	  expressed	  as	  cMyc-­‐tagged	  
version	  and	  was	  found	  to	  localize	  in	  the	  mitochondrion	  [29].	  We	  now	  show	  by	  immunofluorescence	  
microscopy	   that	   also	   full-­‐length	   TbMCP14	   localizes	   to	   the	   mitochondrion,	   co-­‐localizing	   with	   the	  
mitochondrial	  marker	  protein,	  voltage-­‐dependent	  anion	  channel	  (VDAC)	  (Fig.	  5),	  and	  demonstrating	  
that	  the	  N-­‐terminal	  57	  amino	  acids	  of	  full-­‐length	  TbMCP14	  are	  not	  essential	  for	  correct	  targeting	  of	  
the	  protein	  to	  the	  mitochondrion.	  
	  
TbMCP14	  mediates	  the	  effects	  of	  choline	  analogs	  on	  mitochondrial	  membrane	  
potential	  (ΔΨm)	  
It	   has	   been	   suggested	   that	   the	   trypanocidal	   activity	   of	   choline	   analogs	   may	   occur	   via	  
modulation	   of	   mitochondrial	   membrane	   potential	   (ΔΨm)	   [19].	   We	   revisited	   this	   proposal	   by	  
measuring	   drug-­‐induced	   changes	   in	  ΔΨm	   in	   T.	   brucei	   bloodstream	   forms,	   in	   which	   TbMCP14	   was	  
over-­‐expressed	  or	  down-­‐regulated.	  Using	   the	  mitochondrial	  dye,	   tetramethylrhodamine	  ethyl	  ester	  
(TMRE),	  and	  flow	  cytometry,	  we	  found	  that	  G25	  induced	  a	  decrease	  in	  ΔΨm	  following	  treatment	  of	  
parasites	  for	  24	  h	  with	  increasing	  concentrations	  of	  G25	  (Fig.	  6A).	  This	  drug-­‐induced	  decrease	  in	  ΔΨm	  
was	   absent	   in	   parasites	   after	   RNAi-­‐mediated	   down-­‐regulation	   of	   TbMCP14	   (Fig.	   6A).	   Conversely,	  
sensitivity	  of	  ΔΨm	  to	  G25	  was	   increased	   in	  parasites	  after	  over-­‐expression	  of	  TbMCP14	  (Fig.	  6B).	   In	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and	  flow	  cytometry	  analysis.	  We	  found	  no	  difference	  in	  propidium	  iodide	  staining	  between	  parasites	  
before	   and	   after	   incubation	   for	   24	   h	   in	   the	   presence	   of	   G25,	   ruling	   out	   the	   possibility	   that	   the	  
observed	  decrease	  in	  ΔΨm	  was	  the	  result	  of	  parasite	  death,	  rather	  than	  drug	  action	  (Suppl.	  Fig.	  S1).	  
Together,	   these	   results	   demonstrate	   that	   TbMCP14	   is	   tightly	   involved	   in	   drug-­‐induced	   changes	   of	  
ΔΨm	  and	  that	  they	  are	  an	  early	  event	  during	  G25	  action.	  
	  
Generation	  of	  TbMCP14	  knock-­‐out	  parasites	  
To	  further	  study	  the	  importance	  of	  TbMCP14	  in	  T.	  brucei	  viability,	  we	  generated	  bloodstream	  
and	  procyclic	  form	  Tb927.10.13120	  null	  mutants.	  Since	  RNAi	  against	  TbMCP14	  in	  bloodstream	  forms	  
showed	   no	   growth	   phenotype,	   we	   attempted	   to	   generate	   straight	   knock-­‐out	   parasites	   by	  
sequentially	  deleting	  the	  two	  endogenous	  Tb927.10.13120	  alleles.	  Successful	  replacement	  of	  the	  first	  
and	   second	   alleles	   by	   blasticidin	   resistance	   and	   phleomycin	   resistance	   genes,	   respectively,	   was	  
verified	  by	  PCR	  (Fig.	  7A).	  The	  resulting	  TbMCP14	  null	  bloodstream	  forms	  were	  viable,	  however,	  they	  
showed	  reduced	  growth	  in	  culture	  compared	  to	  the	  parental	  cell	  line	  and	  the	  single	  allele	  knock-­‐out	  
mutant	  (Fig.	  7B).	  The	  cell	  doubling	  time	  of	  the	  null	  mutant	  was	  calculated	  to	  be	  12.5	  h,	  compared	  to	  
6	  h	  of	  the	  parental	  strain.	  Together,	  the	  results	  show	  that	  TbMCP14	  is	  essential	  for	  normal	  growth	  of	  
T.	  brucei	  bloodstream	  forms	  in	  culture,	  but	  non-­‐essential	  for	  viability	  under	  these	  conditions.	  
Because	   T.	   brucei	   procyclic	   forms	   showed	   slightly	   reduced	   growth	   in	   culture	   after	   RNAi	  
against	  TbMCP14	  (Fig.	  3A),	  we	  followed	  a	  different	  strategy	  to	  obtain	  procyclic	   form	  TbMCP14	  null	  
mutants	  by	  introducing	  a	  tetracycline-­‐inducible	  ectopic	  copy	  of	  Tb927.10.13120	  before	  knocking	  out	  
the	  second	  allele.	  To	  be	  able	  to	  monitor	  expression	  of	  ectopic	  TbMCP14,	  the	  gene	  was	  extended	  with	  
a	  sequence	  encoding	  cMyc	  at	  its	  3’	  end.	  Again,	  successful	  deletion	  of	  the	  two	  endogenous	  alleles	  was	  
verified	  by	  PCR	  (Fig.	  7A).	  Resulting	  parasites	  cultured	  in	  the	  presence	  of	  tetracycline,	  i.e.	  expressing	  
cMyc-­‐tagged	   ectopic	   TbMCP14,	   grew	   normally	   in	   standard	   growth	   medium	   (Fig.	   7C).	   In	   contrast,	  
after	   removal	   of	   tetracycline	   from	   the	   culture	  medium,	   parasites	   showed	   reduced	   growth	   after	   6	  
days	   of	   culture	   and	   eventually	   stopped	   proliferating	   (Fig.	   7C).	   SDS-­‐PAGE	   and	   immunoblotting	  
revealed	   that	   cMyc-­‐tagged	   TbMCP14	   was	   expressed	   in	   parasites	   cultured	   in	   the	   presence	   of	  
tetracycline,	   but	   disappeared	  during	   ablation	  of	   TbMCP14	  expression	   after	   removal	   of	   tetracycline	  
(Fig.	  7D).	  Together,	  the	  results	  show	  that	  TbMCP14	  is	  essential	  for	  growth	  of	  T.	  brucei	  procyclic	  forms	  
in	  culture	  and	  that	  cMyc-­‐tagged	  TbMCP14	  is	  functional.	  
	  
TbMCP14	  is	  involved	  in	  energy	  metabolism	  
Our	   initial	   approach	   to	   elucidate	   the	   physiological	   function	   of	   TbMCP14	   was	   to	   identify	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TbMCP14	   by	   running	   an	   untargeted	   metabolomic	   analysis	   [32].	   The	   approach	   revealed	   that	   the	  
proline	   metabolite,	   pyrroline-­‐5-­‐carboxylate,	   was	   4-­‐fold	   increased	   in	   parasites	   over-­‐expressing	  
TbMCP14,	  suggesting	  that	  TbMCP14	  may	  play	  a	  role	  in	  amino	  acid	  metabolism.	  Thus,	  we	  investigated	  
if	  down-­‐regulation	  of	  TbMCP14	  may	  show	  a	  more	  dramatic	  effect	  when	  trypanosomes	  are	  grown	  in	  
glucose-­‐depleted	  medium,	  SDM80,	  in	  which	  procyclic	  forms	  are	  known	  to	  increase	  the	  consumption	  
of	  proline	  for	  energy	  production	  by	  >6	  times	  [22].	  The	  results	  showed	  that	   in	  SDM80,	  RNAi	  against	  
TbMCP14	  caused	  a	  much	  stronger	  growth	  defect	  compared	  to	  when	  parasites	  were	  grown	  in	  SDM79,	  
resulting	  in	  cell	  death	  after	  10	  days	  of	  induction	  (Fig.	  8A,	  compare	  with	  Fig.	  3A).	  When	  the	  medium	  
was	  supplemented	  with	  5.5	  mM	  glucose	  the	  effect	  of	  down-­‐regulation	  was	  delayed	  by	  about	  three	  
days	  (Fig.	  8A).	  Together,	  these	  results	  indicate	  that	  TbMCP14	  indeed	  may	  be	  involved	  in	  metabolism	  
of	   amino	   acids	   for	   energy	   production.	   In	   line	  with	   this	   interpretation,	  we	   found	   that	   depletion	   of	  
TbMCP14	   in	  conditional	  knock-­‐out	  parasites	  cultured	   in	  the	  absence	  of	  glucose	  clearly	  reduced	  cell	  
growth	   (Fig.	   8B),	   whereas	   expression	   levels	   of	   TbMCP14	   had	   no	   effect	   on	   growth	   of	   parasites	  
cultured	  in	  the	  presence	  of	  glucose	  (Fig.	  8C).	  
	  
Discussion	  
Several	  studies	  have	  shown	  that	  choline	  analogs	  are	  potent	  inhibitors	  of	  choline	  uptake	  and	  
affect	  PC	  metabolism	  in	  protozoa	  [12,13,19].	  However,	  more	  recent	  results	  [19],	   including	  our	  own	  
involving	   pulse-­‐chase	   experiments	   using	   labeled	   choline	   in	   presence	   of	   G25	   in	   T.	   brucei	   procyclic	  
forms	  [8],	   indicated	  that	   inhibition	  of	  phospholipid	  synthesis	  may	  not	  be	  the	  main	  target	  of	  G25	   in	  
trypanosomes.	   Instead,	   results	   from	   these	   studies	   suggested	   that	   choline	   analogs	   may	   affect	  
mitochondrial	  function	  and,	  as	  a	  result,	   lead	  to	  parasite	  death.	  However,	  a	  clear	  mechanism	  on	  the	  
uptake	  and	  site	  of	  action	  of	  the	  drugs	  was	  not	  proposed.	  We	  now	  demonstrate	  that	  toxicity	  of	  the	  
choline	  analogs	  G25,	  T4	  and	  T3,	  is	  mediated	  by	  the	  mitochondrial	  carrier,	  TbMCP14.	  Evidence	  for	  the	  
involvement	  of	  TbMCP14	  in	  drug	  action	  is	  several	  fold:	  First,	  TbMCP14	  was	  identified	  by	  an	  unbiased	  
screen	  using	  a	  RNAi	  library	  in	  T.	  brucei	  bloodstream	  forms.	  Its	  down-­‐regulation	  resulted	  in	  selection	  
of	  parasite	  clones	  showing	  increased	  resistance	  towards	  all	  three	  drugs	  used	  in	  the	  screen.	  Second,	  
depletion	  of	  TbMCP14	  by	  transcript-­‐specific	  RNAi	  in	  both	  bloodstream	  and	  procyclic	  forms	  increased	  
resistance	  of	  parasites	  towards	  the	  drugs	  by	  8-­‐	  and	  3-­‐fold,	  respectively.	  Third,	  over-­‐expression	  of	  a	  
tagged	   form	  of	  TbMCP14	   in	  procyclic	   forms	   resulted	   in	  hypersensitivity	   towards	  T3.	   Fourth,	  down-­‐
regulation	   of	   TbMCP14	   protected	   procyclic	   form	   mitochondria	   from	   drug-­‐induced	   decrease	   in	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Additionally,	  the	  mode	  of	  action	  suggested	  for	  T3,	  T4	  and	  G25	  can	  also	  be	  extended	  to	  two	  
additional	   choline-­‐derived	   analogs,	   MS1	   and	  M38	   (see	   [19]	   for	   the	   structures),	   because	   a	   similar	  
increase	   in	   the	   EC50	   value	   was	   also	   observed	   after	   down-­‐regulation	   of	   TbMCP14	   in	   bloodstream	  
forms	   (not	   shown).	   In	   contrast,	  no	  difference	   in	   resistance	  was	  observed	  when	  TbMCP14-­‐depleted	  
parasites	  were	   treated	  with	   the	  mono-­‐cationic	   salt	   T1	   (result	   not	   shown),	   indicating	   that	   T1	   has	   a	  
different	  mode	  of	  action.	  
It	   still	   not	   clear	   how	   choline	   analogs	   cross	   the	   plasma	   membrane	   of	   parasites.	   Previous	  
studies	   have	   postulated	   that	   choline	   analogs	   are	   carried	   by	   the	   choline	   carrier	   of	   plasmodium	  
[12,18].	   Using	   radiolabeled	   T16,	   an	   analog	   of	   G25,	   Biagini	   et	   al.,	   studied	   the	   uptake	   kinetics	   into	  
saponin-­‐freed	   plasmodium	   and	   found	   similar	   properties	   with	   choline	   uptake	   kinetics.	   In	   addition,	  
experiments	  using	  radiolabeled	  T3	  and	  choline	  indicated	  reciprocal	  inhibition	  with	  T3	  showing	  higher	  
potency	  on	  choline	  uptake	  inhibition	  then	  otherwise	  [18].	  	  
The	  mitochondrial	  carrier	  family	  (MCF)	  consists	  of	  a	  group	  of	  related	  proteins	  with	  conserved	  
sequence	   features,	   i.e.	   three	   tandem	   repeats	   of	   about	   100	   amino	   acids,	   each	   of	   them	   with	   two	  
transmembrane	   alpha	   helices	   connected	   by	   a	   hydrophilic	   loop	   and	   a	   conserved	   signature	   signal	  
sequence	  motif	   [33,34].	  MCF	  members	  are	   involved	   in	   transport	  of	  mono-­‐,	  di-­‐	   and	   tricarboxylates,	  
co-­‐factors	   like	   NAD+,	   FAD	   and	   coenzyme	   A,	   amino	   acids,	   and	   other	   substrates	   necessary	   for	  
mitochondrial	   function	   [35].	   In	   silico	   analysis	   of	   the	  T.	   brucei	   genome	  using	   conserved	   amino	   acid	  
sequences	  and	  protein	  domains	   suggested	   the	  presence	  of	  24	  MCF	  proteins	   [29].	  Using	  previously	  
described	  and	  characterized	  mitochondrial	  carriers	  from	  yeast	  and	  humans	  as	  a	  reference,	  putative	  
functions	  were	  assigned	  to	  20	  of	  the	  predicted	  MCF	  proteins	   in	  T.	  brucei	   [29].	  However,	  at	  present	  
clear	  biochemical	  data	  about	  their	  substrate	  specificities	  or	  physiological	   functions	   is	  only	  available	  
for	  a	  few	  members,	  one	  of	  them	  being	  TbMCP5,	  a	  T.	  brucei	  ATP/ADP	  translocator	  [36].	  Interestingly,	  
a	   subgroup	  of	  MCF	  proteins	   shows	  poor	  homology	   to	  mitochondrial	   carriers	   of	   higher	   eukaryotes,	  
indicating	  that	  they	  might	  be	  unique	  to	  kinetoplastids.	  Bioinformatic	  analyses	  using	  reciprocal	  BLAST	  
searches	   revealed	   that	   the	   mitochondrial	   carrier	   revealed	   in	   our	   RNAi	   library	   screen,	   TbMCP14,	  
belongs	  to	  this	  subgroup	  of	  MCF	  proteins	  and	  is	  specific	  to	  kinetoplastids.	  	  
By	   constructing	   knock-­‐out	   mutants,	   we	   found	   that	   TbMCP14	   is	   not	   strictly	   essential	   for	  
parasite	  growth	   in	  culture.	  However,	  growth	  of	  T.	  brucei	  bloodstream	  forms	  was	  clearly	  reduced	   in	  
mutants	   lacking	   TbMCP14.	   An	   even	   stronger	   growth	   phenotype	   was	   observed	   in	   procyclic	   form	  
knock-­‐out	   parasites,	   showing	   an	   almost	   complete	   growth	   arrest	   after	   depletion	   of	   TbMCP14.	  
Interestingly,	  we	  observed	  that	  when	  procyclic	  form	  TbMCP14	  conditional	  knock-­‐out	  parasites	  were	  
cultured	  in	  low	  glucose	  medium,	  growth	  arrest	  occurred	  considerably	  earlier	  compared	  to	  standard	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pyrroline-­‐5-­‐carboxylate,	   in	   parasites	   over-­‐expressing	   TbMCP14	   suggests	   that	   TbMCP14	   may	   be	  
involved	  in	  amino	  acid	  and	  energy	  metabolism	  in	  T.	  brucei.	  It	  has	  been	  described	  that	  under	  glucose-­‐
depleted	   culture	   conditions,	  procyclic	   forms	   rely	  primarily	  on	  amino	  acids	  as	   substrates	   for	  energy	  
production	   via	   oxidative	   phosphorylation	   [22].	   Thus,	   the	   observed	   difference	   in	   the	   time	   point	   of	  
growth	  arrest	  of	  parasites	  between	  low	  and	  normal	  glucose	  medium	  may	  be	  due	  to	  impaired	  amino	  
acid	  metabolism	   caused	   by	   depletion	   of	   TbMCP14,	   resulting	   in	   increased	   dependency	   of	   parasites	  
from	  amino	  acids.	  However,	  TbMCP14	  clearly	  is	  also	  necessary	  when	  parasites	  are	  grown	  in	  normal	  
glucose	  medium,	   i.e.	   when	  most	   of	   the	   ATP	   is	   generated	   by	   glycolysis.	   Therefore,	   the	   deleterious	  
effect	  of	  TbMCP14	  cannot	  be	   justified	  by	  reduced	   levels	  of	  ATP	  generation;	   instead,	  TbMCP14	  may	  
be	   involved	   in	   the	  cross-­‐talk	  between	  glycolysis	  and	  mitochondrial	  metabolism.	  This	  would	  explain	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Figure	  Legends	  
	  
Figure	   1.	   Screening	   of	   RNAi	   library	   and	   identification	   of	   TbMCP14.	   A)	   The	   concentrations	   of	   drugs	  
killing	  50%	  (EC50)	  and	  98%	  (EC98)	  of	  T.	  brucei	  bloodstream	  forms	  were	  determined	  using	  Alamar	  blue	  
assays.	   The	   numbers	   represent	   mean	   values	   from	   at	   least	   two	   independent	   experiments	   using	  
triplicate	  determinations.	  B)	  Time-­‐line	  of	  induction	  of	  RNAi	  library,	  selection	  of	  resistant	  clones,	  and	  
sequencing	  of	  RNAi	   inserts	   from	   resistant	  parasites.	   C)	   Scheme	  depicting	   truncated	  and	   full-­‐length	  
TbMCP14.	  The	  horizontal	  grey	  arrows	  represent	  two	  potential	  TbMCP14	  ORFs,	  encoding	  proteins	  of	  
344	   (truncated)	   and	   401	   amino	   acids	   (full-­‐length).	   The	   colored	   lines	   at	   the	   bottom	   indicate	   the	  
alignments	  of	  the	  RNAi	   inserts	   isolated	  from	  resistant	  parasites	  after	  selection	  with	  G25,	  T3	  and	  T4	  
(from	  top	  to	  bottom).	  The	  right	  panel	  shows	  an	  ethidium	  bromide-­‐stained	  agarose	  gel	  with	  the	  RT-­‐
PCR	   products	   amplified	   using	   a	   primer	   hybridizing	   with	   the	   spliced	   leader	   sequence	   (SL)	   together	  
with	  the	  gene-­‐specific	  primers	  1	  and	  2	  indicated	  below	  full-­‐length	  TbMCP14.	  
Figure	   2.	   Sensitivity	   of	   T.	   brucei	   bloodstream	   forms	   towards	   choline	   analogs	   after	   RNAi	   against	  
TbMCP14.	  A)	  Growth	  curves	  of	  RNAi	  parasites	  cultured	  in	  the	  absence	  (squares)	  or	  presence	  (circles)	  
of	   tetracycline	   to	   induce	   RNAi	   against	   TbMCP14.	   B,C,D)	   Alamar	   blue	   assays	   to	   determine	   the	  
sensitivities	   of	   RNAi	   parasites	   towards	   T3	   (panel	   B),	   G25	   (panel	   C)	   and	   T4	   (panel	   D)	   after	   down-­‐
regulation	   of	   TbMCP14	   expression.	   Squares	   and	   circles	   represent	   trypanosomes	   cultured	   in	   the	  
absence	   and	   presence,	   respectively,	   of	   tetracycline	   (added	   three	   days	   before	   the	   assay).	   The	   data	  
points	  represent	  mean	  values	  ±	  SEM	  of	  triplicate	  determinations	  from	  single	  experiments.	  
Figure	  3.	  Sensitivity	  of	  T.	  brucei	  procyclic	  forms	  towards	  T3	  after	  modulation	  of	  TbMCP14	  expression.	  
A)	   Growth	   curves	   of	   RNAi	   parasites	   cultured	   in	   the	   absence	   (squares)	   or	   presence	   (circles)	   of	  
tetracycline	  to	  induce	  RNAi	  against	  TbMCP14.	  The	  inset	  shows	  a	  Northern	  blot	  analysis	  of	  TbMCP14	  
mRNA	   levels	   from	   parasites	   incubated	   in	   the	   absence	   (-­‐)	   or	   presence	   (+)	   of	   tetracycline	   (upper	  
panels);	  rRNA	  levels	  are	  shown	  as	  loading	  control	  (lower	  panels).	  B)	  Alamar	  blue	  assays	  to	  determine	  
the	  sensitivity	  of	  parasites	  towards	  T3	  after	  RNAi-­‐mediated	  down-­‐regulation	  of	  TbMCP14	  (panel	  B),	  
or	   over-­‐expression	   of	   full-­‐length	   (panel	   C)	   or	   truncated	   (panel	   D)	   TbMCP14.	   Squares	   and	   circles	  
represent	  trypanosomes	  cultured	  in	  the	  absence	  and	  presence,	  respectively,	  of	  tetracycline.	  The	  data	  
points	  represent	  mean	  values	  ±	  SEM	  of	  triplicate	  determinations	  from	  single	  experiments.	  The	  insets	  
in	   panels	   C	   and	   D	   represent	   SDS-­‐PAGE/immunoblot	   analyses	   using	   anti-­‐cMyc	   antibody	   of	   protein	  
lysates	   from	   parasites	   cultured	   in	   the	   absence	   (-­‐)	   or	   presence	   (+)	   of	   tetracycline	   to	   induce	   over-­‐
expression	  of	  full-­‐length	  (panel	  C,	  right	  lane)	  or	  truncated	  (panel	  D,	  middle	  lane)	  TbMCP14;	  the	  right	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Figure	   4.	   Viability	   of	   T.	   brucei	   bloodstream	   forms	   towards	   G25	   after	   modulation	   of	   TbMCP14	  
expression.	  Parasites	  cultured	  for	  three	  days	  in	  the	  absence	  (left	  panels)	  or	  presence	  (right	  panels)	  of	  
tetracycline	  to	  induce	  over-­‐expression	  (upper	  panels)	  or	  down-­‐regulation	  (lower	  panels)	  of	  TbMCP14	  
were	   treated	  with	  different	  concentrations	  of	  G25	   for	  24,	  48	  or	  72	  h.	  Digitonin-­‐permeabilized	  cells	  
were	   used	   as	   a	   positive	   control	   of	   PI	   staining	   (PI	   positive	   area	   of	   histogram,	   see	   materials	   and	  
methods).	  The	  results	  from	  one	  of	  two	  separate	  experiments	  are	  shown.	  
Figure	  5.	  Localization	  of	  TbMCP14.	  T.	  brucei	  procyclic	  forms	  expressing	  cMyc-­‐tagged	  TbMCP14	  were	  
fixed	   and	   stained	   for	   DNA	   with	   DAPI	   (first	   panel),	   anti-­‐VDAC	   antibody	   as	   mitochondrial	   marker	  
(second	  panel),	  and	  anti-­‐cMyc	  to	  reveal	  TbMCP14	  (third	  panel).	  The	  merge	  shows	  mitochondrial	  co-­‐
localization	   of	   TbMCP14	   and	   VDAC	   (fourth	   panel).	   Trypanosomes	   are	   shown	   by	   differential	  
interference	  contrast	  (DIC)	  optics	  (fifth	  panel).	  
Figure	   6.	   Analysis	   of	  mitochondrial	  membrane	   potential	   (ΔΨm).	  T.	   brucei	   bloodstream	   forms	  were	  
incubated	   in	   the	   absence	   (light	   grey	   bars)	   or	   presence	   (dark	   grey	   bars)	   of	   tetracycline	   to	   down-­‐
regulate	  TbMCP14	  by	  RNAi	  (panel	  A)	  or	  over-­‐express	  TbMCP14	  (panel	  B)	  for	  3	  days	  before	  treatment	  
with	  G25.	  Parasites	  were	  treated	  with	  different	  concentrations	  of	  G25	  for	  24	  h	  followed	  by	  addition	  
of	  25	  nM	  TMRE	  for	  an	  additional	  30	  min	  and	  analysis	  by	  flow	  cytometry.	  The	  values	  were	  normalized	  
relative	   to	   untreated	   control	   trypanosomes.	   The	   data	   points	   represent	  mean	   values	   ±	   SD	   from	   at	  
least	   four	   independent	   experiments.	   The	   asterisks	   represent	   statistical	   difference	   relative	   to	   the	  
respective	  uninduced	  control	  (*p<0.05,	  **p<0.01,	  unpaired	  student’s	  T-­‐test).	  
Figure	  7.	  Analysis	  and	  growth	  of	  T.	  brucei	  bloodstream	  and	  procyclic	  form	  TbMCP14	  null	  mutants.	  A)	  
In	   bloodstream	   form	   (bs)	   parasites,	   the	   two	   endogenous	   TbMCP14	   alleles	   (∞,	   1363	   bp)	   were	  
replaced	   by	   hygromycin	   (*,	   2762	   bp,	   )	   and	   blasticidin	   (#,	   2135	   bp)	   resistance	   genes,	   whereas	   in	  
procyclic	  form	  (pc),	  the	  endogenous	  alleles	  were	  replaced	  by	  blasticidin	  (#,	  2135	  bp)	  and	  phleomycin	  
(#,	   2111	   bp)	   resistance	   genes.	   B)	  Growth	   of	  T.	   brucei	   bloodstream	   form	  TbMCP14	  null	  mutants	   in	  
culture	  (circles),	  in	  comparison	  with	  the	  parental	  cell	  line	  (squares).	  C)	  Growth	  of	  T.	  brucei	  procyclic	  
form	  TbMCP14	  conditional	  null	  mutants	  in	  the	  presence	  (squares)	  or	  absence	  (circles)	  of	  tetracycline.	  
D)	  SDS-­‐PAGE/immunoblot	  analysis	  of	  lysates	  from	  T.	  brucei	  procyclic	  form	  TbMCP14	  conditional	  null	  
mutants	   grown	   in	   the	   presence	   (+)	   or	   absence	   (-­‐)	   of	   tetracycline	   for	   indicated	   times.	   cMyc-­‐tagged	  
TbMCP14	  was	   visualized	  with	   anti-­‐cMyc	   antibody.	   Hsp70	  was	   visualized	  with	   anti-­‐HSP70	   antibody	  
and	  represents	  a	  loading	  control.	  Molecular	  mass	  markers	  are	  indicated	  in	  the	  margin.	  
Figure	  8.	  Effect	  of	  depletion	  of	  TbMCP14	  on	  growth	  of	  T.	  brucei	  procyclic	  forms	  cultured	  in	  glucose-­‐
depleted	  medium.	  A)	  Parasites	  were	  grown	   in	   SDM80	  containing	  normal	   glucose	   (5.5	  mM;	  dashed	  
lines)	  or	  low	  glucose	  (0.15	  mM;	  solid	  lines)	  in	  the	  absence	  (black	  symbols)	  or	  presence	  (red	  symbols)	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knock-­‐out	   parasites	   were	   grown	   in	   glucose-­‐depleted	   (B)	   or	   glucose-­‐containing	   medium	   (C)	   in	   the	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Figure	  7	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Supplementary	  Figures	  
	  








5'-­‐	  GCCCAAGCTTGGATCCGAGGGGTCTTCGGGCTATTTA	  -­‐3'	  
Primer	  2	  
TbMCP14-­‐R	  




5'-­‐	  ACGCAAGCTTATGAGTATCACCAACATCGCTG	  -­‐3'	  
Primer	  4	  
TbJPM14O-­‐R	  
5'-­‐	  	  CGCGGATCCTATTTGTTTCCAGAGTTCTCGGTC	  	  -­‐3'	  
Primer	  5	  
TbJPM14O-­‐F	  (truncated)	  
5'-­‐	  	  	  ACGCAAGCTTATGCTACGAACGTTGCTGCTG-­‐3'	  
Primer	  6	  
MCP14KO-­‐5’_fw	  	  	  
5’-­‐	  	  	  CCCCTCGAGAACGGATTTATGGAGTTTATTTTTC	  -­‐3'	  
Primer	  7	  
MCP14KO-­‐5’_rv	  
5’-­‐	  	  	  	  GCCCAAGCTTCTAACTTAATGTGAGGACGTC	  -­‐3'	  
Primer	  8	  
MCP14KO-­‐3’_fw	  
5’-­‐	  	  TGGCTCTAGAAGGAGAAATGGTGTGGTACAC	  -­‐3'	  
Primer	  9	  
MCP14KO-­‐3’_rv	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Supplementary	   Figure	   1.	   Viability	   of	   parasites	   used	   in	   mitochondrial	   membrane	   potential	  
measurements	   (Figure	   4).	   T.	   brucei	   bloodstream	   forms	   towards	   G25	   treatment	   for	   24	   h	   and	   after	  
modulation	   of	   TbMCP14	   expression.	   Parasites	   cultured	   for	   three	   days	   in	   the	   absence	   (control)	   or	  
presence	   (tet)	   of	   tetracycline	   to	   induce	   down-­‐regulation	   (left	   panels)	   or	   over-­‐expression	   (right	  
panels)	   of	   TbMCP14	   were	   treated	   with	   different	   concentrations	   of	   G25	   for	   24	   h.	   Percentages	   of	  
propidium	  iodide	  impermeable	  (PI-­‐)	  or	  permeable	  (PI+)	  parasites	  are	  shown.	  Digitonin-­‐permeabilized	  
cells	   were	   used	   as	   a	   positive	   control	   of	   PI	   staining	   (PI+	   area	   of	   histogram,	   see	   materials	   and	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3.	  Additional	  results	  
3.1	  Effective	  concentration	  of	  G25	  doesn’t	  inhibit	  PC	  synthesis	  
Our	   results	   (summarized	   in	   Chapters	   2.1	   and	   2.2)	   strongly	   suggest	   that	   the	  main	   target	   of	  
choline	  analogs	  in	  T.	  brucei	  is	  not	  lipid	  biosynthesis	  but	  mitochondria.	  This	  was	  also	  confirmed	  when	  I	  
assessed	  biosynthesis	  of	  PC	  by	  T.	  brucei	  bloodstream	  forms	  in	  presence	  of	  effective	  concentration	  of	  
G25	  (0.16	  µM).	  To	  do	  that,	  parasites	  were	  pre-­‐incubated	  or	  not	  with	  0.16	  or	  10	  µM	  G25	  during	  21	  h.	  
After	   three	   hours	   incubation	   in	   presence	   of	   [3H]choline	   (2	   µCi/ml)	   and	   [3H]ethanolamine	   (0.25	  
µCi/ml,	   as	   control),	   total	   lipids	  were	   extracted	   and	   cell	   equivalent	   amounts	  were	   applied	   in	   a	   TLC	  
plate	  (as	  described	  in	  [85]).	  
	   This	  lipids	  analysis	  showed	  that	  at	  very	  high	  concentration	  (10	  µM),	  G25	  specifically	  inhibits	  
PC	  biosynthesis	  by	  T.	  brucei	   bloodstream	   forms	   (Figure	  15,	  middle	  panel),	   supporting	  our	  previous	  
results	  ([85]	  manuscript	  in	  Chapter	  2.2).	  Nevertheless,	  treatment	  with	  effective	  concentration	  of	  G25	  
(0.16	   µM,	   EC98	   found	   in	   Chapter	   2.2)	   during	   24	   h	   doesn’t	   affect	   PC	   biosynthesis	   (Figure	   15,	   lower	  
panel).	  The	  integral	  of	  resulting	  peaks	  after	  TLC	  analysis	  corresponding	  to	  PC	  and	  PE	  were	  calculated	  
and	   the	   ratio	  PE/PC	  has	  not	   changed	  between	   samples	   in	   absence	  or	   in	  presence	  of	  0.16	  µM	  G25	  
(Figure	  15).	  These	  results	  clearly	  demonstrate	  that	  the	  toxic	  effect	  of	  G25	  is	  not	  related	  to	  inhibition	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Figure	  15.	  Effect	  of	  G25	  on	  biosynthesis	  of	  [3H]phosphatidylcholine	  (PC).T.	  brucei	  bloodstream	  forms	  
(2	  x	  107	  parasites	  in	  10	  ml	  culture	  medium)	  in	  absence	  (top	  panel)	  or	  in	  presence	  of	  0.16	  µM	  (middle	  
panel)	  and	  10	  µM	  (bottom	  panel)	  for	  21	  h	  were	  subsequently	  incubated	  for	  extra	  3	  h	  in	  presence	  of	  2	  
µCi/ml	   [3H]choline	  and	  0.25	  µCi/ml	   [3H]ethanolamine	   (as	  control).	  Afterwards,	   lipids	  were	  extracted	  
and	  analyzed	  by	  TLC,	  and	   radiolabeled	  products	  were	  detected	  by	   radioisotope	  scanning.	  The	  area	  
under	   peaks	   PE	   and	   PC	   were	   calculated	   and	   the	   ratio	   PE/PC	   is	   shown	   for	   each	   case.	   The	   arrows	  
indicate	  the	  migration	  of	  phosphatidylcholine	  (PC)	  and	  phosphatidylethanolamine	  (PE)	  standards	  run	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3.2	  Effect	  of	  G25	  on	  dyskinetoplastic	  trypanosomes	  
	   Despite	  the	  existence	  of	  natural	  dyskinetoplastic	  trypanosomes	  and	  the	  induced	  loss	  of	  kDNA	  
in	  laboratory	  conditions,	  the	  mitochondrial	  DNA	  in	  T.	  brucei	  is	  essential	  and	  mechanisms	  involved	  in	  
its	  replication	  are	  considered	  valid	  drug	  targets	  [138].	  In	  bloodstream	  forms,	  the	  F1Fo-­‐ATP	  synthase	  is	  
working	   in	   the	   reverse	   direction	   hydrolyzing	   ATP	   to	   produce	   the	   proton	   gradient	   between	   the	  
mitochondrial	   matrix	   and	   the	   cytosol	   [60,62,63].	   The	   subunit	   A6	   of	   the	   membrane-­‐embedded	   F0	  
component	   is	   encoded	   by	   the	   kDNA	   [58].	   Since	   choline	   analogs	   affect	   mitochondrial	   membrane	  
potential,	  we	  hypothesized	  whether	  this	  could	  be	  a	  result	  of	  alterations	  in	  kDNA.	  Therefore,	  we	  used	  
bloodstream	   forms	   that	   tolerate	   dyskinetoplasy	   (L262P	   mutant	   [59];	   kindly	   provided	   by	   A.	  
Schnauffer)	  to	  test	  G25	  sensitivity.	  These	  cells	  bear	  a	  mutation	  in	  the	  nuclear-­‐DNA-­‐encoded	  γ	  subunit	  
of	  the	  F1	  component	  of	  the	  F1Fo-­‐ATP	  synthase	  that	  compensates	  for	  loss	  of	  kDNA	  [59].	  This	  mutation	  
in	  the	  γ	  subunit	  allows	  the	  generation	  of	  ΔΨm	  by	  the	  ‘truncated’	  A6-­‐defective	  F1Fo-­‐ATP	  synthase.	  
To	  test	  our	  hypothesis,	  I	  used	  L262P	  mutant	  bloodstream	  forms	  before	   and	   after	   treatment	   with	  
acriflavine	  or	  ethidium	  bromide,	  DNA-­‐intercalating	  compounds	  that	  induce	  loss	  of	  kDNA	  	  [138,139].	  
Our	   findings	   indicated	   that	   L262P	   mutant	   bloodstream	   forms	   are	   still	   sensitive	   to	   G25	   with	  
comparable	  EC50	   to	  control	  parasites	   (Figure	  16).	  Moreover,	  sensitivity	   is	  not	  changed	  when	   loss	  of	  
kDNA	   is	   induced	   before	   incubation	   with	   G25,	   but	   the	   hill	   coefficient	   of	   acriflavin-­‐	   or	   ethidium	  
bromide-­‐treated	   L626P	   mutants	   is	   changed,	   probably	   due	   to	   secondary	   effects	   caused	   by	   pre-­‐
incubation	  with	  acriflavin	  or	  ethidium	  bromide.	  However,	  since	  there	  is	  no	  shift	  in	  resistance	  to	  G25,	  
kDNA	  is	  unlikely	  to	  be	  the	  main	  target	  of	  this	  choline	  analog.	  
	  
Figure	   16.	   Sensitivity	   of	   dyskinetoplastic	   bloodstream	   forms	   to	   G25.	   Dyskinetoplasy-­‐tolerant	  
bloodstream	   forms	   (L262P)	   were	   pre-­‐treated	   or	   not	   with	   20	   nM	   acriflavin	   or	   10	   nM	   ethidium	  
bromide	  (EtBr)	  until	  kinetoplast	  could	  no	  longer	  be	  detected	  by	  fluorescence	  microscopy	  using	  DAPI	  
staining.	   NY-­‐SM,	   control	   bloodstream	   forms	   (containing	   the	   kinetoplast).	   Data	   points	   are	   mean	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3.3	  T1	  exerts	  a	  different	  mode	  of	  action	  
Apart	   from	  M53,	   all	   choline	   analogs	   depicted	   in	   Figure	   13	  were	   tested	   against	  T.	   brucei	   in	  
vitro	   after	   down-­‐regulation	  of	   TbMCP14.	   This	   group	  of	   choline	   analogs	  was	   shown	   to	   have	   similar	  
mode	  of	  action,	  except	  T1	  that	  showed	  a	  divergent	  mechanism.	  In	  contrast	  to	  G25,	  a	  bis-­‐quaternary	  
ammonium,	   and	   T3,	   a	   bis-­‐thiazolium	   salt,	   T1	   is	   an	   asymmetric	   monocationic	   molecule,	   which	  
contains	  only	  one	  thiazolium	  ring	   (see	  Figure	  13	  for	  structures).	  Drug-­‐sensitivity	  assays	  revealed	  an	  
EC50	  of	  1.35	  ±	  0.08	  µM	  for	  T1	  (results	  from	  two	  independent	  experiments),	  and	  interestingly,	  down-­‐
regulation	   of	   TbMCP14	   did	   not	   confer	   resistance	   to	   T1	   (Figure	   17A)	   indicating	   that	   it	   may	   exert	  
toxicity	  by	  a	  different	  mechanism.	  Based	  on	  that,	  we	  investigated	  weather	  T1	  could	  affect	  ΔΨm.	  We	  
assessed	  ΔΨm	  of	  bloodstream	  forms	  using	  TMRE	  (Figure	  17B)	  and	  found	  that,	  in	  contrast	  to	  G25,	  8	  h	  
of	  treatment	  with	  0.15-­‐5	  µM	  of	  T1	  had	  no	  affect	  on	  ΔΨm.	  Furthermore,	  at	  10	  µM,	  T1	  decreased	  the	  
ΔΨm	  to	  basal	  levels	  only	  after	  30	  min	  of	  treatment	  (not	  shown).	  
	  
	  
Figure	   17.	   Sensitivity	   of	   trypanosomes	   to	   T1	   after	   down-­‐regulation	   of	   TbMCP14	   (A)	   and	   effect	   on	  
ΔΨm	   (B).	   A)TbMCP14	   RNAi	   cells	   were	   induced	   (Tet)	   three	   days	   before	   adding	   different	  
concentrations	   of	   T1	   (for	   more	   details	   see	  Materials	   and	  Methods	   section	   of	   Manuscript	   B).	   The	  
results	  of	  one	  from	  two	  independent	  experiments	  are	  shown.	  Data	  points	  reflect	  mean	  ±	  SEM	  from	  
three	  determinations.	  B)	  Bloodstream	  form	  (NY-­‐SM)	  parasites	  were	   incubated	   in	  presence	  of	  T1	  or	  
G25	  for	  8	  h	  before	  addition	  of	  TMRE	  and	  analysis	  of	  ΔΨm	  by	  flow	  cytometry.	  Experimental	  details	  can	  
be	  found	  in	  Materials	  and	  Methods,	  Chapter	  2.2.	  
	  
A	   second	  piece	  of	   evidence	   that	   T1	  may	  have	   a	   different	  mechanism	  of	   action	   came	   from	  
drug	  sensitivity	  assays	  using	  yeast.	  As	  mentioned	  in	  chapter	  1.10,	  there	  is	  experimental	  evidence	  that	  
T16	  and	  T3	  are	  taken	  up	  Plasmodium	  via	  a	  choline	  transporter	  [83,103].	  Thus,	  we	  assessed	  toxicity	  of	  
selected	  choline	  analogs	  using	  choline	  transporter-­‐deficient	  yeast	  (hnm1)	  [140].	  Our	  results	  showed	  
that	  the	  hnm1	  knock-­‐out	  mutant	  is	  more	  resistant	  to	  T1	  (Figure	  18A)	  indicating	  that	  T1	  could	  indeed	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excessive	   amounts	   of	   choline	   or	   HC-­‐3,	   a	   specific	   inhibitor	   of	   choline	   uptake,	   has	   no	   effect	   on	   T1	  
toxicity.	  Therefore,	  T1	  may	  not	  use	  a	  choline	  carrier	  to	  cross	  the	  plasma	  membrane	  of	  trypanosomes.	  
In	   contrast,	   hnm1	   mutant	   yeast	   are	   more	   susceptible	   to	   T3	   and	   T4	   compared	   to	   hnm1-­‐
complemented	  control	  cells.	  These	  results	  strongly	  suggest	  distinct	  modes	  of	  action	  of	  T1	  in	  T.	  brucei	  




Figure	  18.	   Sensitivity	  of	   choline	   transporter-­‐deficient	   (-­‐	  hnm1)	  and	   -­‐complemented	   (+	  hnm1)	  yeast	  
(A)	   and	   T.	   brucei	   bloodstream	   forms	   (B)	   to	   choline	   analogs.	   A)	   Growth	   in	   plates	   containing	   the	  
indicated	  concentrations	  of	  T1,	  T3	  or	  T4	   for	   three	  days	  after	   serial	  dilutions	   (1:10,	  experiment	  was	  
performed	   in	   collaboration	   with	   C.	   Wirdnam,	   laboratory	   of	   D.	   Rentsch).	   B)	   Drug	   sensitivity	   of	  
bloodstream	   forms	   to	   T1	   in	   presence	   of	   excessive	   amounts	   of	   choline	   (+	   1	   mM	   choline)	   or	  
hemicholinium-­‐3	  (+	  20	  µM	  HC-­‐3).	  The	  results	  of	  one	  from	  two	  independent	  experiments	  are	  shown.	  
Data	  points	  reflect	  mean	  ±	  SEM	  from	  three	  determinations.	  
	  
3.4	  TbMCP14	  and	  mode	  of	  action	  of	  pentamidine	   	  
	   	  The	   mode	   of	   action	   of	   diamidines	   is	   possibly	   multi-­‐factorial,	   but	   there	   is	   evidence	   that	  
pentamidine	   and	   other	   fluorescent	   diamidines	   may	   accumulate	   inside	   mitochondria	   and	   cause	   a	  
decrease	  of	  ΔΨm	  of	  kinetoplastids	  [141,142,143,144].	  For	  this	  reason,	  we	  studied	  if	  TbMCP14	  may	  be	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diamidines,	   pentamidine	   and	   DB829	   (Figure	   19A),	   after	   down-­‐regulation	   or	   over-­‐expression	   of	  
TbMCP14.	   The	   results	   show	  no	   significant	   shift	   in	   parasite	   sensitivity	   towards	   pentamidine	   (Figure	  
19B)	   and	   DB829	   (not	   shown)	   after	   depletion	   of	   TbMCP14.	   Since	   quantitative	   PCR	   showed	   a	   70%	  
down-­‐regulation	  of	   TbMCP14	  mRNA,	  we	   cannot	   exclude	   the	   possibility	   that	   residual	   expression	  of	  
TbMCP14	   contributes	   to	   toxicity	   of	   pentamidine	   and	   DB829.	   Interestingly,	   over-­‐expression	   of	  
TbMCP14	   in	  procyclic	   forms	   resulted	   in	  a	  3-­‐fold	  more	  susceptible	  phenotype	   towards	  pentamidine	  
(Figure	  19C).	   These	   results	  were	   comparable	   to	   the	  effect	  of	   TbMCP14	  over-­‐expression	  on	   choline	  
analogs	  toxicity	  (Chapter	  2.2,	  Figure	  3C).	  Together,	  these	  preliminary	  findings	  suggest	  that	  TbMCP14	  
may	  be	  involved	  in	  the	  mode	  of	  action	  of	  diamidines.	  
	  
Figure	   19.	   Structure	   of	   diamidines	   and	   sensitivity	   of	   trypanosomes	   to	   pentamidine.	   A)	   Chemical	  
structures	   of	   DB829	   and	   pentamidine.	   B)	   Sensitivity	   of	   bloodstream	   forms	   to	   pentamidine	   after	  
inducing	   down-­‐regulation	   of	   TbMCP14	   (tet)	   or	   not	   (control).	   C)	   Sensitivity	   of	   procyclic	   forms	   to	  
pentamidine	  after	  inducing	  over-­‐expression	  of	  TbMCP14	  (tet)	  or	  not	  (control).	  B	  and	  C	  display	  results	  
of	   one	   from	   two	   independent	   experiments.	   Data	   points	   show	   mean	   values	   ±	   SEM	   from	   three	  
determinations.	  
	  
3.5	  Insights	  from	  metabolomics	  analyses	  on	  G25	  effect	  
In	   order	   to	   get	   clues	   about	   the	  mode	   of	   action	   of	   G25	   we	   decided	   to	   run	   an	   untargeted	  
metabolomics	  analysis,	  in	  collaboration	  with	  Michael	  Barrett	  (University	  of	  Glasgow),	  of	  bloodstream	  
forms	   treated	   or	   not	   with	   the	   EC98	   concentration	   of	   G25	   (160	   nM).	   Parasites	   were	   cultured	   in	  
presence	   of	  G25	   for	   48	   h	   (done	   in	   triplicates),	   an	   incubation	   time	   that	   doesn’t	   affect	   growth,	   and	  
total	  metabolites	   from	  108	  parasites	  were	  subsequently	  extracted	  with	  chloroform:methanol:water	  
(1:3:1)	  and	  analyzed	  by	  LC-­‐MS.	  This	  method	  revealed	  global	  changes	  in	  metabolism	  of	  bloodstream	  
forms	   after	   treatment	   with	   G25.	   An	   unbiased	   analysis	   indicated	   changes	   in	   amino	   acid	   levels,	  
peptides	   and	   lipid	   metabolism	   (Figure	   20A).	   In	   addition,	   to	   detect	   further	   alterations	   in	   specific	  
metabolites,	   the	   data	   was	   sorted	   according	   to	   significance	   (e.g.	   p	   <	   0.05),	   resulting	   in	   the	  
identification	  of	  two	  intermediates	  of	  the	  tri-­‐carboxylic	  acid	  cycle,	  malate	  and	  2-­‐oxoglutarate,	  which	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whereas	  that	  of	  2-­‐oxoglutarate	  was	   increased	  by	  3.16,	  which	  could	  be	  explained	  by	  the	  action	  of	  a	  
putative	   malate/2-­‐oxoglutarate	   carrier	   in	   trypanosomes	   [135].	   Another	   changed	   metabolite	   in	  
carbohydrate	   metabolism	   is	   deoxyribose,	   which	   was	   found	   to	   be	   1.87X	   increased	   in	   G25-­‐treated	  
parasites	   (Figure	   21).	   Several	   metabolites	   involved	   in	   amino	   acid	   metabolism	   were	   significantly	  
changed	   after	   G25	   treatment,	   especially	   the	   ones	   related	   to	   metabolism	   of	   glutamate,	   proline,	  
aspartate	   and	   arginine.	   In	   lipid	   metabolism,	   only	   3	   metabolites	   were	   significantly	   changed,	   but	  
without	  apparent	  correlation	  between	  them.	   In	  contrast,	  accumulation	  of	  several	  metabolites	  from	  
nucleotide	   metabolism	   was	   observed	   (Figure	   21).	   In	   summary,	   our	   metabolomics	   analysis	   of	  
bloodstream	   form	   parasites	   treated	   with	   G25	   indicated	   changes	   in	   amino	   acids	   metabolism,	   in	  
addition	   to	   scattered	   changes	   in	   peptide	   and	   carbohydrate	   metabolisms,	   and	   small	   changes	   in	  
metabolites	   involved	   in	  nucleotide	  and	   lipid	  metabolism.	  However,	   the	  relative	  high	  noise	  makes	   it	  
difficult	   to	   conclude	   whether	   the	   changes	   are	   real	   or	   not.	   The	   accuracy	   of	   the	   analysis	   could	   be	  
improved	   by	   performing	   time-­‐course	   experiments	   in	   the	   presence	   of	   G25,	   but	   metabolomics	  





	   78	  
	  
Figure	  20.	  Heat	  maps	  of	  changes	  in	  abundance	  of	  putative	  metabolites	  relative	  to	  untreated	  control	  
cells	  (C).	  A)	  Metabolomics	  analysis	  of	  bloodstream	  forms	  treated	  (G25)	  or	  not	  (C)	  with	  160	  nM	  G25	  
for	  48	  h.	  B)	  Metabolomics	  analysis	  of	  procyclic	  forms	  after	  over-­‐expression	  of	  TbMCP14	  (T)	  compared	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Figure	  21.	   List	   of	   significantly	   (p	   <	   0.05)	   changed	  metabolites	   in	  T.	   brucei	   bloodstream	   forms	  after	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3.6	  Metabolomics	  analysis	  after	  over-­‐expression	  of	  TbMCP14	  
	   Additionally,	   we	   also	   performed	   an	   untargeted	   metabolomics	   analysis	   using	   T.	   brucei	  
procyclic	   forms	   after	   down-­‐regulation	   or	   over-­‐expression	   of	   TbMCP14.	   Unfortunately,	   the	   analysis	  
performed	   with	   TbMCP14	   RNAi	   parasites	   produced	   inconclusive	   results,	   possibly	   because	   of	   the	  
experimental	  conditions;	  i.e.	  in	  SDM79	  with	  three	  days	  after	  induction,	  under	  these	  conditions	  there	  
is	  a	  late	  and	  mild	  growth	  defect	  after	  down-­‐regulation	  of	  TbMCP14	  (see	  Chapter	  2.2,	  Figure	  3).	  	  
An	  unbiased	  analysis	  of	  changed	  metabolites	  in	  procyclic	  forms	  over-­‐expressing	  TbMCP14	  indicated	  
more	   changes,	   in	   metabolism	   of	   carbohydrates,	   nucleotides	   and	   several	   co-­‐factors	   (Figure	   20B).	  
Interestingly,	   after	   filtering	   the	  data	  according	   to	   significance	   (p	  <	  0.05),	   a	   significant	   increase	  of	  4	  
times	  of	  1-­‐pyrroline-­‐5-­‐carboxylate	  (1P5C),	  a	  metabolite	  related	  to	  the	  proline	  degradation	  pathway,	  
was	   detected	   (Figure	   22),	   suggesting	   an	   involvement	   of	   TbMCP14	   in	   proline	   and	   glutamate	  
metabolism	  (Figure	  23	  and	  discussion	  section	  of	  Chapter	  2.2).	  The	  table	  displayed	  in	  Figure	  22	  shows	  
all	  significantly	  (p	  <	  0.05)	  changed	  metabolites	  after	  over-­‐expression	  of	  TbMCP14.	  Minor	  changes	  in	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Figure	  22.	  List	  of	  significantly	  (p	  <	  0.05)	  changed	  metabolites	  after	  over-­‐expression	  of	  TbMCP14	  in	  T.	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Figure	  23.	  Initial	  steps	  of	  proline	  metabolism	  in	  mitochondria	  (based	  on	  KEGG	  pathway	  database).	  
	  
Considering	   these	   results,	   we	   reasoned	   that	   TbMCP14	   may	   function	   as	   a	   proline	   carrier.	  
Hence,	   in	   collaboration	  with	  Moritz	  Niemann	  and	  André	  Schneider	   (University	  of	  Bern),	   I	  prepared	  
pure	  extracts	  of	  mitochondria	  of	  TbMCP14	  conditional	  knock-­‐out	  after	  5	  days	  in	  presence	  or	  absence	  
of	  tetracycline.	  Isolated	  mitochondria	  were	  used	  to	  perform	  uptake	  assays	  using	  radiolabeled	  proline	  
or	  the	  choline	  analog	  T3	  (not	  shown).	  Unfortunately,	  this	  approach	  produced	  inconclusive	  results.	  
3.7	  TbMCP14	  and	  proline	  metabolism	  	  
Three	   observations	   encouraged	   us	   to	   investigate	   a	   possible	   involvement	   of	   TbMCP14	   in	  
metabolism	  of	  proline.	  First,	  G25	  has	  a	  nitrogen-­‐containing	  ring	  very	  closely	  related	  to	  proline	  (Figure	  
24A).	  Second,	  metabolomics	  analysis	  done	  with	  procyclic	  forms	  over-­‐expressing	  TbMCP14	  showed	  an	  
accumulation	   of	   1-­‐pyrroline-­‐5-­‐carboxilate	   (1P5C),	   a	   metabolite	   of	   proline.	   Finally,	   experiments	  
performed	   in	  glucose-­‐depleted	  medium	  (Chapter	  2.2)	   suggested	   that	  TbMCP14	  may	  be	   involved	   in	  
energy	  metabolism.	  Therefore,	  RNAi	  against	  TbMCP14	  was	   induced	  and	  uptake	  of	   radiolabeled	   [U-­‐
14C]proline	   into	   trypanosomes	   was	   determined.	   We	   found	   that	   down-­‐regulation	   of	   TbMCP14	  
promoted	  an	  increased	  incorporation	  of	  proline	  when	  parasites	  were	  cultivated	  in	  standard	  medium	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Figure	  24.	  A)	  Chemical	  structures	  of	  G25	  and	  proline.	  B)	  [U-­‐14C]proline	  incorporation	  by	  TbMCP14	  KO	  
procyclic	  forms.	  Parasites	  were	  cultivated	   in	  standard	  medium	  (6	  mM	  glucose)	  with	  (black	  squares)	  
or	  without	   (red	  diamonds)	  tetracycline	  for	  5	  days,	  collected	  and	   incubated	   in	  PBS	  (+5	  mM	  glucose)	  
containing	   400	   µM	   non-­‐labeled	   and	   2	   µM	   (0.5	   µCi)	   [U-­‐14C]proline.	   Representative	   of	   two	  
independent	  experiments.	  
	  
A	  subsequent	  analysis	  of	  proline-­‐derived	  metabolites	  by	  TLC	  showed	  four	  (0.15	  mM	  glucose,	  
Figure	  25A)	  or	  two	  (6	  mM	  glucose,	  Figure	  25C)	  main	  peaks	  of	  labeled	  metabolites.	  Retention	  values	  
were	  calculated	  based	  on	  standards	  allowing	  us	  to	  identify	  labeled	  proline	  (peak	  p,	  Figure	  25)	  and	  a	  
second	  peak	  co-­‐migrating	  with	  alanine	  and	  glutamate	  (peak	  g/a,	  Figure	  25).	  Unfortunately,	  it	  was	  not	  
possible	  to	  identify	  peaks	  x	  and	  y	  (Figure	  25).	  Curiously,	  in	  both	  conditions,	  there	  was	  a	  reduction	  in	  
peak	  y	  after	  5	  and	  30	  minutes	  labeling	  with	  [U-­‐14C]proline	  (Figure	  25)	  indicating	  that	  metabolism	  of	  
proline	  might	  be	  altered.	  Analysis	   of	   the	   supernatant	  of	   samples	   incubated	   in	  presence	  of	   glucose	  
suggested	   that	   metabolite	   y	   may	   be	   excreted	   and	   can	   be	   detected	   after	   5	   min	   incubation	   with	  
labeled	  proline.	  Since	  it	  has	  been	  shown	  before	  that	  the	  excretion	  products	  from	  proline	  metabolism	  
are	  mostly	   glutamate	  and	   succinate	   [145],	  metabolite	   y	  may	   represent	   succinate.	  Glutamate	   could	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Figure	  25.	  Analysis	  of	  proline	  metabolites	   in	  TbMCP14	  conditional	  KO	  procyclic	   forms	   cultivated	   in	  
glucose-­‐depleted	  medium	  (SDM80,	  A	  and	  B)	  or	  in	  presence	  of	  glucose	  (SDM79,	  C	  and	  D).	  Parasites	  (5	  
x	  106/sample)	  were	  incubated	  in	  PBS	  containing	  500	  µM	  non-­‐labeled	  proline	  and	  1	  µM	  (0.25	  µCi,	  A	  
and	  B)	  or	  2	  µM	  (0.5	  µM,	  C	  and	  D)	  [U-­‐14C]proline.	  A	  and	  C)	  Analysis	  by	  TLC	  allowed	  identification	  of	  2	  
peaks;	  p,	  proline,	  and	  g/a,	  glutamate/alanine.	  Peaks	  x	  and	  y	  are	  unknown	  proline	  metabolites.	  B	  and	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3.8	  ATP	  production	  by	  digitonin-­‐extracts	  of	  TbMCP14	  knock-­‐out	  parasites	  
Growth	   curves	   of	   TbMCP14	   knock-­‐out	   procyclic	   forms	   in	   glucose-­‐depleted	   conditions	  
suggested	  that	  this	  mitochondrial	  carrier	  could	  be	  involved	  in	  energy	  metabolism	  (Chapter	  2.2,	  Figure	  
7).	  To	  investigate	  if	  depletion	  of	  TbMCP14	  affects	  ATP	  production	  by	  mitochondria	  we	  used	  digitonin-­‐
extracts	   from	   TbMCP14	   conditional	   knock-­‐out	   procyclic	   forms	   cultivated	   in	   glucose-­‐depleted	  
conditions	  (SDM80	  supplemented	  with	  10%	  normal	  FBS	  à	  ∼0.5	  mM	  of	  glucose).	  Growth	  curve	  under	  
these	   conditions	  was	   followed	   and	   revealed	   defective	   growth	   starting	   between	   day	   7	   and	   8	   after	  
removing	  tetracycline	  (Figure	  26A).	  Subsequently,	  parasites	  were	  permeabilized	  by	  digitonin	  exactly	  
as	   described	   in	   [146]	   and	   ATP	   production	   was	   assessed	   as	   in	   [147].	   Briefly,	   the	   resulting	  
mitochondrial	   pellet	   from	  108	   cell	   equivalents	  was	   resupended	   in	   750	   µl	   of	   import	   buffer	   (20	  mM	  




,	  0.6	  M	  sorbitol,	  10	  mM	  MgSO
4
,	  10	  mg/ml	   fatty-­‐acid-­‐free	  BSA)	  and	  
71.5	   µL	   of	   suspension	   was	   used	   for	   each	   condition.	   In	   this	   assay,	   ATP	   production	   via	   oxidative	  
phosphorylation	   is	   assessed	   by	   addition	   of	   5	   mM	   of	   succinate	   and	   67	   µM	   ADP,	   whereas	   ATP	  
production	  via	  substrate	  level	  phosphorylation	  can	  be	  induced	  by	  adding	  5	  mM	  2-­‐ketoglutarate	  and	  
67	  µM	  ADP.	  After	  incubation	  at	  room	  temperature	  for	  30	  min,	  the	  reaction	  was	  processed,	  and	  the	  
ATP	   concentration	  was	   determined	   as	   described.	   Inhibitors	  were	   pre-­‐incubated	  with	  mitochondria	  
for	  10	  min	  on	  ice	  and	  used	  at	  the	  following	  final	  concentrations:	  atractyloside	  (33.3	  µg/ml),	  malonate	  
(6.7	  mM),	   antimycin	   (2.7	   µM).	   ATP	   production	  was	   then	   induced	   by	   the	   addition	   of	   substrate	   and	  
ADP.	  	  
Importantly,	  preservation	  of	  an	   intact	  outer	  mitochondrial	  membrane	   is	  crucial	   to	  correctly	  
evaluate	  ATP	  production	  via	  oxidative	  phosphorylation	   (advice	   from	  André	  Schneider,	  University	  of	  
Bern).	   Therefore,	   we	   followed	   the	   recommendation	   to	   perform	   a	   digitonin	   titration	   in	   order	   to	  
ensure	   optimal	   conditions	   (not	   shown).	   Our	   preliminary	   data	   demonstrated	   that	   TbMCP14	   may	  
cause	   a	   reduction	   on	   ATP	   production	   by	   oxidative	   phosphorylation,	   while	   no	   difference	   in	   ATP	  
production	  was	  detected	  when	  2-­‐ketoglutarate	  was	  added	  (Figure	  26B).	  Antimycin,	  specific	  inhibitor	  
of	  complex	  III	  of	  respiratory	  chain,	  or	  atractyloside,	  inhibitor	  of	  ADP/ATP	  translocator,	  were	  used	  to	  
block	   ATP	   production.	   This	   result	   suggests	   reduction	   on	   ATP	   production	   via	   oxidative	  
phosphorylation.	   However,	   we	   are	   still	   missing	   consistent	   data	   to	   take	   conclusions	   about	   ATP	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Figure	   26.	   Growth	   curve	   (A)	   and	  ATP	   production	   by	   digitonin	   extracts	   (B)	   of	   TbMCP14	   conditional	  
knock-­‐out	  procyclic	   forms.	  A)	  Growth	   in	  presence	   (+	  MCP14)	  or	  absence	   (-­‐	  MCP14)	  of	   tertracycline	  
was	   evaluated	   in	   SDM80	  without	   glucose	   and	   supplemented	  with	   10%	   normal	   (complete)	   FBS.	   B)	  
After	  6	  days,	  parasites	   collected	  and	  used	   to	  perform	   the	  digitonin	  permeabilization.	  Upper	  panel,	  
ATP	  production	  via	  oxidative	  phosphorylation	  is	  assessed	  by	  addition	  of	  ADP	  and	  succinate,	  and	  can	  
be	   inhibited	  by	  antimycin.	   Lower	  panel,	  ATP	  production	  via	   substrate	   level	  phosphorylation	  can	  be	  
assessed	  by	  addition	  of	  ADP	  and	  2-­‐ketoglutarate	  and	  is	  inhibited	  by	  atractyloside.	  
	  
In	  addition,	   I	  have	  also	  evaluated	   the	  ATP	  production	  by	   isotonically	   isolated	  mitochondria	  
[147]	  from	  TbMCP14	  conditional	  knock-­‐out.	  These	  experiments	  suggested	  limited	  ATP	  production	  via	  
oxidative	   phosphorylation	   in	   both	   conditions	   (+	   and	   –	   TbMCP14,	   not	   shown),	   probably	   due	   to	  
damaged	   outer	   mitochondrial	   membrane.	   In	   contrast,	   three	   different	   experiments	   done	   with	  
aliquots	  of	  pure	  mitochondria	  from	  the	  same	  extract	  suggested	  50%	  reduction	  on	  ATP	  production	  via	  
substrate	   level	   phosphorylation	   (not	   shown).	   Therefore,	   these	   results	   couldn’t	   be	   reproduced	   by	  
using	  digitonin-­‐extracts	  so	  far.	  
Alternatively,	  I	  used	  the	  ATP	  production	  assays	  to	  address	  whether	  TbMCP14	  could	  transport	  
glutamate,	   threonine	   or	   fumarate.	   For	   that,	   digitonin-­‐extracts	   of	   TbMCP14	   conditional	   knock-­‐outs	  
were	   used	   but,	   unfortunately,	   production	   of	   ATP	   by	   addition	   of	   glutamate	   to	   was	   comparable	   in	  
presence	  or	  absence	  of	  the	  carrier,	  whereas	  not	  ATP	  production	  could	  be	  detected	  when	  threonine	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3.9	  Two	  additional	  candidates	  identified	  by	  the	  RNAi	  library	  screen	  
The	  library	  screen	  described	  in	  Chapter	  2.2	  identified	  not	  only	  TbMCP14,	  but	  also	  additional	  
genes	   that	  may	  be	   involved	   in	   the	  mode	  of	  action	  of	  choline	  analogs	   (Table	  2).	  The	   first	   candidate	  
gene,	   Tb927.9.3630,	   was	   identified	   in	   the	   two	   independent	   screens	   using	   G25	   or	   T3.	   The	   second	  
candidate	   gene,	   Tb927.5.3870,	   was	   identified	   in	   the	   screen	   using	   T4.	   RNAi	   constructs	   of	   both	  
candidate	   genes	   were	   cloned	   and	   transfected	   into	   trypanosomes.	   Unfortunately,	   I	   only	   obtained	  
resistant	   clones	   expressing	   RNAi	   constructs	   against	   Tb927.9.3630	   and	   stopped	   trying	   to	   obtain	  
Tb927.5.3870	  RNAi	  cell	  lines.	  	  
Afterwards,	   relative	   quantification	   of	   Tb927.9.3630	   mRNA	   by	   quantitative-­‐PCR	   suggested	   ∼60%	  
reduction	   for	   bloodstream	   forms,	   while	   in	   procyclic	   forms	   down-­‐regulation	   was	   not	   quantified.	  
Growth	   curves	   after	   down-­‐regulation	   of	   Tb927.9.3630	   in	   bloodstream	   forms	   showed	   no	   defect,	  
whereas	   in	   procyclic	   forms,	   a	   growth	   defected	   could	   be	   seen	   after	   6	   days	   of	   induction	   with	  
tetracycline	   (Figure	   27).	   After	   several	   attempts,	   drug-­‐sensitivity	   assays	   using	   these	   RNAi	   cell	   lines	  
after	   down-­‐regulation	   of	   Tb927.9.3630	   suggested	   no	   difference	   in	   sensitivity	   to	   G25	   or	   T3	   (not	  
shown).	   However,	   since	   Tb927.9.3630	  was	   identified	   in	   two	   independent	   RNAi	   library	   screens,	  we	  
cannot	   rule	   out	   its	   involvement	   in	   the	   mode	   of	   action	   of	   choline	   analogs.	   Moreover,	   proteomic	  
analysis	  indicated	  Tb927.9.3630	  to	  be	  enriched	  in	  mitochondrial	  fraction	  [148].	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Figure	  27.	  Growth	  curves	  of	  T.	  brucei	  bloodstream	  (A)	  and	  procyclic	  (B)	  forms	  in	  absence	  (control)	  or	  
in	  presence	  (tet)	  of	  tetracycline	  to	  induce	  RNAi	  against	  Tb927.9.3630.	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4.	  General	  discussion	  and	  perspectives	  
	  
The	   present	   thesis	   focuses	   on	   the	   mechanism	   of	   choline	   uptake	   in	   trypanosomes,	   a	  
prerequisite	   for	   PC	   synthesis.	  We	   studied	   the	   inhibition	  of	   this	   process	  by	   a	   group	  of	   anti-­‐malarial	  
drugs,	   known	  as	   choline	  analogs,	   and	   in	  addition,	  used	   these	  drugs	   to	  get	  new	   insights	  on	   choline	  
metabolism	  and	  their	  trypanocidal	  effect.	  	  
We	  demonstrated	  for	  the	  first	  time	  that	  T.	  brucei	  procyclic	  and	  bloodstream	  forms	  take	  up	  
choline	  and	   readily	  use	   it	  as	  a	   substrate	   for	   synthesis	  of	  PC.	  This	  observation	  has	  added	  a	  possible	  
explanation	  for	  the	  essentiality	  of	  the	  CDP-­‐choline	  branch	  of	  the	  Kennedy	  pathway	  under	  laboratory	  
conditions;	   i.e.	  CDP-­‐choline	  pathway	   is	  essential	  because	  synthesis	  of	  PC	   from	  free	  choline	   is	  a	  key	  
metabolic	  pathway	  in	  T.	  brucei	  procyclic	  and	  bloodstream	  forms.	  Furthermore,	  we	  demonstrated	  for	  
the	   first	   time	   that	  anti-­‐malarial	   choline	  analogs	  are	  potent	   inhibitors	  of	   choline	  uptake	   in	  T.	  brucei	  
[85].	  We	  studied	  the	  kinetics	  of	  this	   inhibition	  under	  culture	  conditions	  and	  demonstrated	  that	  the	  
mode	   action	   of	   choline	   analogs	   is	   independent	   of	   their	   potency	   to	   inhibit	   choline	   uptake	   [85].	  
Subsequently,	   three	   different	   choline	   analogs	   were	   used	   to	   screen	   an	   RNAi	   library	   in	   T.	   brucei	  
bloodstream	  forms,	  resulting	  in	  the	  identification	  of	  a	  mitochondrial	  carrier,	  TbMCP14,	  as	  key	  protein	  
in	   the	  mode	   of	   action	   of	   choline	   analogs.	   In	   addition,	   we	   demonstrated	   that	   the	   choline	   analogs	  
target	  the	  trypanosome	  mitochondrion.	  Together,	  our	  findings	  revealed	  a	  previously	  uncharacterized	  
mitochondrial	  carrier,	  TbMCP14,	  that	  is	  directly	  involved	  in	  the	  mode	  of	  action	  of	  known	  trypanocidal	  
drugs.	  
The	  mode	  of	  action	  of	  the	  drugs	  in	  T.	  brucei	  differs	  from	  the	  mechanism	  previously	  proposed	  
in	  Plasmodium	  [100,105,106,107].	  This	  point	  can	  be	  explained	  partially	  by	  two	  reasons:	  i)	  there	  is	  no	  
homolog	   of	   TbMCP14	   in	   Plasmodium,	   suggesting	   that	   Plasmodium	   parasites	   lack	   a	   mitochondrial	  
carrier	   for	  choline	  analogs;	   ii)	   the	  fact	  that	  Plasmodium	  spp.	  are	   intracellular	  parasites	  that	  triggers	  
new	   permeability	   pathways	   to	   scavenge	   nutrients	   and,	   ‘shooting	   itself	   in	   the	   foot’,	   also	   promotes	  
uptake	   of	   choline	   analogs,	   increasing	   in	   about	   400	   times	   the	   concentration	   of	   these	   drugs	   in	   the	  
parasite’s	  vicinity	  [103].	  	  
Plasmodium	   spp.	   are	   compartmentalized	   inside	   erythrocytes,	   i.e.	   protected	   from	   the	   host	  
immune	   system	  as	  well	   as	   from	   therapeutic	   drugs	   circulating	   in	   the	  plasma.	  However,	   it	   has	   been	  
observed	   that	   T3	   accumulates	   inside	   Plasmodium-­‐infected	   erythrocytes	   compared	   to	   non-­‐infected	  
[103],	   which	   is	   consistent	   with	   a	   previous	   study	   involving	   T16,	   another	   choline	   analog	   [83].	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it	  enters	  primarily	  via	  the	  so-­‐called	  new	  permeability	  pathway	  [103].	  This	  pathway	  is	  defined	  as	  the	  
Plasmodium-­‐induced	  permeability	  in	  red	  blood	  cells	  to	  low	  molecular	  weight	  substrates	  allowing	  the	  
sporozoites	   to	   scavenge	   blood	   substrates	   from	   inside	   the	   erythrocyte	   [149,150].	   Thus,	   toxicity	   of	  
choline	   analogs	   may	   largely	   be	   due	   this	   accumulation	   inside	   erythrocytes,	   thereby	   increasing	   the	  
concentrations	   of	   choline	   analogs	   tremendously,	   leading	   to	   higher	   toxicity	   to	   the	   parasites	   [103].	  
Activity	   of	   the	   three	   enzymes	   involved	   in	   PC	   synthesis	   in	   Plasmodium	   was	   investigated	   in	   the	  
presence	   of	   increasing	   concentrations	   of	   T3	   [103].	   Interestingly,	   inhibition	   was	   reported	   only	   at	  
millimolar	   concentrations	   of	   T3,	   i.e.	   at	  much	   higher	   concentrations	   than	   those	   reported	   to	   inhibit	  
choline	  uptake	  into	  Plasmodium	  parasites	  [103].	  Thus,	  the	  primary	  target	  of	  T3	  is	  likely	  the	  uptake	  of	  
choline,	  rather	  than	  the	  inhibition	  of	  PC	  synthesis	  [103].	  For	  this	  reason,	  one	  of	  the	  most	  promising	  
features	   of	   choline	   analogs	   in	   the	   treatment	   of	   malaria	   is	   their	   ability	   to	   accumulate	   inside	  
erythrocytes,	  by	  a	  similar	  pathway	  that	  ensures	  parasite	  proliferation,	  and	  thus,	  reducing	  the	  risk	  to	  
develop	  drug	  resistance	  mechanisms.	  
Is	  still	   too	  early	  to	  draw	  final	  conclusions	  about	  the	  mode	  of	  action	  of	  choline	  analogs	   in	  T.	  
brucei,	   since	  only	   two	   studies	   have	   addressed	   this	   issue	   till	   to	   date	   [70,85].	   In	   vivo	   studies	  will	   be	  
necessary	  to	  evaluate	  whether	  choline	  analogs	  are	  suitable	  compounds	  in	  the	  treatment	  of	  sleeping	  
sickness.	  Based	  on	  pharmacodynamics	  data	  of	  T3	   [103],	  we	  could	  speculate	  that	  trypanosomes	  are	  
exposed	   to	   as	   little	   as	   100	   nM	   of	   T3	   in	   the	   blood.	   This	   concentration,	   based	   on	   the	   cytotoxicity	  
studies	   involving	  T3	  on	  parasites	  under	  culture	  conditions	  (showing	  an	  EC50	  of	  1.22	  µM),	  would	  not	  
affect	   parasite	   viability.	   However,	   no	   in	   vivo	   study	   using	   choline	   analogs	   to	   treat	   trypanosome-­‐
infected	   animals	   has	   been	   done	   so	   far.	   A	   potentially	   interesting	   approach	   would	   be	   to	   test	  
effectiveness	  of	  choline	  analogs	  against	   infections	  of	   intracellular	   trypanosomatids,	   like	  Leishmania	  
and	  T.	   cruzi,	  which	   have	   obvious	   gene	   homologs	   of	   TbMCP14	   in	   their	   genome.	   In	   this	   case,	   there	  
would	   be	   a	   possibility	   to	   combine	   the	   promising	   feature	   to	   accumulate	   inside	   the	   host,	   delivering	  
high	  concentrations	  of	  drugs,	  and	  the	  potentially	  high	  sensitivity	  of	  trypanosomatids	  partially	  due	  to	  
presence	  of	  TbMCP14	  homologs.	  However,	  accumulation	  of	  choline	  analogs	  inside	  Leishmania-­‐	  or	  T.	  
cruzi-­‐infected	  cells	  has	  never	  been	  tested.	  
A	   second	   question	   raised	   by	   our	   study	   is	   related	   to	   the	   functional	   and	   essential	   role	   of	  
TbMCP14	   in	  T.	   brucei.	  Our	   data	   clearly	   show	   that	   down-­‐regulation	  or	   knocking-­‐out	   of	   TbMCP14	   is	  
lethal	   for	  procyclic	   forms	   in	  culture.	   Interestingly,	  under	  glucose-­‐depleted	  conditions,	   the	  defect	   in	  
growth	  after	  depletion	  of	  TbMCP14	  in	  procyclic	  forms	  occurs	  earlier	  compared	  to	  parasites	  cultured	  
in	   presence	   of	   standard	   concentrations	   of	   glucose,	   suggesting	   an	   important	   role	   of	   TbMCP14	   in	  
metabolism	   of	   amino	   acids	   for	   energy	   production.	   Indeed,	   we	   obtained	   different	   indications	   of	   a	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specifically,	  in	  procyclic	  forms,	  over-­‐expression	  of	  TbMCP14	  caused	  an	  accumulation	  of	  1-­‐pyrroline-­‐5-­‐
carboxylate	   (1P5C),	   a	   metabolite	   of	   proline	   degradation	   or	   synthesis.	   Furthermore,	   depletion	   of	  
TbMCP14	   caused	   changes	   in	   proline	   uptake	   and	   metabolism.	   However,	   we	   still	   don’t	   know	   how	  
TbMCP14	   influences	   proline	   metabolism	   in	   T.	   brucei	   procyclic	   forms.	   Since	   it	   is	   a	   mitochondrial	  
carrier,	  one	  could	  hypothesize	   that	  TbMCP14	  functions	  as	  proline	  carrier,	  but	  we	  don’t	  have	  direct	  
evidence	  supporting	  this	  hypothesis.	  	  
Interestingly,	  knocking-­‐out	  TbMCP14	  in	  procyclic	  forms	  is	  also	  lethal	  in	  presence	  of	  glucose,	  
suggesting	  that	  lethality	  is	  not	  related	  to	  lack	  of	  ATP,	  since	  it	  is	  mostly	  produced	  by	  glycolysis	  under	  
these	   conditions.	   Hence,	   considering	   our	   observation	   that	   under	   glucose-­‐depleted	   conditions,	  
depletion	  of	   TbMCP14	   results	   in	   an	  earlier	   growth	  defect,	  we	   speculate	   that	   TbMCP14	  may	  play	  a	  
role	   in	  the	  crosstalk	  of	  metabolites	  between	  glycolysis	  and	  mitochondrial	  metabolism.	   It	   is	  possible	  
that	   TbMCP14	   transports	   the	   end	   product	   of	   glycolysis,	   pyruvate,	   which	   represents	   a	   crucial	  
metabolite	   for	   production	   of	   ATP	   via	   substrate	   level	   phosphorylation,	   into	   mitochondria	   [151]	   to	  
produce	  acetate,	  an	  important	  substrate	  for	  fatty	  acid	  synthesis	  [152].	  However,	  preliminary	  results	  
(not	   shown)	   indicated	   that	   TbMCP14	   knock-­‐out	  mitochondria	   are	   still	   capable	   to	   produce	   normal	  
levels	   of	   ATP	   in	   the	   presence	   of	   pyruvate	   and	   succinate	   as	   subsrates,	   indicating	   that	   it	   may	   not	  
transport	  pyruvate.	  
	  Since	  mitochondrial	  carriers	  play	  a	  central	  role	  in	  metabolism,	  finding	  the	  physiological	  role	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